Clinical Pharmacology in the UK, c.1950-2000: Industry and Regulation by Reynolds, LA & Tansey, EM
Clinical Pharmacology in the UK, c.1950-2000: Industry and Regulation













Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
CliniCal PharmaCology in the UK,  
c. 1950–2000: indUstry and regUlation  
The transcript of a Witness Seminar held by the Wellcome Trust Centre 
for the History of Medicine at UCL, London, on 25 September 2007
edited by l a reynolds and e m tansey
Volume 34 2008
©the trustee of the Wellcome trust, london, 2008
First published by the Wellcome trust Centre
for the history of medicine at UCl, 2008
the Wellcome trust Centre for the history of medicine
at UCl is funded by the Wellcome trust, which is 
a registered charity, no. 210183.
isBn 978 085484 118 9




Please cite as: Reynolds L A, Tansey E M. (eds) (2008) Clinical Pharmacology in the UK c.1950-2000: Industry
and regulation. Wellcome Witnesses to Twentieth Century Medicine, vol. 34. London: Wellcome Trust Centre 
for the History of Medicine at UCL.    
Contents
illustrations and credits v
abbreviations  vii
Witness seminars: meetings and publications; acknowledgements 
E M Tansey and L A Reynolds ix
introduction 
Professor Parveen Kumar  xxiii
transcript 
Edited by L A Reynolds and E M Tansey 1
references 73





Figure 1 AstraZeneca Clinical Trials Unit, South Manchester. 
Reproduced by permission of AstraZeneca. 6
Figure 2 A summary of the organization of clinical trials. 
Adapted from www.clinicaltrials.gov/ct2/info/glossary 
(visited 1 May 2008). 10
Figure 3 Clinical trial certificates (CTC) and clinical trial 
exemption (CTX), 1972–1985. Adapted from Speirs 
(1983) and Speirs (1984). 14
Figure 4 Professor Desmond Laurence and his monthly burden 
of documents for a meeting of the Committee on 
Safety of Medicines. Provided by, and reproduced 




ABPI  Association of the British Pharmaceutical Industry
BMA  British Medical Association
BPS  British Pharmacological Society
CDSM  Committee on Dental and Surgical Materials
CHM  Commission on Human Medicines
CRA  Clinical research associate 
CRM  Committee on Review of Medicines
CRO  Clinical research organization
CSD  Committee on Safety of Drugs
CSM  Committee on Safety of Medicines
CTX  Clinical trial exemption
DHSS  Department of Health and Social Security
DoH  Department of Health
FDA  Food and Drug Administration (US)
GMC  General Medical Council
GPRD  General practice research database
GSL  General sales list
ICI  Imperial Chemical Industries
IMP  Investigational medical product
ISIS  International studies of infarct survival
MCA  Medicines Control Agency
MDA  Medical Devices Agency
MHRA  Medicines and Healthcare products Regulatory Agency
MoH  Ministry of Health
Abbreviations 
viii
MRC  Medical Research Council
NICE  National Institute for Health and Clinical Excellence
OTC  Over the counter
P medicine  Pharmacy medicine
POM  Prescription only medicine
PPRS  Pharmaceutical price regulation scheme
SEAR  Safety and Efficacy, Adverse Reactions Subcommittee  
of the CSM
TCT  Therapeutics and Clinical Trials Subcommittee
UCH  University College Hospital
UCL  University College London
WHO  World Health Organization
ix
Witness seminars: 
MEETINGS AND PUBLICATIONS 1
In 1990 the Wellcome Trust created a History of Twentieth Century Medicine 
Group, associated with the academic unit of the Wellcome Institute for the 
History of Medicine, to bring together clinicians, scientists, historians and others 
interested in contemporary medical history. Among a number of other initiatives, 
the format of Witness Seminars, used by the Institute of Contemporary British 
History to address issues of recent political history, was adopted to promote 
interaction between these different groups, to emphasize the potential benefits 
of working jointly, and to encourage the creation and deposit of archival sources 
for present and future use. In June 1999 the governors of the Wellcome Trust 
decided that it would be appropriate for the academic unit to enjoy a more 
formal academic affiliation and turned the unit into the Wellcome Trust Centre 
for the History of Medicine at UCL from 1 October 2000. The Wellcome 
Trust continues to fund the Witness Seminar programme via its support for 
the Centre.
The Witness Seminar is a particularly specialized form of oral history, where 
several people associated with a particular set of circumstances or events are 
invited to come together to discuss, debate, and agree or disagree about their 
memories. To date, the History of Twentieth Century Medicine Group has held 
more than 50 such meetings, most of which have been published, as listed on 
pages xiii–xxii. 
Subjects are usually proposed by, or through, members of the Programme 
Committee of the Group, which includes professional historians of medicine, 
practising scientists and clinicians, and once an appropriate topic has been 
agreed, suitable participants are identified and invited. This inevitably leads to 
further contacts, and more suggestions of people to invite. As the organization 
of the meeting progresses, a flexible outline plan for the meeting is devised, 
usually with assistance from the meeting’s chairman, and some participants are 
invited to ‘set the ball rolling’ on particular themes, by speaking for a short 
period to initiate and stimulate further discussion.
1 The following text also appears in the ‘Introduction’ to recent volumes of Wellcome Witnesses to Twentieth 
Century Medicine published by the Wellcome Trust and the Wellcome Trust Centre for the History of 
Medicine at UCL.
xEach meeting is fully recorded, the tapes are transcribed and the unedited 
transcript is sent to every participant. Each is asked to check his or her own 
contributions and to provide brief biographical details. The editors turn the 
transcript into readable text, and participants’ minor corrections and comments 
are incorporated into that text, while biographical and bibliographical details are 
added as footnotes, as are more substantial comments and additional material 
provided by participants. The final scripts are then sent to every contributor, 
accompanied by forms assigning copyright to the Wellcome Trust.3 Copies of 
all additional correspondence received during the editorial process are deposited 
with the records of each meeting in archives and manuscripts, Wellcome 
Library, London. 
As with all our meetings, we hope that even if the precise details of some of the 
technical sections are not clear to the non-specialist, the sense and significance 
of the events will be understandable. Our aim is for the volumes that emerge 
from these meetings to inform those with a general interest in the history of 
modern medicine and medical science; to provide historians with new insights, 
fresh material for study, and further themes for research; and to emphasize to 
the participants that events of the recent past, of their own working lives, are of 
proper and necessary concern to historians.
2 Sir Iain Chalmers authorizes the Wellcome Trust to publish his work and to report or reproduce it in any 
form or media, including offprints, provided that it is understood that the Wellcome Trust’s right to do so 
is nonexclusive.
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What exactly is clinical pharmacology and how did it develop? This Witness 
Seminar gave some fascinating personal historical eye-witness accounts of how 
the specialty of clinical pharmacology developed. But who are the clinical 
pharmacologists? How were they trained, where did they work and how were 
the products they developed regulated? These questions are not easy to answer 
as the specialty developed in a rather haphazard way over the last half century. 
The realization –‘Well, perhaps we are clinical pharmacologists’– only came 
after a number of papers on clinical pharmacology had been published (page 
17). Whatever the modest development of the specialty, its importance cannot 
be underestimated; we are dependent on it for drug innovation, whether it is 
done by industry alone or in collaboration with academia. We were all taught 
pharmacology at medical school, but often the basic elements of pharmacology 
were forgotten unless, of course, there were drug interactions or adverse drug 
reactions. Often individual interest was only stimulated if clinical trials of new 
drugs were requested for the completion of the phases of drug development. 
Many learned their clinical pharmacology while being employed by the 
industry and, indeed, there was a jointly funded Department of Health/ABPI 
scheme that was successful in training for a while (pages 29–30). However, 
the awareness and profile of clinical pharmacology was mainly raised by the 
development of the diploma of pharmaceutical medicine (DipPharmMed) with 
a syllabus containing aspects of clinical pharmacology and also the creation of 
the Faculty of Pharmaceutical Medicine in 1989 (page 28). 
So who calls the tune? Much has been written and said about the interaction 
between industry and the influence of the pharmaceutical industry on everyday 
medical practice. A parliamentary health select committee considered this issue 
recently in 2005.3 The general view was that the drug industry influenced 
medical practice, education and the prescription of non-generic drugs. Its 
infiltration was often subtle, for example, through support for weekly journal 
clubs, X-ray sessions and, more nationally, conferences and workshops. The 
interface was blurred and said to be tainted by ‘drug industry money’. 
However, the interface was never thus in the earlier days when the pharmaceutical 
industry and academia worked alongside each other. Nevertheless, the question 
remains as to whether new drug development was pushed by the academic 
3 House of Commons, Health Committee (2005). 
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departments of the pharmaceutical industry or by the marketing strategies that they 
employed. Drug companies are vast empires and often the marketing side does not 
impinge on the scientific development limb. It was argued that the industry was not 
a homogenous mass although this wasn’t a view held by all. 
The question was asked whether the pharmaceutical industry was benign or 
malign (page 40). Either way, there was a critical problem. There has been 
declining productivity and little drug innovation: in the past ten years, industry 
has put an increasing investment into marketing, lobbying and public relations. 
This has resulted in ‘over-medication’ of patients, particularly in the US, not 
an ideal or indeed an acceptable situation. An interesting suggestion that the 
reason why the pharmaceutical industry was neither benign nor malign was that 
pharmaceutical companies were ‘socially blind’. The web is full of adverts for 
cheaper drugs, and patients who are influenced by advertising will push their 
general practitioners into giving them a prescription. 
However, the inter-relationship between academia and industry in this country 
has not always been viewed suspiciously. The interaction, in fact, started with 
Henry Wellcome and the Burroughs Wellcome Company. Henry Wellcome 
set up the first research labs in this country and employed people like Henry 
Dale, George Barger and John Gaddum. As Tilli Tansey explained (page 31), 
they all started their research careers in the Wellcome laboratories and then 
moved on either into the MRC or into academia. Henry Dale became the first 
member from a pharmaceutical industry to be elected an FRS in 1914. There 
was no prejudice against electing people coming from industry. However, this is 
different in the US, where, for example, the American Society for Pharmacology 
and Experimental Therapeutics has not allowed members from industry. Neither 
could a pharmacologist in industry become a member of a professional body. 
This situation lasted until 1942 and may account for some of the differences that 
have been raised about in-house research in British and European companies, 
as opposed to the US tradition. In this country, pharmacologists could move 
between the two, but Tilli Tansey, who has a historical interest in this, thought 
these barriers may have become more firm recently.4 This has had the effect 
that phase I clinical trials have drifted further and further from academia as 
the establishment felt that industry-sponsored research was somehow tainted. 
Clearly, this has major implications on training as well as on the experience that 
young pharmacologists can gain by moving between academia and industry.
4 See Church and Tansey (2007).
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Regulation has also become more structured and rigid. It is a salutary fact that 
proper regulation was only forced by the thalidomide tragedy. Alasdair Breckenridge 
reminded the seminar that it was exactly 50 years ago to that week that thalidomide 
had been introduced into medicine. In the early 1900s a huge number of drugs 
were put onto the market and a health select committee was appointed in 1911 
to look at the regulation of this but unfortunately reported as the First World War 
broke out.5 Nothing was then done officially until the thalidomide tragedy, which 
led to the subsequent development of the Committee on Safety of Drugs (CSD) in 
1963. The Committee had no power or legal force behind it apart from a moral one 
and was working on goodwill – much to the surprise of US colleagues. Sir George 
Godber (Chief Medical Officer, 1960–73) assured the Committee that it would 
only last three years before the Medicines Act, but in fact it lasted for seven years. 
The CSD’s major concern was safety (pages 43–4), and it considered efficacy only 
in so far as it concerned safety. However, subsequently, the Committee on Safety 
of Medicines (CSM) was established and treated efficacy as a major factor, but 
decisions on safety were difficult, as often the number of patients included in clinical 
trials was small. ‘How do you get a handle on the safety of marketed drugs?’ asked 
Alasdair Breckenridge, a discussion that started in the 1970s and continues today. 
Post-marketing surveillance was set up. Adverse drug reactions were monitored 
and later a reporting system on-line (ADROIT) was a major step forwards.6 It was 
commented (page 46) that the reports of these reactions did not mainly come, as 
was expected, from hospitals but were more often reported by general practitioners. 
Now, of course, patients can also have an input into this. 
The Medicines Act came into being in 1968. Industry was very powerful in 
determining what would be in the Act. For example, there was no definition 
of the ‘relative’ efficacy in clinical practice. There was no concept of whether 
a medicine was needed or not, or indeed any discussion about the price. The 
Medicines Act appointed a Medicines Commission that appointed other 
committees, including the Committee on Safety of Medicines. This regulatory 
system worked extremely well for almost 40 years. The question of cost didn’t 
come into the equation until the formation of the National Institute for Health 
and Clinical Excellence in 1999; licensed drugs were now considered on their 
5 House of Commons, Select Committee (1914). 
6 The database for storing and monitoring suspected adverse reactions to drug substances was started in 
1993 by the Medicines Control Agency (MHRA since 2003) with data from 1964, and is available by 
subscription to AEGIS (ADROIT Electronically Generated Information Services). See www.info.doh.
gov.uk/doh/iar.nsf/0/80256F4F0030DD2180256EBE004B5F31?OpenDocument (visited 24 September 
2008). See also Wood and Coulson (1993). 
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cost and clinical effectiveness but clearly there was a limit to the number of 
drugs that could be considered per year. However, with the changes in regulatory 
systems in Europe and with the various recognition systems across countries, it 
was felt that the basic structure of the Medicines Commission and the CSM 
should be changed. A new Commission on Human Medicines was formed in 
2005 to be more compatible with the European regulatory system. Sadly, I was 
the last chairman of the Medicines Commission as appointed by the Medicines 
Act of 1968, but I felt that the Commission had done a worthwhile job extremely 
well over the years. 
This Witness Seminar on the history of clinical pharmacology provides an 
invaluable record of the development of clinical pharmacology. As always, one 
is grateful to Tilli Tansey, Lois Reynolds and their team for doing the hard 
work and to Rod Flower and all the participants who gave their personal 
recollections.
Parveen Kumar 
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dr tilli tansey: I am the convenor of the Wellcome Trust History of Twentieth 
Century Medicine Group. Several years ago, the Wellcome Trust initiated the 
group to try to bring together historians of medicine, clinicians and scientists 
in an effort to create, in particular, archives for future research. One of the 
devices we’ve organized is this: having a Witness Seminar where we get together 
a number of people who’ve been involved in a particular debate or discovery to 
sit together to discuss, disagree and have frank discussions about what happened 
and why, and how.
This is the second meeting we’ve had on clinical pharmacology.1 The first 
one, which focused on individual pharmacologists and relevant institutions, 
engendered so much debate and interest, even before we held it, that we decided 
that we should hold a second one to look particularly at regulatory and industrial 
aspects of the subject. And I’m delighted that Jeff Aronson, who helped organize 
the first meeting, has helped us very much in organizing the second, and Rod 
Flower, who chaired the first one, has agreed to do the same for this one. Let me 
hand over for the rest of this meeting to the chairman, Rod Flower.
Professor rod Flower:2 Thanks very much indeed, Tilli. It’s a pleasure to be back 
here again. We had a very enjoyable meeting on 6 February 2007 and I would like 
to welcome back colleagues who attended on that occasion. Those of you who 
couldn’t attend ought to know that we tried, during that session, to answer various 
questions, including: what clinical pharmacology actually was; how it started 
in medical schools and other institutions; how networks and interactions arose; 
who became clinical pharmacologists and why; and how they were influenced 
by government reports and other initiatives. We also discussed the role of various 
learned societies and journals in the development of the subject and later in the 
afternoon we touched upon the diversity and expansion of clinical pharmacology.
We decided to split our original Witness Seminar on clinical pharmacology 
into two sections, because it was evident that the more regulatory side of the 
discipline deserved a separate airing, and that’s why we are here today.
My main job is really to act as a sort of facilitator. It’s a very informal format. 
We will break for tea at 4 o’clock and at 6 o’clock for drinks, and in between 
those times I will do my best to encourage discussion, to field questions and so 
on, but it is really your reminiscences we want, not mine, and this is very much 
your afternoon!
1 See Reynolds and Tansey (eds) (2008b). 
2 Biographical notes appear on pages 89–102.
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On behalf of Jeff Aronson and myself, I’d like to thank the staff here at the 
Centre: that is to say, Tilli, Wendy, Daphne and Lois. I’d especially like to thank 
Jeff as the whole thing was his idea and he has mapped a lot of the important 
areas for discussion.
I suppose medicine and the law have always been inextricably entwined. We 
hear, for example, that in ancient Egypt a healer who killed a patient could 
himself be sentenced to death if it could be shown that he did not follow the 
exact prescriptions as laid down in the sacred books of Hermes. That was in 
around 2000 BC but, by extension, the same type of reasoning applies to us 
today. I guess most of the discussion this afternoon will be about the regulation 
which arose in the post-thalidomide era, that is to say, the Dunlop Committee 
and before that its immediate predecessor, the Cohen Committee.3
I would anticipate that events that took place after that are really going to 
constitute the main subject of our consideration later today.
However, to start off with we are going to call upon Nigel Baber, who is going 
to talk a little bit about his own experiences in the pharmaceutical industry, the 
sorts of drugs he was interested in and some of the personalities he encountered. 
We are then going to talk about the development of the clinical pharmacology 
industry and then later we are going to talk more about the regulatory side of 
things. So Nigel, may I kick off with you? 
Professor nigel Baber: Thank you very much, chairman. I’m very aware that 
the industrialists are probably in the minority here, and my recollections are 
going to be personal. They are about three major companies for which I’ve 
had the honour and privilege, and the fun, to work. The period I’m going to 
be talking about is 1975 up to 1998. The first company I worked with was 
ICI Pharmaceuticals, long before it became Zeneca and certainly long before 
it became AstraZeneca. In fact, funnily enough, Astra was one of its main 
rivals at the time. The period when I joined was, in some ways, ICI at its 
zenith. Propranolol had just been registered for hypertension, thanks largely to 
Professor Brian Prichard’s work.4 Practolol had gone into decline a little while 
before because of the oculomucocutaneous syndrome.5 That was the end of 
practolol, though it took a very long time to die. I think the most practical 
3 See Glossary, pages 103–4. 
4 Prichard and Gillam (1964).
5 See Mann (2005); Abraham and Davis (2006). 
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thing I learnt from practolol was how to run a major post-infarction study. 
Ken Green was then the manager of clinical research.6 It was not called clinical 
pharmacology in those days. So I learnt under him and others how you set up 
major post-infarction studies. These were the predecessors of ISIS and the Trent 
study and all that followed from them.7 Atenolol was rapidly being developed 
at that stage. That was the golden hope – to supplant propranolol as the latter 
faded and became generic. Clofibrate was another drug that bit the dust about 
a month or so after I joined – I don’t think it was cause and effect – with the 
World Health Organization (WHO) study,8 and I can clearly remember the 
medical director of ICI at the time, Colin Downie, who really had a pretty 
bad time of it then, wading his way through all the reports on clofibrate and 
all the reports on practolol.9 Tamoxifen was another very important drug 
for ICI at that time, and we all know what a remarkable medicine that has 
become in the treatment of breast cancer.10 But ICI was predominantly a 
cardiovascular company. 
The department there responsible for early-phase evaluation was called ‘clinical 
research’ not ‘clinical pharmacology’ for the first few years after I joined. The 
manager was Ken Green. When he retired it was taken over by John Nicholls, 
whom some here may well remember. John did one of the most important 
things, I think, for clinical pharmacology at ICI, which was to build one of the 
first in-house clinical trials units, a splendid unit on stilts, over the reservoir, 
and I think it’s still functioning (the South Manchester Unit of AstraZeneca 
Pharmaceutical Research Laboratories, Alderley Park, Cheshire; see Figure 1). 
Our volunteers were employees of ICI, either from the Alderley Edge research 
site or from the manufacturing site in Macclesfield. I think later, after I left, 
volunteers were drawn from outside. But the philosophy of ICI was that 
volunteer studies should be done in-house if at all possible. 
6 Professor Baber wrote: ‘Dr Kenneth Green was manager of clinical research at ICI Pharmaceuticals from 
about 1975–85. He was a cardiologist, best known for pioneering the first large multicentre, multinational 
post-infarction trial with a b-blocker (practolol) which set the benchmark for future secondary prevention 
trials.’ Note on draft transcript, 8 July 2008. See Green (1975). 
7 On the ISIS (International Study of Infarct Survival) study see ISIS-1 (1986); ISIS-2 (1988); ISIS-3 
(1992); and Reynolds and Tansey (eds) (2005): 105–7; for the Trent study see Wilcox et al. (1986).
8 See Heady (1973); Principal Investigators (1978, 1980, 1984).
9 On practolol see Wright (1975); Amos et al. (1978). On clofibrate see note 8. 
10 See Jordan (1988).
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Rod has asked me to talk about the interface between industry and the 
regulatory authorities as a separate issue, and I will certainly try to do that. So I 
have compacted nine years into a few words. Perhaps mention should be made 
of one other very interesting development compound. Professor Breckenridge 
was involved in this: that was a drug called clobuzarit (Clozic, ICI 55897). 
This was designed as a disease-modifying agent for the treatment of rheumatoid 
arthritis and it was related to clofibrate.11 This is quite an interesting bit of 
history, if you’ll forgive me for a few moments. We talk these days about the 
speed with which translational medicine allows rapid entry into major clinical 
trials, but we very rapidly did single and repeat dose studies in volunteers with 
clobuzarit. We then moved quickly to dose-ranging studies, now called ‘proof of 
concept’, in patients with early rheumatoid arthritis. This was done in the UK, 
Switzerland, Germany, Austria, South Africa and Italy, and Arthur Rushton 
and I managed this programme. This was a drug which we were just about 
beginning to convince ourselves had disease-modifying properties in terms of 
falls in C-reactive protein and erythrocyte sedimentation rates in comparison 
with indomethacin and changes in X-ray scoring.12 We then had our first three 
11 See McConkey et al. (1980); Bird et al. (1983).
12 See Jones et al. (1982); Lewis et al. (1989). 
Figure 1: astraZeneca Clinical trials Unit, south manchester
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cases of Stevens–Johnson syndrome.13 These were scattered all over the world 
(Austria, South Africa and France) – they weren’t just in one centre. We had 
about 1500 patients exposed to the drug, and Bill Duncan, who was then deputy 
chairman, technical – I think that was the correct term – called us together and 
told us, ‘We’re going to pull the plug on Clozic’.14 I think he was absolutely 
right, but there was tremendous resistance from the physicians who were using 
the drug and who wished to continue with it. It was a most interesting drug 
to work with – one of the most interesting that I’ve ever dealt with. So, that’s a 
summary of my experiences at ICI. 
I then joined Merck Sharp & Dohme Limited (hereafter Merck), and I think 
then, Merck, too was probably at the height of its powers. I was there for three 
and a half years as European director of clinical pharmacology. Keith Jones was 
overall director of clinical pharmacology based in the US. Between us we took 
every single new compound of Merck’s into human in Europe. The reason was 
very simple, of course; investigational new drug applications for the US Food and 
Drug Administration (FDA) were extremely difficult to come by, and that’s why 
European clinical pharmacology was so important to Merck. Merck’s philosophy 
was totally different from ICI’s and, as we shall see, from Glaxo’s. They did not 
have in-house trials units of their own: they expected us to go to ‘centres of 
excellence’, as we call them now, which could be anywhere in the world, where 
we could get expert advice in design and conduct of phase I and IIa studies. The 
main programme that we looked after was the leukotriene programme, and I’m 
sorry Colin Dollery isn’t here, but it was with Colin we did a lot of the work. 
Donald Davies will remember that as well. The key leukotriene challenge was to 
develop a leukotriene D4 antagonist, and this was conducted by Neil Barnes at 
Kings.15 I doubt if current regulations would allow such a rapid programme, but 
it put Merck really in front of the leukotriene race. Of course Merck was, at that 
time, financially very sound. Its main portfolio consisted of enalapril (Vasotec), 
simvastatin (Zocor) and mevinolin (lovastatin, Mevacor) in the US. Interestingly, 
as an aside, nearly all of Merck’s clinical pharmacology work on those major drugs 
13 A severe form of erythema multiforme with lupus-like symptoms, thought to be caused by an allergic 
reaction to medication.
14 Professor Baber wrote: ‘There was a meeting of all of the principal investigators from the countries listed 
who presented their results and there was a debate at which Bill Duncan and Colin Downie (medical 
director) were present, on the future of Clozic. It was following this meeting that Bill Duncan announced 
the termination of the development programme.’ Note on draft transcript, 8 July 2008. 
15 See, for example, Barnes et al. (1984); Barnes et al. (1987).
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was not done in America: everything was repeated in the US. Scandinavia was where 
most of the enalapril work was done, and the same with the statin programmes, as 
most of you will know if you read the old literature.16 Merck was a good place to 
work. Ed Skolnick was the R&D director, a most fearsome intellect. 
After three and a half years at Merck I moved to Glaxo, or rather to the Glaxo 
Group Research as it was then. Richard Sykes had just become research and 
development director. I was there for nine years; the latter two years were under 
the GlaxoWellcome amalgamation. The philosophy of clinical pharmacology 
was more like the ICI model: in-house work on volunteers from the workforce. 
We set up three new centres and there was no shortage of money. Zantac 
(ranitidine) was the first billion-dollar drug.17 We put a clinical pharmacology 
unit at Northwick Park, Harrow, in place, long before Parexel (a US clinical 
research organization) was on the horizon. And the important thing here, I 
think, was that it was the first time I had tried to set up a panel of patients – and 
this was with troglitazone in mind for the potential treatment of type 2 diabetes. 
Just on that one drug: I will say we were able to detect weight gain after repeat 
dosing in volunteers, and small changes in blood pressure.18 We could predict 
very early on that it was likely to be a problem.
So, other drugs that were of interest at Glaxo, of course, were the 5HT 
(serotonin) agonists and antagonists, and perhaps I could talk here a little about 
our interactions with the regulatory agencies, in reference to sumatriptan and 
ondansetron.19 Those are the two drugs I had most to do with when I was 
there. I didn’t take sumatriptan into human the first time – that had been done 
before I joined – but we were interested in investigating the peculiar chest 
symptoms: difficulty in breathing, pressure on the chest, and whether it was 
vasoconstriction.20 
So that is a very rapid summary of 23 years in the pharmaceutical industry, 
in three major pharmaceutical companies. I’d be happy to talk about other 
interesting characters that I came across. Perhaps I will just pick out one 
16 Cleary and Taylor (1986). See also Vagelos and Galambos (2004).
17 See Christie and Tansey (eds) (2002): 175–6, 131; Berstad et al. (1980); Brittain and Daly (1981).
18 See Parker (2002).
19 See Fowler et al. (1991); Peroutka (1990); Baber et al. (1992); Chaffee and Tankanow (1991); Christie 
and Tansey (eds) (2007): 51–2, 59–60, 64. 
20 See Mueller et al. (1996).
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outstanding personality whom people might know, to finish with: hands up 
those who remember Jeff Thorp. He was probably the one real genius at ICI 
while I was there. Jeff really invented clofibrate and Clozic.21 He was an engineer 
from South Africa who had a BSc and nothing else. He was an absolute delight 
to talk to and he shared his knowledge liberally. I’ll stop there, chairman, and 
be happy to reminisce about any other characters that people remember from 
those days. 
Flower: That’s a very good introduction, Nigel. Just as a matter of interest, since 
we’re concerned with the development of clinical pharmacology, you mention 
that when you first went to ICI, your outfit was called clinical research. Was 
there a point at which it transitioned into clinical pharmacology – and if so, 
how did that happen?
Baber: Yes. I think this was really due to John Nicholls. John clearly saw that 
there was a need to try to understand the physiology of disease in parallel 
with the pharmacology of drugs. He set up two small departments: clinical 
pharmacology, under John Harry – I wasn’t in that department at the time; and 
what he called clinical physiology under Ron Stark, whom some of you may 
well know, and that was quite successful. But it was really John Nicholls who 
commuted the term of clinical research into clinical pharmacology, and that has 
stuck since.22
Flower: And what about the size of your department in those days? 
Baber: In terms of medics, about six or seven. In terms of support staff, PhDs, 
clinical research associates (CRAs) and nurses, it was probably 20–25. And 
that’s something perhaps one ought just to mention as we go on with our 
discussions. I guess we are all medics in the room, but there is an awful lot 
of clinical pharmacology in industry which owes much of its success to non-
medical people: pharmacokineticists and clinical toxicologists and statisticians, 
so they are important to us as clinical pharmacologists in industry.23 
21 See Thorp and Waring (1962); Thorp (1963); see also Fitzgerald (2003). 
22 See, for example, Nicholls (1972).
23 Professor Baber wrote: ‘Designing and executing a phase I study in healthy normal volunteers as patients 
was a multi-disciplinary team activity. It required input from: 1) the pharmacologists who discovered the 
investigational medical product (IMP); 2) the statisticians; 3) pharmacokineticists to develop an assay for 
the IMP and its metabolites and calculate pharmacokinetic parameters; 4) research nurses and clinical 
research scientists to conduct and monitor the trial, under the jurisdiction of the clinical pharmacologist.’ 
Note on draft transcript, 8 July 2008. 
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Flower: In your talk, I was interested in how you contrasted the styles of the 
different companies in terms of their attitude to clinical pharmacology, and this 
leads me neatly on to the next topic, which is a consideration of whether there 
really is such a thing as ‘the pharmaceutical industry’ as an entity, or whether 
it is really just a collection of individual companies, each with its own style, 
procedures and clinical ethos.
I don’t know whether anyone would like to comment on this: I think John 
Griffin may have something to say about that. 
Professor John griffin: I was pre-warned that I might be asked to make this sort 
of contribution. I’ve had three hats in the last 40 years. I was head of clinical 
research for 3M; I then, after a period of time, became head of the UK drug 
regulatory authority, which was in those days called the Medicines Division; 
and I then became director of the Association of the British Pharmaceutical 
Industry (ABPI). In the 1970s, just after the introduction of the 1968 Medicines 
Act, which came into force on 1 September 1971, having taken nearly four 
Figure 2: a summary of the organization of clinical trials. 
adapted from: www.clinicaltrials.gov/ct2/info/glossary (visited 1 may 2008).
Phase I trials
initial studies to determine the tolerability, metabolism and pharmacological actions 
of a drug in humans; the adverse effects associated with increasing doses; and to 
gain early evidence of effectiveness. may include healthy participants and/or patients  
(c. 20–80 people).
Phase II trials
Controlled clinical studies conducted to evaluate the effectiveness of a drug for a 
particular indication or indications in patients with the disease or condition under 
study and to determine the common short-term adverse effects and risks  
(c. 100–300 people).
Phase III trials
expanded controlled and uncontrolled trials to evaluate the overall benefit to harm 
balance of the drug and provide a basis for labelling (c. 1000–3000 people).
Phase IV trials
Post-marketing studies to delineate additional information, including the drug’s 
adverse effects, benefits and optimal use.
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years to implement, the ABPI consisted of 150 companies or thereabouts, and 
the common bond was that they all supplied prescription medicines to the 
NHS.24 That was the bond that held them all together. This meant that, by 
and large, their profits and prices were regulated through the Pharmaceutical 
Price Regulation Scheme (PPRS). The companies were very different, disparate. 
There were native British companies which conducted basic research, clinical 
trials, manufacture and marketing in the UK, and exported goods from the UK. 
Examples of this are Glaxo, Beechams, Wellcome, ICI and Fisons. There were 
also major multinational companies that also conducted a full range of activities 
within the UK. However, other research-based multinational companies only 
conducted limited activities in the UK; for example, limited phase III or IV 
studies and marketing. Maybe they didn’t even manufacture. Also within ABPI’s 
ambit were manufacturing companies for generic medicines, other companies 
that specialized in the manufacture of specialized formulations, and those 
that were involved in research in delivery systems rather than in new chemical 
entities. It is important to realize that the PPRS didn’t involve all companies 
in the same way. Companies with a large capital investment in the UK were 
allowed profits, which were based on the return on capital. Companies with a 
small investment were allowed profits that were based on a percentage of sales 
to the NHS. Generic sales were outside the control of the PPRS; it was a very 
disparate group. The only thing that bonded them all together was, in fact, the 
PPRS and the fact that they were selling to the NHS. 
The introduction of the Medicines Act of 1968 also introduced a collection of 
disparate activities within ABPI companies. For example, when the Medicines 
Act came into operation, there were 39 000 products that were granted Product 
licences of right. About 6000 of these were outside the remit of the European 
directives that required a review. For example, there were blood products, 
homoeopathic products, etc. So there was an enormous breadth of work that 
was required to review these products. In addition, under the Medicines Act 
1968 there was the need to process clinical trial certificate applications.25 That 
meant that companies intending to conduct clinical studies in the UK had 
to obtain permission to do so. Phase I studies were outside the remit of the 
Medicines Act, so human pharmacology on normal, healthy volunteers was not 
24 The Medicines Act received the Royal Assent in 1968, based on proposals set out in the 1967 White 
Paper (Scottish Office et al. (1967)). For further details see Great Britain (1968); Griffin and O’Grady 
(2006): 457–88.
25 Great Britain (1968): section 31. 
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controlled by the Medicines Act, but phase II and III studies were. In 1971, 170 
clinical trial certificates were granted.26 
The Medicines Division was grossly under-resourced. There were enormous 
delays in handling clinical trial certificates, and by 1981 there were only 74 
clinical trial certificates processed per year.27 So something radical had to be done, 
otherwise clinical pharmacology in the UK was going to suffer enormously. A 
clinical trial exemption scheme (CTX) was introduced, and this stimulated the 
conduct of clinical trials in the UK so that by 1985 there were approximately 
240 clinical trial exemptions issued for clinical trials in the UK.28 The maximum 
was 263 in the year before that. So there was a tremendous stimulus.29 
The other problem that affected the UK was the fact that when the Medicines 
Act was implemented in the early 1970s, it was taking about eight months 
to process an application for a new chemical entity. By 1984 it was taking 
23 months. 
Abridged applications were another problem. I dealt with the problem of 
clinical trial certificates and something having to be done then. In 1982 we 
had an investigation by Sir Derek Rayner, later Lord Rayner, who suggested 
that abridged applications should all be dealt with within two months. We 
had 6 000 applications for abridged applications, variations and generics per 
year. That meant that if all the medical staff were directed to dealing with this, 
they would have to deal with two applications such as this per day, in addition 
to dealing with clinical trial certificates, clinical trial exemptions, product 
licences for new chemical entities, adverse drug reactions and the review of 
19 000 product licences of right still outstanding; an impossible task and grossly 
under-resourced. The next phase, of course, was the even worse scenario that 
had developed by 1986, which set up the investigation by Evans and Cunliffe 
 
26 Griffin (1989): 13.
27 Griffin (1989): 13. 
28 The clinical trial exemption scheme exempted pharmaceutical companies from the need to have a clinical 
trial certificate in order to develop rapid clinical trials for chemicals of interest. See House of Commons 
(1981). Professor John Griffin wrote: ‘Devised by John Long, Assistant Secretary to the Department of 
Health and Social Security, and myself. See Griffin and Long (1981).’ Note on draft transcript, 8 November 
2007. For details see also Mann (1984): 631–2.
29 Speirs and Griffin (1983); Speirs et al. (1984).
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into the operation of the Medicines Division.30 The result was that the Medicines 
Division became a first step agency, and then other factors came in and it later 
became the Medicines Control Agency (MCA) in 1989. It has now progressed 
even further in changing its name to become the Medicines and Healthcare 
products Regulatory Agency (MHRA), but it has the same problems we had 
in 1980.31 So, we’ve always had a problem of under-resourcing the regulatory 
authority, and this has had an effect on the conduct of clinical studies and 
clinical pharmacology in the UK.
Professor david grahame-smith: Observing the working of the Act at the 
time, one of the things that people wondered about outside ‘the business’ was 
whether abridged applications and exemptions from clinical trial certificates 
would, in a sense, be decreasing the effectiveness of regulations – something 
that worried me, because plainly it was possible for things to slip through a less 
rigorous system; but I don’t think it happened. John Griffin probably knows 
better, but I don’t think it actually happened, which was a blessing. 
Professor Joe Collier: I find the position taken about clinical pharmacology in 
this country by John Griffin a trifle bizarre. It was certainly not in keeping with 
my own view but rather more reflected that of industry. It certainly had little to 
do with what I think academic clinical pharmacologists were doing. John Griffin 
said that if clinical trials numbers weren’t to be increased, clinical pharmacology 
in the UK would suffer enormously. This suggests to me that in Griffin’s view, 
and maybe that of others, a primary role of clinical pharmacologists was to 
do clinical trials. I don’t think I’ve ever done an industry-funded traditional 
clinical trial actually, because I’ve spent my whole time doing interpretation 
and transitional studies and many other of my colleagues have done the same. 
If what Professor Griffin implied were true, and that all clinical pharmacologists 
do is to service the industry by doing clinical trials, it would account for the 
failing of clinical pharmacology as a disicpline. 
Flower: John, do you want to get back on that point?
griffin: I think the pressure for looking at the clinical trial certificates and the way 
it was operated came equally from industry and from academia. The number of 
applications for clinical trial certificates that were processed fell, literally, by 50 
30 Evans and Cunliffe (1987). See also Keen (1991); Griffin and Shah (2006): 480. 
31 See House of Commons, Health Committee (2005): 104: ‘We do not believe that the MHRA has sufficient 
resources for effective post-marketing surveillance.’ On the formation of the MHRA, see page 60.
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per cent in ten years.32 And if that doesn’t have an adverse effect on the conduct 
of clinical trials and clinical pharmacology in the UK, I don’t know what does.
Professor tim mant: I think mention has to be made not just of pharma and 
academia, but also of contract research organizations (CROs). May I say a little 
bit of what happened to me? I did a degree in pharmacology – one of the reasons 
I did clinical pharmacology was that I heard the man in front of me (Michael 
Rawlins) speak on variability in human drug response, and it was inspiring.33 I 
had wonderful professors at Guy’s Hospital; Roy Spector, John Trounce and 
then Howard Rogers, who unfortunately died very young. I worked at the 
32 See Figure 3, above. Professor John Griffin wrote: ‘I did not say that the role of clinical pharmacologists 
was solely to conduct clinical trials, although that is certainly within their competence. I agree that clinical 
pharmacology has not developed as we all hoped it would. This is in no small measure due to the anti-
industry stance of some.’ E-mail to Mrs Lois Reynolds, 19 October 2008.
33 Professor Michael Rawlins’ inaugural lecture, delivered at the University of Newcastle upon Tyne on 
22 January 1974. See Rawlins (1974). Professor Mant wrote: ‘Also delivered in London in 1976, which is 
where I heard it.’ E-mail to Mrs Lois Reynolds, 19 September 2008.
Figure 3: Clinical trial certificates (CtC) and clinical trial exemptions (CtX), 1972–1985.  
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Hammersmith Hospital with Colin Dollery for a short time, and then went to 
the poisons unit at Guy’s. That was practical clinical pharmacology, seeing people 
after overdose, and interesting. The academic department of clinical pharmacology 
at Guy’s was involved in conducting drug studies for the pharmaceutical industry. 
We always had a Wellcome registrar and, I think, a Glaxo or Ciba registrar. So, the 
industry was helping to fund the health service in many ways. I remember clearly 
Howard Rogers telling me that if you want to work on new drugs, you have to 
work with the industry, who are the only people who have the finance to develop 
drugs. Certainly, when I saw the standards required to conduct trials to US FDA 
guidelines, I was very impressed. I think it is rather sad that phase I trials have 
drifted further and further from academia. The establishment seemed to have felt 
that industry research was somehow tainted. I don’t know why. I felt academia 
considered industry-sponsored research as somehow inferior, and to be kept at arm’s 
length. We at Guy’s Drug Research Unit started with one full-time employee when 
I first started doing phase I work. The rest were all employed by the university or by 
the hospital. We now employ over 180 people. I think one of the sad things is that 
walls are being set up between academia, the NHS and the industry. We should 
all be working together in this, and I’m hoping that with the way the government 
is supporting translational medicine at the moment we will see better partnerships 
between industry, academia and the NHS. That’s my hope.
Baber: I want to support something that Tim said, and also to come back to 
your original question: is there such a thing as the pharmaceutical industry, 
as opposed to individual companies? When I went to Merck, having worked 
with academic departments, I was aware of a divide, real or otherwise, that 
we were second-rate if we worked in the pharmaceutical industry. And one 
of the ways I tried to tackle this, with three of my colleagues, was to set up 
the Association of Human Pharmacologists in the Pharmaceutical Industry in 
1985. The originators of this were John Harry at ICI, myself from Merck, John 
Posner at Wellcome, and Roy Drucker, who used to work at Sterling Winthrop. 
This has grown enormously now, and Tim will be able to say far more about 
its present form. Originally it was simply a discussion group – not meant to be 
political in any shape or form. There were no publications and no minutes. We 
just met on different premises to talk about common problems, shared by us 
all, such as doing kinetic and dynamic studies. We were very snooty to begin 
with and excluded CROs and this was evidently wrong, but at that stage most 
major companies had got their own trials units. We opened the invitation also 
to non-medics right from the inception. We believed it was very important that 
we had nurses and CRAs who were doing hands-on work. So, at that stage, a 
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number of us who were relatively senior in the industry were worried about 
this potential divide between industry and academia. I want to say that I can 
feel much sympathy for what Tim is saying, even though I am now somewhat 
withdrawn from the situation. 
Flower: So, Arthur Fowle, I’ll put that question directly to you. Did you feel 
when you were at the Wellcome Foundation that you were part of a different 
organization?
dr arthur Fowle: Yes, indeed, I did. I think the last two contributions would 
have been, should have been, displaced. They shouldn’t really have followed Joe 
Collier, with whom I’ve got 100 per cent sympathy. I became head of clinical 
pharmacology at the Wellcome Foundation in 1968, and at the beginning it 
wasn’t really about clinical trials. I think if we got back to pursuing the origins of 
clinical pharmacology, it would be fair to say that when I went to the Wellcome 
Foundation, it dawned on me only after I’d been there for a few years that I 
was a clinical pharmacologist. I didn’t go there as one. I went to the Wellcome 
Foundation in November 1965 and went because it was very uncongenial as a 
senior registrar on an academic unit elsewhere in London. The head of medicine 
at the Wellcome Foundation, David Long, had a brilliant idea and I hope he gets 
some recognition for it. He thought that a good idea would be to be surrounded 
by medical advisors, whom he arranged to hold appointment on an honorary 
basis in academic units around the country; largely in London, of course. The 
advisors only gave opinions and advice to him when it was necessary. That 
seemed to turn out to be about once a month at a meeting in the building next 
door here (183 Euston Road, London, then housing the headquarters of the 
Wellcome Foundation), and for the rest of the time Long’s staff went about 
doing clinical research in various units around London. I followed the same 
system. First I had remained senior registrar for a further year in the cardiac 
unit at the Middlesex Hospital, London, until I became locum consultant, then 
got a part-time consultantship in the NHS. I was followed by a team which 
we eventually built up, and where there was a certain irreverence about us all, 
which was due to the fact that we had mostly come from the Hammersmith 
Hospital. And when I got in charge at Wellcome, I actually inculcated more or 
less the atmosphere of the lower medical corridor.34 The kind of work I did was 
to look at pharmacodynamics, and that seemed to be successful.35 Our outlook 
34 Dr Arthur Fowle wrote: ‘This was a well-known part of the Hammersmith Hospital where staff of the 
medical unit worked.’ Note on draft transcript, 19 November 2007. See Booth (1985).
35 See Fowle et al. (1971).
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on success was to write papers for Clinical Science or to address the Medical 
Research Society. That was what gave us pleasure and nobody stopped us doing 
it. It was only after a while, after Colin Dollery published a lot on cardiovascular 
system pharmacodynamics, we began to realize, ‘Well, perhaps we are clinical 
pharmacologists.’36 I was then made head of a clinical pharmacology department 
in 1968. Before that, we did things because they seemed to be worthwhile. It 
was successful because David Long saw to it that he only employed people with 
the membership of the Royal College of Physicians, which made it rather easy 
for dealing with the board of the Wellcome Foundation as to the level of our 
remuneration. This was also really quite a good political move. So, we were all 
very much the same kind of people, and doing similar things. I have to admit 
that, then, I had never heard of clinical pharmacokinetics. It was a revelation to 
me when we began to study pharmacokinetics. And at the time of the digoxin 
debacle,37 which was after I’d been in the business quite a long time, it occurred 
to me that many of the great and the good in clinical medicine also had not 
heard of pharmacokinetics, and even if they had, they didn’t believe in it. In fact, 
I was hauled over the coals by some very eminent people with whom I’d worked 
at the National Heart Hospital for interfering with their use of digoxin, because 
it hadn’t occurred to them that when a drug was administered pharmacokinetics 
really mattered; you could not take absorption and dissolution for granted.38 
The problems we had with digoxin were met rather unsympathetically by the 
great and the good in cardiology. Even at that time pharmacokinetics hadn’t 
made a very big mark, and I own, what was to me a revelation, was one of John 
Wagner’s early papers, which obviously made it an exciting subject to study.39 
His conclusion from the pharmacokinetics of tetracycline was that you should 
use many more doses of tetracycline than I knew was clinically necessary.40 So, 
it wasn’t always that pharmacokinetics gave the answer, but it certainly became 
a very interesting subject to study. At the Wellcome Foundation I was given the 
job of setting up the clinical pharmacology unit and recruiting more people 
like myself by Dr David Long, head of the medical division. And I’ll hand 
over to Tony Peck in a minute, who was very successfully looking after the 
psychopharmacology side of events. But at the beginning, like Colin Dollery, 
36 See Dollery (2006). 
37 See Staff reporter (1972). 
38 See Johnson et al. (1973); Johnson et al. (1974). 
39 Wagner (1967a). 
40 Wagner (1967b).
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whose background was largely in cardiovascular research, most people in the 
early days of clinical pharmacology had a background in cardiology. That was 
probably because when cardiology blossomed at the time of Paul Wood’s pre-
eminence,41 it was the branch of medicine which was given most to clinical 
investigation. There was more money associated with starting off a clinical 
cardiac unit with a catheter lab; it cost a lot of money. And it was not surprising 
that most of the work that we did in the beginning was cardiovascular. That 
suited the Wellcome Foundation, because it itself was strong in cardiovascular 
research. In fact the non-cardiovascular research was also due to the business 
outlook of the Wellcome Foundation. It was very strong in immunological 
compounds. It had a huge and highly respected capacity for making 
immunizations against various things. And also there was an Empire Preference 
when I first joined there, which helped the company sell drugs in various parts 
of the world where tropical medicines were much in demand.42 Gradually 
we moved away from that as clinical pharmacology became the subject that 
we all now recognize. But it certainly wasn’t recognized when I started 
in 1965. I have to say that I knew about a clinical pharmacology book, 
which I regarded as a good book, and along the lines of Samson Wright’s 
Applied Physiology, which I thought was just about the best book I ever 
read as a medical student, but it didn’t actually turn me into an applied 
physiologist any more than the first clinical pharmacology textbook turned 
me into a clinical pharmacologist.43 It didn’t start like that, good though 
those books were. It required something different for a subject to really 
blossom, as I think Joe Collier was indicating, into largely the study of 
pharmacodynamics in the first instance, even including what we came to 
call phase I studies and the first testing of drugs in humans. And because 
ethics wasn’t controlled by ethics committees in those days, it so happened 
that I took ten drugs myself for the first time in the course of drugs coming 
into the medical department.44 Another thing which would cause a gasp 
now but didn’t cause a gasp in those days was that I didn’t pay any of 
41 See Silverman and Somerville (2000).
42 See Church and Tansey (2007): 227–32.
43 Laurence (1963); Wright (1934). 
44 For details of the development of research ethics committees, see Professor Desmond Laurence’s note 
on ‘The initiation of research ethics committees in the UK’, which has been deposited along with other 
records of Reynolds and Tansey (eds.) (2008b) in archives and manuscripts, Wellcome Library, London, 
in GC/253.
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the volunteers. We had 1500 people on site when we decided to move 
down to Beckenham from the place next door here (183 Euston Road) and 
everybody was keen to take part. It never occurred to us to offer to pay 
anybody, everybody was very pleased to take part.
Flower: You seem to be saying that some people are born clinical pharmacologists, 
some people become clinical pharmacologists, and some have clinical 
pharmacology thrust upon them!
Fowle: Yes, indeed. I wonder whether the discipline is a ‘busted flush’ or whether 
it doesn’t exist any more.45
Flower: I’d like to ask a couple of other people about their views on the ways 
that clinical pharmacology started in their neck of the woods. Peter, do you 
think there is such a thing as a pharmaceutical industry – or simply a collection 
of individual entities?
dr Peter lewis: I joined industry from Colin Dollery’s department at the 
Hammersmith in 1983. I went to France to work for an international company, 
Merrell Dow at the time, it’s now gone through a number of transformations, 
and I can’t remember quite what it is called any more.46 
On the subject of whether companies are all the same or different, I was very 
struck by what Nigel Baber was saying, as I had exactly the same experience. I 
went to work for a US company, although the research centre I was responsible 
for was located in France. They shared Merck’s attitude to clinical pharmacology: 
nothing in-house: ‘Go somewhere and get it done.’ I found that quite frustrating 
because I’d been doing quite a lot of phase I work and I naturally thought I 
could do some in-house. Of course one couldn’t do clinical studies in healthy 
volunteers in France at the time because it was forbidden by law, but we had 
a little lab over the border in Germany, not far from Strasbourg, and there 
was a phase I effort there, carried out by our German colleagues on a very 
45 Dr Arthur Fowle wrote: ‘In about 40 years clinical pharmacology has become an essential part of general 
medicine. Recognition of the subject has entirely succeeded in its purpose. Specialist teachers of the 
subject should therefore become less essential and “consultant” status for specialist clinical pharmacologists 
correspondingly harder to justify. At the meeting today I have heard of one teaching department (St George’s, 
University of London) proud never to have conducted a clinical trial or perhaps taught the art of them (see 
page 16). I regard the clinical trial as the only sure proof of clinical efficacy, even when it is not the highest 
intellectual medical endeavour. Perhaps industry will become the natural home for the specialty.’ E-mail to 
Dr Daphne Christie, 7 January 2008.
46 Merrell Dow became part of Sanofi Aventis in 2004. See Irwin (1994). 
Clinical Pharmacology in the UK, c. 1950–2000: Industry and regulation 
20
small scale, a few studies a year. When I arrived in Strasbourg, I discovered this 
in-house clinical pharmacology unit in Freiburg, and so I was naturally very 
interested to go and see them. And I found – I was absolutely horrified by what 
they were up to – that they were doing phase I studies but in a very peculiar, 
Germanic fashion, in that the young volunteers who were being exposed to 
our compounds were being forced to do numerous psychometric tests, so it 
was impossible to find out whether there was any drug effect or not because 
they were so consumed with mental arithmetic. So, that was a bit of a frost. 
I had rather a lot of difficulty converting them to what I thought was a more 
reasonable way of doing things. 
I think the US companies generally didn’t like doing clinical pharmacology or 
human experimentation in-house, and there was a completely different ethos 
among the mainstream British companies, who were quite keen on employing 
clinical pharmacologists and on doing in-house research. Apropos of who 
the clinical pharmacologists were, I think that there were very few people 
who were ever actually recruited from clinical pharmacology departments in 
the UK into pharmaceutical companies. When I joined the industry in 1983 
my experience was that most of the people whom I came across in industry 
had actually acquired their clinical pharmacology knowledge in-house while 
working for the pharmaceutical companies. There are quite a number of good 
examples. It was very difficult in my personal experience, and that of others, to 
prise anybody away from a clinical pharmacology academic unit in the UK to 
go and work in industry. There was a terrific barrier. Generally speaking, our 
medical people who came to work in clinical pharmacology were recruited into 
industry at a junior stage when they were senior registrar or registrar and then 
they were either sent on courses or educated up in the company itself, and that’s 
how the industry got the majority of its clinical pharmacologists. That was my 
impression. I checked this on the telephone this morning with Tony Chandler, 
whom many of us here must have received gratifying phone calls from when he 
was running Talentmark and one of his activities as a headhunter was to try to 
poach people from academic work to work in pharmaceutical companies. And 
he shared with me this morning his experience: it was extremely difficult to get 
people out of academic units into the pharmaceutical industry. 
My own case is, I think, illustrative. I was in Colin Dollery’s department for 
quite a long time, and at his festschrift I was asked along to talk about the 
industry, because basically there wasn’t anybody else who could do so, because 
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none of them had actually joined the industry.47 They had a lot of contact with 
industry in different roles – a lot of them are here – but nobody had actually 
made the jump and left academia and joined the industry. So, I was very much 
the exception. In fact, for Colin’s festschrift I did a headcount of the members 
of the British Pharmacological Society (BPS).48 At the time there were 2300 
members; about 25 per cent of them had an industry address – presumably 
they worked in industry. But of those, I was only able to identify 32 who were 
actually clinical pharmacologists. And that was an arbitrary definition on my 
part; they had a medical degree and they had some postgraduate training or 
contact in clinical pharmacology before they joined industry. It’s a very small 
number. When you’re talking about clinical pharmacologists in industry, I 
think it was largely home-grown, I mean the transformation of people inside 
the company, rather than academics joining the industry.
Flower: That’s very interesting. I’m going to ask Tony Peck if he wants to 
comment on that and then I will go to Ray Hill. I’d like to try to pursue this for 
a few minutes longer because I think it is a very interesting topic.
dr anthony Peck: Well, I certainly joined the Wellcome group from a background 
of dissent. I was utterly dissatisfied with the outlook, at least for myself, in the 
health service and in academia, in 1969, when I returned from a year in the US. 
And there was Arthur Fowle, and in particular Douglas Munro-Faure, who really 
should have been here today, but alas, he said he’s a bit too old to come along. 
He was the one who got my interest going in clinical pharmacology. I wanted 
to do human pharmacology, but I saw no chance for it at all in my old stable 
in the Middlesex. At Beckenham (the Wellcome Foundation research base), 
Munro-Faure gave me the problem: ‘Here’s a compound, benzylpiperazine, 
the basic pharmacologists say it might be an antidepressant. I think it’s a pep 
pill. Sort it out.’ Arthur had, by that stage, organized a soundproof room at 
the buildings at Beckenham, for four subjects, designed to be equivalent to 
the one in Baltimore that Horsley Gantt had built (the Pavlovian Laboratory, 
Johns Hopkins University, Baltimore, Maryland), Horsley Gantt being the last 
Westerner to work with Pavlov. Anyway, I inherited this question: ‘How do you 
sort out whether something really is a pep pill or not?’ Rather than reinvent the 
wheel, we had the philosophy of going along to groups who have got tests to tell 
you whether a drug was alerting. I went along to Bob Wilkinson at the Medical 
47 George (1996).
48 The BPS was established in Oxford in 1931. See Reynolds and Tansey (eds) (2008b): 121; Cuthbert 
(2006); Bynum (1981).
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Research Council (MRC) applied psychology unit at Cambridge, and he was 
enormously helpful, and gave me his audio vigilance tapes.49 I copied them 
there and used them, and, of course, our benzylpiperazine was monumentally 
alerting.50 We used a group of subjects that we had at Beckenham, who were 
mainly pretty informed people who understood what you were trying to do – 
they were all our scientific colleagues. Then after that – another feature of our 
unit was that when we couldn’t do something ourselves we took it outside to 
units – we went out to Whitchurch Hospital in Cardiff, where Merdyn Evans 
had a group of post-amphetamine addicts, and we set up studies with design 
help from Hubert Campbell. Of course, they liked our compound better than 
amphetamine, and it did the same sorts of things to them. So my first lesson 
in the industry in the first year or two: if you can axe a drug fairly quickly 
before it goes into patients, that’s a great service to the company. So we axed 
benzylpiperazine and we published the work.51 It has taken 30 years for that to 
be rediscovered in the literature and the substance is out there on the streets 
being abused.52 So that, sadly, was not a good point. 
But then I went for 11 years before I got a new compound which was likely to 
be a product. Munro-Faure would often ask: ‘Have you got a product, Tony?’ 
And usually I said, ‘No.’ But then we got one. From 1975 onwards, the ‘basic 
boys’ developed lamotrigine, which eventually became Lamictal, and it’s used 
in epilepsy.53 And by that stage, of course, all we wanted was a better phenytoin 
and we would have settled for phenytoin with half-decent pharmacokinetics.54 
Pharmacokinetics bores me to tears, as I think it does many people, but to see 
those first plasma concentrations of Lamictal, lamotrigine, coming back from 
those first studies and seeing that it had first-order kinetics and linear handling, 
that was a very exciting time. Then, to work out the human pharmacodynamics 
and compare it with phenytoin in the lab, we went to Tony Nicholson and Dick 
Borland, and got their adaptive tracking stuff from the Royal Air Force Institute 
of Aviation Medicine (Farnborough, Hampshire) and set up those tests and 
could see that it wasn’t as impairing as phenytoin and diazepam. So we were 
49 See Reynolds and Tansey (eds) (2003).
50 See Campbell et al. (1972); Campbell et al. (1973).
51 See note 50, above.
52 Brennan et al. (2007); Butler and Sheridan (2007).
53 Peck (1991); Cohen et al. (1985). 
54 Hvidberg and Dam (1976).
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into epilepsy trials. Then of course, it had to leave the Wellcome Foundation 
because we were by then looking for surrogate endpoints in epilepsy patients – 
because we couldn’t test for these on healthy volunteers. Down the road at the 
Maudsley Hospital, London, was Colin Binnie with photosensitive epilepsy, and 
Alan Richens, of course, over in Cardiff, and Chalfont.55 So we were exploring 
their expertise in surrogate endpoints before anybody had ever mentioned 
surrogate endpoints. And that was really very satisfying, and we carried on and 
got, we think, a better phenytoin.56 The lesson to me was the importance of 
axing compounds early on if they’re not going to be any use. Additionally, it 
is terribly important in clinical pharmacology not to try to reinvent the wheel 
when there are units out there that can help you with methodology that will 
be useful, like Nicholson and Borland, and Wilkinson – the work had all been 
done before and we used it. 
dr robert smith: I want to talk about pharmacokinetics because we’ve 
alluded to it a few times, occasionally in a dismissive air, if I might say so. I 
was in clinical pharmacology in Sheffield and went on sabbatical to the US, 
particularly to learn more about pharmacokinetics with John Wagner, for nearly 
two years.57 Of course, he had other postgraduates who were going through his 
unit. Even before I came back to Sheffield I started looking around for suitable 
British people who were trained. As it happened, three of them were already 
in the US and I encouraged Geoff Tucker to join the unit in Sheffield and 
there he remains. But I think pharmacokinetics has made a great difference to 
this specialty, especially in industry. Once you’ve got that information, you can 
begin to plan your development programme far more sensibly and avoid a lot 
of pits that you may otherwise fall into. 
Flower: I’m going to ask Ray Hill to talk now. We’re still trying to pursue 
this thread of discussion about whether there is a separate industry or many 
individual entities, as well as listening to reminiscences about the early days of 
clinical pharmacology.
Professor ray hill: Yes, I think that there are different styles between US 
and UK companies, or there were before all the companies started merging. 
I suspect that many of those differences have now gone. But I think that my 
55 The Chalfont Centre for Epilepsy, Buckinghamshire, is run by the National Society for Epileptics. Binnie 
et al. (1986); Jawad et al. (1986). See also Peck (1991).
56 Steiner et al. (1999). 
57 John Wagner was professor of pharmacy at the University of Michigan (1968–82). See also page 17. 
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own memories come obviously from the side of the basic scientist who, I think, 
has always found clinical pharmacologist colleagues to be absolutely invaluable 
at the transition stage from discovery into development. I can remember my 
first experience, actually talking to Tony Peck when I was a graduate student 
and was working with colleagues in pharmacology on molecules that gave rise 
to lamotrigine some five years later, and saying what we would like to do if we 
ever got a molecule that had the right properties. I think one of the problems is 
synchronicity. You put a phase I unit in place for that drug when you discover it, 
but you can’t always guarantee that the discovery scientist will produce the drug 
in the right timeframe. And events in Merck gave a very good example of putting 
a phase I unit into Terlings Park (Merck Neuroscience Research Centre, Harlow, 
Essex), where the phase I unit had almost closed before the first development 
compounds came through some ten years later. It’s very important, I think, 
to have a dialogue between the clinical pharmacologist and the preclinical 
pharmacologist to make sure that things that you’ve seen preclinically don’t get 
rediscovered when you get into the human. And then if you do see something 
unexpected, you can go back and talk to the people who have done the animal 
work. And certainly in developing the triptan rizatriptan at Merck, I think the 
dialogue between the clinicians and the preclinical scientists on the same site 
really saved us a lot of time and stopped us going round in circles.
grahame-smith: Could I ask the clinical pharmacologists in industry a question 
that from time to time has disturbed me? How often have they felt threatened, 
constrained or irksomely influenced by the ‘marketing men’ who want to get on, 
when in fact the clinical pharmacologists, the clinical scientists, know that there 
is still a lot of work to do with the compound in humans before they can take the 
next step? Just how often – I have certainly seen it happen – in the wide experience 
of people here has that happened? It’s a very, very important matter.
Flower: Both Bob and Nigel have their hands up immediately so you have 
obviously touched a raw nerve there.
smith: I think, first of all, it depends on your own personal attitude when 
someone is trying to pressurize you. You also need a very good boss. When 
I joined Glaxo I had David Jack, and nobody would push him around.58 The 
marketing people would keep away from him. Before that I was in Roche and 
I was responsible for new drug development internationally as medical director 
in Basel. There was a long history of marketing people beginning to influence, 
58 See Jones (2001): 326–30. 
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if they could, the development programme. And, needless to say, I fought hard 
to reduce the number of compounds in development. You’d be amazed that 
when I arrived I had 134 products in some stage of development in the medical 
division, which is impossible. I recommended that we got them down to 23 
and we compromised on 34. That was not a popular move, although it was very 
popular among the staff who had to handle the workload. I only stayed four 
years with Roche.
Baber: The short answer is that I never felt pressured by the marketing 
people in any of the three companies I worked with. I actually enjoyed the 
interaction because, particularly as time went on, they recruited brighter 
and brighter guys and girls into the marketing department, PhDs and so on. 
You could have a real rough and tumble discussion with them. One occasion 
when I could have been under pressure – Bob Smith will remember this – 
was when we were getting very worried about these funny pressure symptoms 
with sumatriptan. The drug was well into patients by then and clearly had 
the potential to be a very big blockbuster. I thought, ‘I’m going to have to 
go and tell a certain Dr Richard Sykes (research and development director) 
about this.’ So I went to see him, and I said: ‘Look, you’ve got to know 
something. This could kill this drug, or at least result in some very severe 
warnings.’ He was fine about it. He wanted to know the facts, exactly what it 
meant, and what the implications were. No, all right, he was not a marketing 
man, but he was in charge of the research and development directorates. So, 
I had no concerns or pressures which were ever unduly brought to bear on 
me in my career.
lewis: I actually had the reverse experience. I was always trying to save drugs 
that the marketing people were not in the least interested in and tried to kill 
off. I remember my best triumph in that,59 we had an antibiotic – teicoplanin 
– which was a very narrow-spectrum agent, only effective on Gram-positive 
organisms.60 This was the time when everybody had a ‘gorillamycin’ that killed 
everything. So something with a narrow spectrum was thought useless. I pleaded 
in vain that aztreonam was doing well, and that was a narrow-spectrum drug 
for Gram-negatives.61 But there was a big argument about teicoplanin and they 
thought it was absolute rubbish and tried to kill it off. I remember a phone call 
59 At Merrell Dow in 1983. 
60 See Lewis et al. (1988); Babul and Pasko (1988).
61 See Reynolds and Tansey (eds) (2008a): 54.
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in the middle of the night from the big boss in the US saying that they were 
just about to start a large feedlot experiment on a Texas farm, feeding this stuff 
to steers as a growth enhancer, and was I sure that the drug was actually likely 
to be a pharmaceutical, because if it was, he was going to have to kill off this 
experiment. They were, however, going to lose $2 million, because the farmer 
would have already prepared all the steers. So it was one of those moments.
Flower: Did you go back to sleep again?
lewis: Well, it took some years for me to get my equilibrium back, but it 
actually turned out to be the most successful drug I’ve been associated with in 
the industry. Not saying an awful lot, but anyway, it’s still going and, you know, 
it did well. But the company was risk-averse at that time; they had had some 
nasty experiences, and the last thing they wanted was anything that was going 
to go wrong. The marketing department only wanted blockbusters. That’s one 
of the terrible things; nobody wants ‘niche products’ and it has gotten worse 
and worse and worse. If you can’t show that this compound is likely to be 
a billion-dollar agent, nobody’s interested. So it’s very difficult for people in 
pharmaceutical industry research to keep working on things that might turn 
out to be interesting, because they tend to get killed off at a very early stage. 
dr Julian shelley: The pressure I experienced was actually from the preclinical 
side.62 We had project teams that comprised members from pharmacology, 
biochemistry, toxicology, pharmaceutical development and medicine. When 
we got into phase I and early phase II studies, the pressures to continue with 
the drug actually came from the preclinical representatives of the project team, 
because the marketing people were not members of the project group at that 
stage. So, my pressures were actually from pharmacology mainly.
Peck: Very briefly, I had to pressurize the marketing people in the Wellcome 
Foundation because in 1975 the entire anti-epileptic market was worth something 
like £29 million and they had no interest whatever in a new anticonvulsant. It was 
only when the problems of phenytoin really started to appear, that the zero order, 
saturation pharmacokinetics and the toxicity problems ensued, and suddenly they 
saw valproate taking off, that it was possible to get any interest at all.63 
62 At C H Boehringer Sohn, between 1975 and 1990. 
63 See Richens and Dunlop (1975); Richens (1979); Jeavons and Clark (1974); Hassan et al. (1976).
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Flower: It’s the prostacyclin story again, isn’t it?64 Andrew Herxheimer, do you 
have any concerns about the relationship between the marketing side of the 
pharmaceutical industry and the scientists and clinicians who develop and 
test drugs?
dr andrew herxheimer: I think that the power relationships within companies 
are crucial to that. If the senior managers are on the marketing side, then what 
they say goes. On the other hand, if the people who have clinical experience 
and their feet in clinical reality can resist that, then things can be balanced. So 
I think from that point of view, it would be quite interesting to hear about the 
culture of different companies: how leadership gets allocated to different kinds 
of people, and how they behave when they are leaders. Some leaders just change 
when they become leaders and include everybody in an even sort of way, but 
I don’t think that’s so likely with marketing people. But that is just my gut 
feeling. I have no data. We want to hear about experience.
Fowle: I want to point out that you’ve had a range of replies to the question: 
‘What was the pressure?’ I wouldn’t say it was always pressure, but there was 
always an interesting discussion that went both ways. I made a discovery very 
early on that nitrates applied to the skin caused venous dilatation. This was 
not recognized physiology when I discovered it; it was thought that nitrates 
went into the system and worked centrally, but they clearly didn’t. There was 
vasodilatation and we were trying to get the Wellcome Foundation interested 
in it. And as Peter Lewis said, you can’t always get them to take an interest. I 
do share their problem, and I’d just like to point it out to you. I thought it was 
a little unfair of marketing, but the argument they would use to me was: ‘If we 
try to make this drug, we have to divert our resources from something which is 
making a great deal more money, and that’s not a very good idea for something 
as minor as a local vasodilator.’ They took a punt as to how big a market it 
would have been. Possibly they got it right, but it was an argument that was 
very difficult to resist, and I did feel slightly aggrieved that they wouldn’t accept 
that. Neither would they accept a very nice device we got, a sort of dipstick to 
make a very rapid diagnosis of urinary tract infection, which also would have 
been very handy clinically. But I accept their argument that to make it would 
64 Professor Rod Flower wrote: ‘This refers to a power struggle between the scientists and the marketing 
division at the Wellcome Foundation which followed the discovery of prostacyclin. It was said that there 
was no market for a drug of this type by the marketing division, but nevertheless it was finally licensed 
and sold. It still brings a regular income.’ E-mail to Mrs Lois Reynolds, 14 July 2008. On the discovery of 
prostacyclin, see also Reynolds and Tansey (eds) (2005): 52–3. 
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divert resources from something that was making a great deal more unit profit. 
I throw that in for the sake of fairness.
Professor sir Charles george: Two points: having looked at the fate of people 
who are senior registrars or lecturers in academic departments, I think David 
Grahame-Smith exported more of his trainees into the pharmaceutical industry 
than anybody else’s unit in the UK. 
The second is, given the fact that we’ve heard that quite a lot of people in 
industry learned their clinical pharmacology while being employed by the 
industry, we shouldn’t forget that two things happened: first of all, the diploma 
of pharmaceutical medicine (DipPharmMed), for which there was a syllabus that 
included aspects of clinical pharmacology, and then subsequently the creation 
of the Faculty of Pharmaceutical Medicine, which I think has done a lot to raise 
awareness of clinical pharmacological principles within the industry.65
Professor owen Wade: May I ask you, or the people here, about the other way 
around: people coming from industry into academic work? Robin Shanks came 
to me at Queen’s University, Belfast from ICI, and I’m sure this was certainly a 
very valuable thing for my department. And between 1975 and 1977 Martin 
Kendall went from my department in Birmingham to industry for a bit and 
then came back. This was, I thought, very valuable.66
Baber: Just a brief comment on my own case. I had the privilege to work with 
Alasdair Breckenridge and Mike Orme while I was at ICI. For that whole 
nine years, I had a position at Liverpool University with the department of 
clinical pharmacology and spent one, sometimes two, days a week over there. 
So, I probably fall very much into that camp of learning much of my clinical 
pharmacology, if not most of it, while I was actually employed in the industry. 
It was a great privilege to have that opportunity, working with that company. 
But I think there were a number of clinical pharmacologists in industry who 
probably did have academic appointments, but who did not move completely 
back into academia. 
65 The Faculty of Pharmaceutical Medicine of the Royal College of Physicians was formed in 1989, see www.
fpm.org.uk. (visited 9 July 2008). For details on the DipPharmMed see www.fpm.org.uk/examinations/
dippharmmed (visited 5 June 2008).
66 One of the best known examples of such movement is the career of Sir James Black. After lecturing at 
the universities of St Andrews, Malaya and Glasgow, Black worked in industry for ICI and Smith, Kline 
and French. He then became professor of pharmacology at UCL. From 1978 he moved back to industry as 
director of therapeutic research for the Wellcome Research Laboratories, then returned again to academia in 
1984, joining King’s College London as emeritus professor of analytical pharmacology.
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lewis: Apropos of that point, when I joined industry from the Hammersmith, I 
asked Colin Dollery what would happen if I didn’t like it. And he said, ‘If you’re 
not back within two years, forget it.’ 
Flower: John, would you like to comment on this? And while you’re at it, I 
wonder if you could add a few remarks about the ABPI, which you touched 
upon briefly a few minutes ago?
griffin: I’d like to pick up on the point that Nigel made about having days seconded 
out into academic departments. When I was working in the pharmaceutical 
industry, I was privileged to have two days a week working with Paul Turner at 
Bart’s, and that was extremely valuable.67 That was something that continued 
on a one-day-a-week basis when I moved into the Medicines Division of the 
Department of Health and Social Security (DHSS) in 1971. This is something 
that was encouraged and I’m not sure that it’s still being encouraged. I think it 
would be very useful for young doctors doing clinical pharmacology within the 
industry and in the regulatory authority to have the opportunity that we had.
As far as ABPI is concerned: since I left ABPI they’ve started sponsoring clinical 
pharmacology within the industry and/or academia. I don’t know whether 
anybody would like to comment more on that, because that happened after I 
left, but I think it’s a very useful initiative. 
Baber: Yes, this was an idea which was, if I may say, designed by Morris Brown 
and myself on the back of an envelope one day.68 This is when I was at Glaxo. 
It may be possible to get funding, I suggested, from the postgraduate deans 
or whoever it was at the time, to finance half of a clinical pharmacology post, 
say at registrar level, and industry would fund the other half. I talked to many 
of my colleagues in industry and they thought it was a good idea, that there 
was probably more money available at that time from industry for doing this 
sort of thing. We were able to put the industry part of it in place, and that 
was done eventually through the ABPI. What we hadn’t planned, really, was to 
track the careers of the holders of these joint posts. This seemed to be a very 
welcome opportunity for further amalgamation of function between industry 
and academia. The idea was that the person wouldn’t be pressurised to follow a 
career in either industry or academia: they would make the choice of what they 
wanted to do. I doubt if that sort of thing is going to be possible now with the 
67 Barts and the London School of Medicine and Dentistry, University of London since 1995.
68 See Baber and Brown (1996). 
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current arrangements and training, but it was a good initiative at the time. I’d 
be interested if anybody has comments on that, those who have actually had 
registrars going through this system.
Professor denis mcdevitt: I was just coming back to this point about people 
moving from industry into academia. Earlier we were discussing ICI 50172 
(practolol) that many of us had interaction with.69 My recollection is that the 
two people in ICI who were dealing with it were Mike Barrett, subsequently 
professor of pharmacology at Leeds University, and Desmond Fitzgerald who, 
for a period anyway, became the professor of clinical pharmacology at McMaster 
University, Ontario, Canada.
Professor Brian Prichard: We had two senior appointments of the sort that 
have just been discussed at consultant level. Dr Richard Waldon had a joint 
appointment with Sandoz Basel; this was set up with Dr Walter Aellig, well known 
as a regular contributor to the Clinical Section of the British Pharmacological 
Society.70 Dr Walden had a Sandoz office at UCL to enable him to fulfil his 
industrial commitment, although most of his time – about 70 per cent – 
was spent working in the department of clinical pharmacology at UCL. This 
arrangement went on for many years. Another similar appointment was that of 
Dr Chris Owens. Dr Owens was a senior lecturer in clinical pharmacology and an 
honorary consultant physician at University College Hospital (UCH), in which 
capacity he participated in running a general medical firm. This appointment 
was set up with Dr Denis Burley, medical director of Ciba Horsham. Dr Owens 
spent on average two days a week, 40 per cent of his time, there in Horsham as 
a senior medical advisor, with the remainder at UCL. 
Professor John reid: May I just go back to the Department of Health/ABPI 
training scheme? I have different memories from Nigel of that being set up. I 
certainly attended a meeting with the council of the ABPI plus representatives 
of the Clinical Section of the BPS. We’ve had four people through that scheme. 
Some of them have done very well, some of them have not gone anywhere. 
Aberdeen has a long running programme – we still have someone now who is in 
his third year of a specialist registrar training post. He is funded jointly by Merck 
and the local postgraduate deanery through the scheme. I think overall it’s been 
successful, as our links with both Pfizer and Merck coincided with the existing 
collaboration we’d had in early drug development with these companies. In our 
69 On practolol see page 4.
70 For example, Aellig (1976). 
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case it was used to create an extra academic training slot rather than creating a 
cohort of people to go into industry. 
sir iain Chalmers: I don’t know if one is allowed to do this at one of Tilli Tansey’s 
Witness Seminars, but this issue of movement between industry and academia 
is something in which she’s had a fairly intense interest as a historian herself. I 
would be very interested, if it’s allowed, for Tilli to reflect on the discussion that 
we’ve been hearing.
tansey: Thank you, Iain. I’m very interested, as you pointed out, in this question, 
and I think it is very company-specific. I’m particularly interested in what has 
been said about the differences between UK and US companies. In this country 
we have a very long history of interaction between academia and industry, and 
it started very much with Henry Wellcome, with the Burroughs Wellcome 
Company.71 It was Henry Wellcome who first set up industrial research labs in 
this country that employed people like Henry Dale, George Barger and John 
Gaddum. They all started their research careers in the Wellcome Laboratories 
and then moved either into the MRC or into academia. That established a long 
tradition in this country that it was perfectly kosher to work in industry and to 
move then into research institutes or into universities. And of course Henry Dale 
himself became the first member from the pharmaceutical industry to be elected 
an FRS in 1914. And there was no prejudice – I have looked through minute 
books of the Physiological Society and Pharmacological Society – there was never 
any prejudice against electing people coming from industry. Now, in the US it 
was very different. The American Society for Pharmacology and Experimental 
Therapeutics did not allow members from industry. If a pharmacologist was in an 
industrial position, they could not become a member of that professional body. 
And if a member of the professional body joined the industry, then they had to 
resign from the society.72 That lasted until 1942 and that may account for some 
of the differences that have been raised today about in-house research in British 
companies and European companies, as opposed to the US tradition we’ve been 
hearing about. So, I do think it’s rather different. I also think those barriers have 
actually become less free. I think the barriers have become much firmer in the 
more recent past. And I think there are training issues that have come up that 
71 See Church and Tansey (2007): 475–95. Dr Derrick Jackson, who was unable to attend the meeting, is 
among several others who have made this point and has provided an account of his career in academia and 
industry, which has been deposited along with other records of this meeting in archives and manuscripts, 
Wellcome Library, London, in GC/253. 
72 See Parascandola (1990).
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are very important. But in the 1950s and 1960s from what I’ve been told by 
people like Tony Peck and Arthur Fowle and Douglas Munro-Faure about some 
of these exchanges, it was much more fluid, with people moving backwards and 
forwards. I think, however, it has changed in the past 20 years. 
sir alasdair Breckenridge: When Michael Orme and I were in Liverpool, I 
guess we had about eight or nine of these ABPI-sponsored trainees. I would 
say I would regard about three or four of these as being successful. These three 
or four were people who came into the scheme with the aim of finishing up in 
industry. This was their aim, and they achieved this and they have done very 
well. Those people who had wanted to stay in academia or were open-minded 
about their future, very often resented their time in industry when they felt that 
they were being used as a pair of hands, very often in phase I units, diverting 
them from what they really wanted to do. For those who were interested in 
academia, when we tried to synchronize their work in the department and their 
work in industry so that there was a seamless passage from one to the other, 
this proved incredibly difficult, very often for very good reasons. Either the 
compound they were working on had been discarded, or there were production 
delays. So, I’ve got a very mixed view of the scheme and, as I’ve said already, I 
would regard it as very good for people who would want to go into industry, but 
not for those who wanted to progress in academia.
smith: Nigel and I just exchanged thoughts. I don’t accept Sir Alasdair's 
analysis. Particularly in the last 30 years in the US, I think there’s very good 
interchange between academic departments and the industry. There were 
people going backwards and forwards. If you go to the national meetings, this is 
self-evident. 
tansey: I’m interested in hearing that. One of the things I’m very struck by 
looking through, say, the British Journal of Pharmacology in the 1950s and 1960s, 
is the amount of collaboration between people and interchange between drug 
companies. I’ll be very interested to learn if that’s something that has changed 
in the past 30–40 years. In the 1950s and 1960s, one can read papers where 
there are three or four authors from different drug companies all working on a 
compound together, particularly in tropical medicine.73 
73 Dr Len Goodwin wrote: ‘At that time, relations between scientists in the pharmaceutical industry were 
easy and friendly, and we (Wellcome) co-operated in a study of a whole series of antimony compounds.’ 
Goodwin (1995): 340. For an example of Wellcome/Glaxo collaboration, see Goodwin and Page (1943). 
For earlier evidence of industry collaboration, between Allen & Hanburys and British Drug Houses on 
insulin production in the 1920s, see Church and Tansey (2007): 299–309.
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Baber: Just a quick comment. Again, it’s very Merck-specific, because that’s a 
company I worked for. They supported financially a PhD for a person working 
with me, not a medic, and also with a topic of interest to the company but with 
a good academic background for his PhD. After I left Merck they appointed 
a professor of clinical pharmacology recruited in the US to head up the 
department, so there was an easy passage of academics into Merck.
Professor Cameron swift: A very quick comment, again on the joint-training 
issue. It seems to me that we have anecdotal information with small n-numbers 
to feed back on the success or otherwise of these schemes. We’ve had a couple 
in my own unit at King’s. One, in fact, came to us with a career interest in 
clinical pharmacology, and found the time at Harlow with GlaxoSmithKline 
(GSK), particularly the exposure to high-quality industry drug development 
programmes, absolutely invaluable. The experience broadened his outlook, and 
he has achieved his objective of a senior post in academic clinical pharmacology. 
The other proved unsuccessful, in that he didn’t actually complete the course, and 
ended up in industry without full training as a clinical pharmacologist. I think a 
variety of accidental routes have emerged. It would be very useful, if possible, to 
try to get an analysis of just what has happened with a larger n-number, because 
our perception is of the potential for the scheme to be incredibly successful, for 
the right individuals. It’s good and should be encouraged. 
reid: Simon Maxwell and David Webb are actually gathering this information 
at this time. I recall, within the last 12 months, being contacted about it.74
dr Jeffrey aronson: I was going to make a quick comment about the ABPI 
training scheme. For the anecdotal part, in Oxford we have only had one such 
individual. I think I’m right in saying that he came to us with no intention of 
going into work for a pharmaceutical company. He had a six-year course and 
one year was an attachment to a drug company, GSK. He went off and came 
back as though he had been on the road to Damascus. He left a year early and 
is now very successfully working with GSK. I think that was a success story. 
My view of the scheme that Nigel and Morris instituted, under the aegis of the 
Royal College of Physicians with the ABPI and the NHS Executive, is that the 
intention, as far as I see it, should have been to train clinical pharmacologists in 
academic departments. This would provide academic departments with high-
quality individuals for their purposes, but also enable those who wanted to, 
and that needn’t be all of them, to find a place in a pharmaceutical company, 
74 Heaton et al. (2008). 
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because academic jobs are not readily available, certainly less so nowadays than 
they were. I think that the one story that we had was a success in that case. Now 
the scheme has not completely fallen into disuse, but it has not been formally 
pursued, and we are, as John Reid said, trying to find out what has happened 
to all the trainees that have been through the scheme. David Webb and Simon 
Maxwell in Edinburgh are surveying what’s gone on. We hope that we’ll have 
some information about that to follow up.75 
I wanted also to make a comment about the question about diffuseness of the 
different companies, because I confess that I suggested the question, ‘Are there 
differences between companies and is there such a thing as “the pharmaceutical 
industry” that we all talk about’. And I think my prejudice that there is no 
such thing has been largely confirmed by the discussion today. We’ve heard 
a lot of disparate views on how things are conducted in different companies, 
but I think it is more diverse even than that, because we’ve only heard in the 
main about ‘Big Pharma’, as we call it. We’ve heard about Glaxo, the Wellcome 
Foundation, GlaxoWellcome, GlaxoSmithKline, Pfizer, Roche, AstraZeneca 
and ICI. We haven’t heard about the small drug companies because we don’t 
have people here who have been largely in these companies.76 We’ve had a word 
from Tim Mant about clinical research organizations. We haven’t heard about 
biotech companies, genetics companies or companies that mix pharma with 
genetics. I think there’s huge diversity and I’m not clear at all that we can think 
about a single industry in one word, that we should regard as a single entity, and 
I think – I’d be interested to know what people think – but I think it’s a mistake 
and the public has this view that the industry is one homogeneous mass, and 
it is not the case. There are different companies and they all behave differently. 
I do think that my prejudice in that has largely been confirmed by what we’ve 
heard today. 
75 Heaton et al. (2008).
76 Professor Laurence wrote: ‘After the major success of propranolol Sir James Black proposed to ICI that 
he develop a second class of histamine H2 receptor blocker (cimetidine) that might revolutionize the 
treatment of the peptic ulcer (another potential money-spinner). ICI declined to implement his proposal, 
the consequence of which was that Jim left ICI in 1964 and went to Smith Kline and French. He was 
completely successful there and was eventually awarded the Nobel Prize for these two successes. Once I put 
to Dr Garnet Davey, ICI research and development director, that ICI could have had cimetidine “and you 
let the chance go”. He replied that if Black was unhappy it was best that he should move. He said he had no 
reason for regret. I was dumbstruck. It was then that I realized that a giant private enterprise company could 
be as inflexible as any government department.’ Letter to Mrs Lois Reynolds, 10 August 2008. 
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mant: To emphasize how correct you are, I’m very fortunate in that I work 
with big pharma, small pharma, biotech companies, academia, charities, and 
across the industry, and there are dramatic differences. Often though, it is a 
leading person who has come from academia and is now the medical director 
or the scientific advisor to a biotech company, which is sort of almost three 
men and a dog, and they are often superb. Other people are not so good. As a 
CRO it is fascinating because sometimes you have to provide all of the clinical 
pharmacology backup; other times it is a learning experience from an innovative 
expert. So, complete diversity. 
Collier: I couldn’t disagree with you more, Jeff. It seems to me, that while there 
are differences from one company to another in certain respects, and there 
clearly have to be, from the outside there’s so much that binds them, they can 
certainly be seen as ‘the industry’. They have certain features that are absolutely 
standard: their information requirements; their legal requirements; their profit 
motive; their basic arrangements of determining trials, and so on. So, there’s so 
much about them that’s actually common, you can certainly say: ‘That is what 
the pharmaceutical industry would do, and that’s probably what the individual 
company would ultimately do’, or you can guess what they would do, and 
they’ll do it. I think it has always been so. However, in terms of how clinical 
pharmacologists function within any one company, clearly it is different, and 
maybe that’s why you’re saying it’s different. But from my observations from 
outside, they are very similar. 
Flower: I’d like to change topics now, to discuss, in a bit more detail, the interface 
that developed between academic departments and the pharmaceutical industry. 
Before we began this session, I asked Nigel Baber if he’d very kindly prepare a 
few words on the latter. 
Baber: Again, this is going to be personal recollections. I’m certainly not the 
right person to give a historical perspective from thalidomide to the present day 
– there are others in this room far better qualified to do that than I. I guess you’ve 
asked me to do this because I’ve spent eight years at the MHRA, previously the 
MCA. But I would say that I did not work in the clinical trials unit, which is the 
department which dealt particularly with clinical pharmacology and the post-
CTX system.77 The industry I have described I could perhaps call the ‘golden 
days in clinical pharmacology in industry’, in some ways. It was the days of the 
CTX when we didn’t require regulatory approval but we could move quickly 
77 See note 28.
Clinical Pharmacology in the UK, c. 1950–2000: Industry and regulation 
36
into volunteers after local ethics committee approval. It was the raison d’être 
why US companies wanted clinical pharmacology to be done in their European 
subsidiaries. Of course, a question must arise from that – and I think Professor 
Grahame-Smith touched on it: were we as safe as we could have been without 
regulatory scrutiny? Our guardians were the ethics committees, who had to act 
both as ethics committees and scientific committees.78 I like to think we were 
as safe as now: we had some very tough times getting our protocols through 
ethics committees at the companies for which I worked, when we had company 
volunteer studies, i.e. ICI and Glaxo. For Merck, of course, it was the ethics 
committee associated with the academic centre where we were working. So, 
that’s been the big change for me, the obvious change, this pre- to post-European 
clinical trials directive.79 Even with my time at Glaxo it was still the pre-European 
clinical trials directive. My impression from talking to the managers and people 
working in the clinical trials unit at the MHRA before I left – where, as I said, I 
was not responsible for this part of the business – is that the problems are not so 
much with industry and their protocols, with regard to getting permission to do 
phase I studies, but with academia. I’m sure that Alasdair will comment on this 
as well. I think that might be a very interesting source of debate: were the ethics 
committees in the past adequate to give protection to volunteers? We lost speed, 
time, and I must say interest as well, since the European clinical trials directive, 
because many clinical pharmacologists now in industry don’t do hands-on 
work. Again, I’d be interested in Tim Mant’s comments. When I was in these 
three organizations, all clinical pharmacologists wrote protocols, administered 
drugs and ran studies. And, I suspect, many clinical pharmacologists in the 
big companies now – I do stress the big ones – are very remote. They sign off 
but rarely write protocols; they are organizers and managers. It is a pity there 
aren’t any younger clinical pharmacologists from industry here today to find 
out whether that is true or not. So, I think the divide between the CTX system 
and the European clinical trials directive has made a tremendous change in the 
interface of industry with the regulatory authorities. 
Two quick anecdotes about personal interactions with the regulatory authorities: 
in all my time in industry, I was never asked to appear before the regulatory 
authorities. The CTX system worked very, very well indeed. I completed 
the technical part of the CTX application, then it was sent to the regulatory 
department of the company who did the administrative bit. I once had to appear 
78 See Glossary, page 107; Reynolds and Tansey (eds) (2007): 195.
79 European Parliament (2001).
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before the Dutch authorities when we were about to launch a combination 
of bendrofluazide.80 The authorities wanted me and my colleagues to defend 
the dose that we’d selected for this fixed combination. The chairman was Dr 
Graham Dukes, and it was a very tough couple of hours. The other time was 
with sumatriptan, as I mentioned before, when we had these peculiar chest 
symptoms.81 I actually asked for a meeting with the MCA. I thought we ought 
to go down and talk to them. Pat Humphrey came with me, as did the head of 
toxicology, Michael Jackson, so we could give them a full picture of findings, our 
interpretations of them and what we intended to do.82 And they said, ‘Thank 
you very much, that’s very interesting. We will wait to see further data’. So my 
personal interactions of industry with the regulatory authorities over that long 
period of time were always minimal, and quite benign. 
Breckenridge: To follow up the points that Nigel made: there is no question 
that the European clinical trials directive was welcomed by the industry; it 
was formalizing a procedure that it had followed anyway, and it presented few 
problems. He’s absolutely right: the problems that there have been have been 
with academia, both in terms of the cost of the applications and in terms of 
sponsorship. Coming on to the question of ethics committees, I think it is very 
important to make the point that TGN1412 was an absolutely crucial issue 
for the European clinical trials directive, and for ethics committees.83 Many 
people are now questioning what the scientific roles of ethics committees are 
and whether or not they are qualified to make the decisions asked of them. I 
think one of the shakeouts is going to be the role of ethics committees in the 
light of the European clinical trials directive.84 This is an area that I am very 
uneasy about at the present time.
grahame-smith: Could I give a slightly different angle? In 1988 I met with 
Keith Mant and David Morgan at Beecham’s, when Beecham’s were in the 
process of developing Seroxat (paroxetine) and they, it became apparent, 
wanted some external 5HT know-how; serotonin know-how. We talked, and 
80 See Agrawal et al. (1979). 
81 See note 20.
82 Professor Baber wrote: ‘Pat Humphrey was the lead pharmacologist at Glaxo (Glaxo Group Research) 
on the serotonin programmes. He is largely credited with the discovery of sumatriptan’. Note on draft 
transcript, 8 July 2008. See Humphrey et al. (1991).
83 On TGN1412 see pages 59–60 and Glossary, page 107. 
84 On changes to the role of ethics committees in light of EU Directive 2001/20/EC, see MHRA (2004).
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a unit was established that they supported, within, or attached to, the MRC 
unit of clinical pharmacology. This was mainly concerned with serotonin, both 
its basic pharmacology and its clinical pharmacology, in terms of its clinical 
psychopharmacology, which was examined in the department of psychiatry, all 
in Oxford. And so a unit of about 14 scientists, including technicians and so on, 
was founded just below the MRC unit of clinical pharmacology in the Radcliffe 
Infirmary, Oxford, and ran for ten years alongside the university department of 
clinical pharmacology.85 Now, it’s not for me to say whether it was successful or 
not, because the science moved along from what I would call a straight kind of 
receptor pharmacology to neuro adaptive responses, and the neurobiology of 
neuro adaptive responses, which became very murky indeed, and is still pretty 
murky and very interesting, but a different sort of science to that to which we 
were really used. I thought it was a very good combination of pharmaceutical 
industry’s strategic interest and an academic unit with both clinical and basic 
expertise, which was able to move things along. Now one of the things we haven’t 
really mentioned in terms of research in industry is that views change when 
scientific management changes. In other words, if a senior scientist is brought in 
at some level, to manage things, the views change as to what is useful and what 
is not useful, and what you want to go with, or what you don’t want to go with. 
That can alter relationships within the company and external relationships as 
well, something which is one of those human things, that we all know about, 
but can actually have a big effect upon research and development. 
Flower: A very interesting point. Phil Routledge, I am going to ask you whether 
you had any comments about your clinical trials unit in Cardiff? 
Professor Phil routledge: Yes. Alan Richens set it up – I think in about 1982 – 
and it ran until his retirement about ten years ago. It was very important; I met 
a lot of people in this room for the first time through that unit, and learned a 
lot about the industry. Also it obviously generated income, which was used to 
do research which was perhaps not in the pharmaceutical company’s particular 
interest, but which was of academic interest, sometimes leading to useful 
pharmacology. I always remember it as being a very positive experience, and I 
think that it did encourage us to understand the pharmaceutical industry and 
to work better with them. I think that is always an important thing, especially 
in medicines management, we forget that the drugs we are using are from the 
industry and without them we wouldn’t have those tools. 
85 See Reynolds and Tansey (eds) (2008a). 
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I would just like to comment on the ABPI scheme, because as clinical secretary 
of the BPS I was also involved in the early negotiations in setting it up and I 
believe it has been extremely useful. We actually have one candidate at present 
in Cardiff who is sponsored by AstraZeneca, and I think again it does help us 
to understand the role of the industry and hopefully for industry to understand 
better the role of academia, in us working together. 
Professor michael orme: I just want to go back, since we’ve just mentioned 
clinical trials, as someone who has never actually worked in the pharmaceutical 
industry, because actually I have worked alongside them in a number of 
studies. Clinical trials to me have always been fairly fundamental, but it is not 
the only thing in clinical pharmacology. So, it surprised me slightly earlier on 
when Joe Collier said – I think he said – ‘I have never done a clinical trial’ 
or words to that effect.86 As someone who has had a lot to do with training 
clinical pharmacologists, both in the UK and Europe, I regard clinical trials as 
something that clinical pharmacologists should have done and had practical 
experience. And perhaps Joe now feels differently. 
Flower: Do you feel differently, Joe?
Collier: I have done trials in patients, directed by me, under my own protocol, 
resolving things that I wanted to know. I have not kow-towed to protocols 
thrust upon me by money-making arrangements, and which are not particularly 
interesting to me. So I have done small clinical trials on my own terms. Of 
course, I learned about clinical trials from my reading, but I have not got the 
sort of experience that people in this room have, in terms of managing vast 
clinical trials.
swift: Just a quick point. I have a self-destructive (or perhaps self-interested) 
interest in the general area of ageing and in the need for industry to obtain data 
for drug development relevant to that. In the early stages when that became 
necessary, regulation was very non-prescriptive as to what particularly the 
equivalent of phase I studies in older subjects should contain. Equally, within 
academic clinical pharmacology and our own research interests, there was 
considerable flexibility of approach. The point I am trying to make is that for 
quite a bit of that work it was perfectly possible to have, at a pretty fundamental 
level, an exploratory dialogue between those in industry who for development 
needed to acquire pre-licensing data and ourselves who wanted to know more 
about the ageing process; how it affected drug handling and drug response. 
86 See page 13. 
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Then we could agree protocols that were capable of peer-reviewed publication, 
contributing to the field at a basic level, and also met the requirements of 
industry for drug development. It seems to me that that kind of symbiosis was 
useful and constructive across the divide on both sides.
Prichard: Large-scale trials are clearly very important in the evaluation of new 
drugs and defining their efficacy. I think actually one of the most interesting 
studies that I got involved with was with four different doses of propranolol and 
placebo, in a dose–response study, just asking the patient to record their attacks 
of anginal pain. We got a lovely relationship, everything as good as gazing at the 
guinea-pig ileum, which is something I did for three solid months. 
griffin: The comment I would like to make in summing up whether there is a 
single industry or a diverse collection of companies is: yes. The industry acts as 
a unit, in response to those things that are thrust upon it from outside, whether 
they be regulation or whether they be PPRS. But each individual company has 
its own ethic, its own needs and its own scope of activities. And outwith that 
area they are, or they can be, very diverse. So there are common reactions and 
diverse needs. 
Flower: Well I think that’s a very fair summary, and I think that’s a good point 
to draw the pre-tea discussion to a close. 
So, we shall begin the second part of the afternoon. There is one topic which 
we should have addressed before tea, but didn’t get around to, and I’d like to 
rectify that by asking Andrew Herxheimer to address the subject of whether 
pharmaceutical companies are benign or malign. 
herxheimer: Thank you – I say neither benign nor malign. The industry has 
a critical problem: declining productivity in drug innovation, and it must solve 
it or adapt to it. But for the last ten years it has responded mainly by increasing 
investment in marketing, lobbying and public relations. There was the 
introduction of heavy direct-consumer advertising of prescription drugs in the 
US in 1997, and ever since the industry has pressed to introduce something like 
it elsewhere. And then there has been massive investment to secure forceful and 
systematic involvement in professional, government and public affairs. That’s 
created a new health climate, especially in the US, resulting in over-medication, 
and that poses three threats to public health. One is iatrogenesis, personal 
illness – I was thinking of asking Cameron Swift if there’s a systematic review 
of clinical trials in older patients of withdrawing their medicines, because that’s 
where the problem is most visible, perhaps. But it’s also social and cultural: it’s 
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the spread of health anxiety. The second threat is unsustainable demand, which 
will lead to breakdown of health services, and to divisive inequity and access 
to health services. Thirdly, over-medication strengthens a drug establishment 
that perpetuates under-medication elsewhere in the world. Under-medication 
is the main problem for 2 billion people who can’t get the essential drugs they 
need. Improved access to medicines could save 10 million lives a year. Now, 
what’s this got to do with clinical pharmacology? Well, clinical pharmacologists 
in industry and in government are caught up in all this. They must serve their 
employers; they can’t step out of line or they will be out of a job. So, it’s a pretty 
grim situation, and the reason why they are neither benign nor malign is that 
pharmaceutical companies are socially blind.
Fowle: I’m not erudite enough to take on the philosophical side of what Andrew 
has just said, but I would like to point out that I worked as locum for several 
GPs when I was younger. And some of them used to say to me; ‘No patient 
must leave this surgery without being given a prescription.’ That had nothing 
to do with clinical pharmacology. And also, I formed a view that many of the 
GPs who flourished near teaching hospitals were not so good as those who 
flourished further away, because GPs in my early days were expected, if they 
lived near a teaching hospital, to send their patients to hospital because the 
patients demanded it. The GPs didn’t have sufficient authority, or whatever 
they needed, to persuade patients otherwise. So not all of these bad things about 
prescribing arose because of professionals at the top of the profession, but for 
purely cultural reasons. And I suppose the remuneration of GPs had something 
to do with it.
george: While agreeing with Andrew that there is over-medication, I think that 
we should be aware of the fact that pharmaceutical physicians have an agreed 
code of conduct and very strong ethics guidance as to what they should not do 
within their company if there is pressure on them.87 And that seems to be very 
potent as an antidote to what you just said, Andrew.
Chalmers: I think that the Faculty of Pharmaceutical Medicine is, as far as I 
know, alone among medical organizations in this country to have made some 
very clear ethical guidelines as to how pharmaceutical physicians should behave. 
Because one of my interests is publication bias, I’m particularly impressed by 
the statements they have made about the need to publish research that is done 
on humans. My question is: where on the board of companies is that ethical 
87 Bickerstaffe et al. (2006). 
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dimension? It seems to me that there ought to be, as a matter of course, a 
medically qualified person on the boards of all pharmaceutical companies, 
because otherwise some of the problems that Andrew has described won’t really 
have any ethical reference point in the way that the Faculty of Pharmaceutical 
Medicine has provided through its ethics committee. 
Flower: Joe, did you want to come in on this?
Collier: Yes, I could do that. I just wanted to respond a bit about whether the 
influence of the industry was benign or malign. Years ago I attempted to define 
what academic clinical pharmacologists did, and there seem to me to be four 
key strands: the first is that we teach, primarily medical students and young 
doctors, about medicines and their best use; the second is we advise, and that’s 
pretty broad, but we might advise our trusts, colleagues, ministers, MPs, health 
departments, media, consumers, select committees or whatever, so advice is 
very important; third, as most of us are doctors, we also prescribe; and finally 
our fourth role is to do research.88 Now, when it comes to the first three of 
those – teaching, advising and prescribing – the amount of misinformation 
that I receive from the industry, or the amount of distortion I get from the 
industry, makes them malign, because I can’t necessarily trust them. Trust is 
a real problem. When it comes to research, they are clearly benign in some 
respects, because by the very nature of one’s work with them, they prompt 
change and provide new products, they can respond to your interests and so 
on. So in this last role, provided one can control oneself and them, then I think 
the relationship is a benign one. But in the other three the industry causes no 
end of confusion and difficulty. If the industry was better behaved, a lot of the 
things I do would be unnecessary. So I would say, in three out of the four roles 
of my life as a clinical pharmacologist, the influence of the industry is on the 
side of malign. 
Flower: Does anyone else want to get back on that question before I ask Joe to 
talk about the development of regulation in the post-thalidomide era?
Collier: I’ve been asked to give a bit about the background to the Medicines 
Act of 1968. As I’m sure all of you know it was the outcome – as in many, 
many other countries (apart from the US, which already had legislation in 
place) – of the thalidomide disaster.89 I think everybody was piqued, infuriated, 
88 See Collier and Herxheimer (1991). 
89 See Tansey and Reynolds (eds) (1997): 106.
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annoyed by the claim of absolute safety made by the drug company, ‘safe in 
mother and child’ or something like that, which was clearly wrong and a claim 
for which they had no evidence.90 These and other outrageous and misleading 
claims meant that we needed to introduce tight controls. The Medicines Act 
was passed in 1968 in the UK and became law in 1971. Since then, much of the 
Act has been subsumed into the legislation as it relates to the European Union. 
It is now difficult to discover what the Medicines Act itself still covers and what 
is a specific remnant of the Medicines Act and what effect now relates to the 
European Union. I’m not going to try to distinguish between those, but there 
are differences; for example, in the UK the legal position on the availability 
of a medicine is based on the Medicines Act and states that a drug medicine 
can be sold as a pharmacy (P) medicine, as a prescription-only medicine 
(POM) or as general sales list (GSL) medicine. This differs from the rest of 
the EU where there are only two categories (POM and over-the-counter). As 
might be expected, much of what became European Union legislation came 
from the Medicines Act, while other sections will have been derived from 
other countries.91 The first thing that I want to say is that the Medicines Act is 
primarily directed at controlling pharmaceutical industry practices. It controls 
the manufacture, marketing, supply and promotion of its products. It also, to an 
extent, controls pharmacists and pharmacies. By contrast, it has relatively little 
direct effect on doctors and how they prescribe. People often forget that the 
Medicines Act is not aimed at the actual activity of doctors in their prescribing, 
although it has become part of what people think. It is no surprise, therefore, 
that it directs most of its attention to industry and similarly is very sensitive to 
industry’s needs. 
Let me talk about the history of the Medicines Act. When any agency is 
introducing legislation, there are lobbying groups who work to ensure that 
their interests are reflected in the new law, and the Medicines Act is a very 
good example of what is known as ‘legal capture’. The industry – a powerful 
body – was very influential in determining the contents of the Medicines Act. 
And so, for instance, when one looks at the criteria to be used for licensing a 
new medicine there is no definition in the Medicines Act of relative efficacy in 
clinical practice. There’s no requirement to determine relative efficacy as such in 
90 Dr Walter Kennedy, who was then medical advisor to Distillers, the first company to put thalidomide 
onto the market in the UK, wrote a glowing report on the drug after visiting its German manufacturer, 
Chemie Grunthal. See Tansey and Reynolds (eds) (1997): 116.
91 See Griffin and Shah (2006): 489–534.
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the same way as you might want to look at relative safety.92 There’s no concept of 
the notion of ‘need’ – for many, the question ‘do we need this medicine?’ would 
seem very appropriate. There is no concept of price; indeed price must not be 
taken into account. Finally, there’s no concept of the notion of convenience. 
And, of course, tied in with all this, there was the very powerful notion of 
secrecy, which is set out so forcefully in Section 118.93 Much of this secrecy still 
lingers, which means that if doctors would wish to know how decisions were 
made, they couldn’t easily find out. Now it is improving, but for years it has 
been very difficult to get explanations for decisions made during licensing. 
Another weakness of the Act is that by and large it excludes the involvement and 
interests of prescribers and patients. It is not absolute, but the notion of patients 
being involved in any part of the considerations of the Act has only come in 
recently. It was certainly not part of the Act as such. The idea of prescribers 
being closely involved is equally omitted from the system. So much so that 
on the whole – in my experience and that of others – doctors, prescribers and 
others don’t feel as though they know quite how the Act determines the ways 
in which drugs are controlled and licensed, and with this most prescribers and 
others involved in the use of medicines do not feel as if they own it. I don’t 
know what the situation is in this group here, but I have had two copies of the 
Medicines Act for about 30 years, one of which I keep on my desk at work, 
one at home. I expect no one else here has got a copy apart from those working 
directly in legislation, it’s perfectly obvious. I know Tilli Tansey has one, but for 
a different reason; I’m talking about active clinical pharmacologists. Now, of 
course, those in industry might have their own copies. When I go to meetings, 
it is very common for people not to know things about the Medicines Act, and 
even grand people know nothing, or very little, about it. So, recently there was 
92 Professor Laurence wrote: ‘Bradford Hill (the great statistician, founder of modern clinical trials and a 
delightful man) took a perverse pleasure in reminding the medical members of the bizarre requirement that 
comparative efficacy could not be taken into account, for he was himself a master of comparative efficacy. I 
have no doubt that this requirement was included to please pharmaceutical companies that understandably 
dislike their own products to be inferior or redundant’. Letter to Mrs Lois Reynolds, 10 August 2008. 
93 Great Britain (1968): Chapter 67, Section 118: ‘Restrictions on disclosure of information. (1) If any 
person discloses to any other person – (a) any information with respect to any manufacturing process or 
trade secret obtained by him in premises which he has entered by virtue of section 111 of this Act, or (b) 
any information obtained by or furnished to him in pursuance of this Act, he shall, unless the disclosure 
was made in the performance of his duty, be guilty of an offence. (2) Any person guilty of an offence under 
this section shall be liable – (a) on summary conviction, to a fine not exceeding £400; (b) on conviction on 
indictment, to a fine or to imprisonment for a term not exceeding two years or to both.’
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a very important paper from the British Medical Association about prescribing, 
and they got it completely wrong. They completely misquoted the Medicines 
Act, saying that medicines need a licence before they can be prescribed in the 
UK.94 This is just not so. Now, it’s because no one cares about the details of the 
Act, it is because it’s ‘over there’ and it’s left to other people, because there is no 
ownership, that there’s no reason to work for its change. 
Finally, I want to address how the Medicines Act has worked over the years in 
that, by and large, it’s been reactive rather than proactive. And it has had to 
respond to others saying: ‘That’s wrong’. It could be ministers saying it’s wrong 
due to pressures from other MPs; it could be select committees saying it’s wrong; 
it could be the National Audit Office saying it’s wrong or whoever. So the Act 
itself can be interpreted in various ways, but the implementation of the Act has 
allowed things to seem to go rather wrong, to become rather secretive, to be 
not particularly interested in patients. So, my own view is that while things are 
changing, but very slowly, the Medicines Act has failed patients to an extent, and 
doctors to an extent – by not involving them, not seeing them as important, and 
not having terms of reference which take up their interests – and the same for 
prescribers. If you just compare the wording of the Medicines Act and the terms 
of reference, let’s say, of any single drugs and therapeutics committee, they are 
very different. Drugs and therapeutics committees have relevant considerations 
to medical practice, and, of course, the Medicines Act doesn’t. 
Flower: Since we are in the business of collecting personal reminiscences, is 
there anyone here who would like to talk about their experience on the Dunlop 
Committee? It was a long time ago. Owen?
Wade: I thought you’d start in 1963, which was when the Committee on Safety 
of Medicines (CSM) was created. Our first meeting was in a horrible building 
which is the Ministry of Health building down by the Elephant and Castle, 
London.95 George Godber, Chief Medical Officer 1960–73, assured us that the 
Committee on Safety of Drugs (CSD) would be in business for about three 
years, and then there’d be the Medicines Act.96 We were in business for seven 
94 British Medical Association, Board of Science (2007): ‘Medicines must have a licence, termed a “marketing 
authorization”, to be prescribed or sold in the UK, which is granted if they meet standards of safety, quality 
and efficacy.’ (page 1). See www.bma.org.uk/ap.nsf/Content/evidencebasedprescribing?OpenDocument&
Highlight=2,evidence,based,prescribing (visited 23 June 2008).
95 See Tansey and Reynolds (eds) (1997): 122.
96 Brindle (2008).
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years. I don’t know what you’d like me to say about the CSD. The person who 
dominated it was Derrick Dunlop. I was a very junior member, a tiny chap 
really, and for the first few months of our meetings I kept my mouth shut, 
because Derrick Dunlop – when we first met, in 1963 – didn’t explain to us 
what the remit of the meeting – the CSD – was, and what the limits, what 
our activities were to be, and what powers we had. I learnt all this slowly and 
was then able to make some contributions, but it was a little bit difficult at the 
beginning. The first meeting was in 1963, and we were not supposed to be in 
action until 1 January 1964.97 But at that first meeting we were told about the 
adverse reactions part of the outfit, of which I was a member. We were warned 
about nasty adverse reactions happening with monoamine oxidase inhibitors. 
And we collected up the information about this and sent out the first of the 
yellow letters.98 And we were amazed. Two things, I think, surprised us: one was 
the tremendously adverse criticism, which we received from – let me put my 
glasses on, who was it? It was William Sargant.99 He thought that these drugs 
were wonderful and took great exception to us criticizing them, and I think he 
thought we were actually banning their use completely, which, of course, was 
untrue. I think the other surprising thing for all of us was, when we started – I’m 
talking now about the Adverse Reactions Subcommittee, because that’s what I 
knew most about – we had expected most reports to come from the hospital 
service. They didn’t. Well, not surprisingly, most medicines in our country 
are prescribed by general practitioners, and 70–80 per cent of the reports we 
got about adverse reactions, and the yellow cards we got, came from general 
practice. Chairman, I think there’s a lot more I could talk about but you’ve got 
a lot ahead of you.
Professor sir michael rawlins: Can you ask Owen to tell us about why they 
are ‘yellow’ cards?
Wade: Well, there’s a bit of argument about this, but it just so happened that 
my department in Belfast had some rather cheap yellow paper, which we used 
internally. And it just happened that when we got the draft of the message 
that was going to be sent out to general practitioners about these monoamine 
97 Professor Owen Wade’s own records of the first meeting of the CSD will be deposited in archives and 
manuscripts, Wellcome Library, London, along with the records of Tansey and Reynolds (eds) (2008b) in 
GC/253. The National Archives hold 67 registered files (CSD and CSM series) for the CSD and CSM at 
MH 171 for the period 1963–76.
98 See Tansey and Reynolds (eds) (1997): 119, 123–4. See also Committee on Safety of Drugs (1964).
99 See Tansey and Reynolds (eds) (1997): 124.
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oxidase inhibitors, I read it. It was typical of civil service statements. I knew the 
way it was written would be hated by doctors, so I wrote out what I thought 
they ought to say on the cheap yellow paper. When Lesley Witts, who in those 
days was the chairman of the Adverse Reactions Subcommittee, read out, first 
of all, the one we were presented with from the secretariat, and then mine, 
everybody chose mine. And, it just happened to be on yellow paper, but the 
boys liked that. So that was why we got yellow paper.100
Flower: Owen, before you go, Joe said he felt that the Committee – at least in 
its present incarnation – didn’t really address the needs of patients or doctors. 
What was your experience on that committee?
Wade: Well, I think the Adverse Reactions Subcommittee from 1963 to 1971 
was very much in touch with doctors, who were the people who sent the reports. 
Certainly, I had to go to see doctors sometimes in order to find out a little bit 
more about what they were reporting. The other two committees: Professor 
Hunter of Dundee ran the Clinical Trials Subcommittee and Professor Frazer of 
Birmingham the Toxicity Subcommittee at the beginning. I’m sorry; I just can’t 
speak competently about those other two subcommittees.101
Professor duncan Vere: Briefly; I came into that business a bit later than 
Owen, but certainly on the Adverse Reactions Subcommittee.102 I can only agree 
with what Joe Collier has said. It struck me from those earlier days that the 
whole procedure was in a sort of legal straitjacket. There was always a barrister 
sitting there and he would be asked about interpretation of the Act and so on. 
There were some strange legal rules. I won’t go into all that at the moment, but 
the main problem that I had was the utterly unbiological thinking that was 
involved in some of those aspects of the straitjacket. This was true of the CSM 
and to some extent the Committee on Dental and Surgical Materials (CDSM), 
where there was endless debate about what a device was and what a drug was, 
100 For other versions of the origin of the yellow card for reporting suspected adverse reactions, see Tansey 
and Reynolds (eds) (1997): 111, 117–19, 121, 124 and 127.
101 Professor Owen Wade wrote: ‘These two subcommittees clearly were thinking deeply about the safety 
of patients and the need to get information to doctors about the drugs being licensed, but were not as close 
to doctors as the Adverse Reactions Subcommittee, Professor Witts, Dr Bill Inman and I, were. We did not 
have any barrister present and were a very happy subcommittee under the chairmanship of Leslie Witts of 
Oxford and later under me. Perhaps things changed a lot after the Medicines Act came into action’. Note on 
draft transcript, 20 November 2007. For fuller comment see Wade (1996): 110–14; Inman (1999). 
102 Professor Owen Wade wrote: ‘This became the Adverse Reactions Committee in 1971, after the 
Medicines Act’. Note on draft transcript, 10 November 2007.
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and when you had devices that were impregnated with drugs, you know, it all 
became desperately difficult. But it still had to be within this strange framework 
of legality. And there was a lot of fear about what happens with two things: 
either if somebody protests or is upset and there’s danger of litigation from 
that angle; or if you haven’t kept within the provisions of the Act. I think the 
provisions of the Act are very unbiological here, in fact, in their understanding, 
like lots of things that happen in law and in court.
Wade: I think the Dunlop Committee didn’t have any legal power whatsoever, 
and the advice that we gave to the firms or other people didn’t really have to be 
obeyed, but they did. I remember how amazed my US colleagues were when 
they found out we hadn’t got any power at all, and it was all working with 
goodwill.103 And, in fact, I think the old Committee on Safety of Drugs did do a 
good job. Remember, nobody had ever done anything like it before, and it was 
quite exciting. Certainly I found it extremely interesting. 
Flower: Has anyone else got any other reminiscences about that era or comments 
they would like to make? 
griffin: Joe and Owen are quite right. The Committee on Safety of Drugs had 
no legal force behind it, other than a moral force. And it didn’t take account in 
its justification of putting a new chemical entity on to the market, evidence of 
efficacy. Efficacy was built into the Medicines Act in 1968. Now, there is a flaw 
in the Medicines Act in that you cannot take comparative efficacy into account. 
You can take into account comparative safety or lack of safety by virtue of lack 
of efficacy, but you cannot take into account comparative efficacy. And this is 
still perpetuated in the various EU directives: you cannot take into account 
relative efficacy.104 
I became very unpopular with an article I wrote in the British Journal of Clinical 
Pharmacology in 1981, in which I reviewed the new chemical entities that 
reached the market from 1971 to 1981. There were 204 new chemical entities. 
Of those new chemical entities, there were three new therapeutic concepts. I 
defined a new therapeutic concept as something that enabled a doctor to do 
something which he hadn’t been able to do before. And that covered 12 of the 
103 Professor Laurence wrote: ‘The CSD had no legal authority. Its sanction was to make a public 
announcement that company “X” had marketed a drug against its advice. I doubt that any company would 
risk the consequences of that, I do not know that it was ever implemented’. Letter to Mrs Lois Reynolds, 
10 August 2008. 
104 See pages 43–4.
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204 new chemical entities. So, if you want to look at it, there were 21 non-
steroidal anti-inflammatory drugs and 13 steroids.105 Clearly you could have 
made an argument about need, if you’d had the power. The other thing that 
concerned me, and still concerns me, about the operation of the regulatory 
authority in this period, was the problem of dealing with adverse reactions. 
We had two working parties chaired by David Grahame-Smith, which made 
recommendations.106 And I hate to say it, but none of them were implemented. 
And David, I think they should have been.
Flower: That’s a good point to pull you in, David. What do you want to say to 
that? You could say, ‘I told you so.’
grahame-smith: Well, yes. I’ve got a number of things to say because we’ve 
moved from the Committee on Safety of Drugs, after the Medicines Act was 
published, to the Committee on Safety of Medicines which was established in 
1970, but started work in 1971, something like that.107 
Now, there was one summer afternoon, and I’d only just arrived in Oxford, 
and remember: (a) I didn’t know anything about clinical pharmacology, really; 
and (b) I was professor of clinical pharmacology and was appointed to head the 
MRC unit of clinical pharmacology in Oxford. But just to liven proceedings up 
a bit: I knew all about serotonin and I knew a lot about digoxin. I knew a bit 
about the sharp end of practical therapeutics. But anyway, sitting in my office 
on a nice summer’s afternoon, in came Richard Doll. And he said, ‘Would you 
like to sit on the Committee on Safety of Medicines?’ To which my reply was, 
‘What’s that?’ So he said, ‘Well, you know what it is, don’t be silly’. And so I said 
I’d be interested. So, the weeks went by, as these things go, you know. Looking 
back, I met a number of people and I was introduced to a number of people, 
and I realize now it was the establishment at work. Do you know what I mean? 
The word was being dropped here and there, and ‘Is he a good chap?’ and all 
that sort of thing. So anyway, I went to the first meeting of the Clinical Trials 
Committee, as it was called, and Desmond Laurence was chairing it. I’m sorry 
Desmond isn’t here because he was a great man chairing that committee.108 I 
105 Griffin and Diggle (1981).
106 See Grahame-Smith (1983, 1986).
107 The CSM held its first meeting on 25 June 1970 and took over the work of the CSD on 1 September 
1971. See Griffin and Shah (2006): 473–4; see also Tansey and Reynolds (eds) (1997): 114, 131.
108 Professor Laurence was unable to attend this meeting, but contributed to the first meeting on 6 February 
2007 [Reynolds and Tansey (eds) (2008a)]. 
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wasn’t on the main committee then. And I sat down next to Austin Bradford 
Hill. Now, you know, there are some people who just take your breath away, 
and Austin Bradford Hill was one of those people. I had his book on medical 
statistics and didn’t understand a word of it, because I’m not a numerate sort of 
person. So I sat next to Austin Bradford Hill and we were going through some 
data on something or other, and he handed me an envelope, showing me on its 
back just upright marks as it were, indicating the number of patients in each 
group that was being treated in this particular study. And he said to me, ‘What 
do you think?’ I was greatly heartened that this great man, who knew everything 
about medical statistics and so forth, was relying upon me just looking at these 
little marks on a bit of paper to decide whether this drug was effective or not. 
Flower: We’re dying to know what your answer was, by the way! 
grahame-smith: Well, I can’t remember what it was or what my answer was. 
Now, this was in Finsbury Square and I still have a pair of shoes that I bought at 
a shoe shop on my way to the meeting of the Committee on Safety of Medicines 
in 1975.109 I regret that the Committee was moved to Market Towers (Vauxhall, 
London) because there weren’t any shoe shops nearby. No, no shops at all, except 
for Covent Garden fruit and vegetable market, which had moved there, and of 
course, you could walk through that, couldn’t you? Anyway, when I arrived 
there was the main committee. Now, Joe has been berating the Committee, ‘the 
committees’, ‘the system’, for not looking after patients and doctors. Well, I did 
read the Medicines Act, Joe, once upon a time – I can’t remember all of it, of 
course – but I used to go back to it quite often to check up on things. And, as 
John Griffin says, safety of drugs is one of the main things, whether it’s during 
development or when it’s on the market, doesn’t matter: safety is important. In 
the 1968 Act efficacy is very important.110 That’s important to patients. Both 
those things are important to patients and they’re important to doctors too: 
to know that drugs work. The system doesn’t always get it right, but generally 
speaking it’s been right. 
And then there are pharmaceutical standards. In other words, do the pills contain 
what they’re supposed to contain? Alasdair Breckenridge has been telling me 
that very often with counterfeit medicines they don’t know, but by and large 
109 The Medicines Division moved to Finsbury Square House, 33/37a Finsbury Square, London in April 
1971 from its original location in Queen Anne’s Mansions, Queen Anne’s Gate, London. It moved to Market 
Towers, 1 Nine Elms Lane, Vauxhall, London, in March 1980. See Griffin and Shah (2006): 464. 
110 See pages 43–4 and 48. 
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they do. And, they are manufactured to standards which guarantee, generally 
speaking, that the drug gets into the body in a fairly predictable sort of way. 
So, to say that our drug regulatory system ignores patients’ and doctors’ needs 
is quite wrong. It may not be as refined as Joe Collier would like it, but it is 
certainly serious about these matters, and we operated under the law. Eventually 
I became chairman of the Subcommittee on Toxicity and Clinical Trials, and I’d 
better tell you about the evolution of that committee. ‘Adverse reactions’ was 
taken into the Toxicity and Clinical Trials Subcommittee because it was felt that 
we had the expertise around the table there to deal with the adverse reactions, 
which I think by and large was true. And so it became the Adverse Reactions, 
Safety and Efficacy committee.
rawlins: And we decided that wasn’t appropriate.
grahame-smith: Wait a minute. The acronym for that, Rawlins, is rather rude. 
So we called it the Safety and Efficacy, Adverse Reactions Subcommittee (SEAR) 
and avoided the rudeness of the other.
rawlins: Much more fun, though, David. 
grahame-smith: Much more fun. And no doubt would have created a lot of 
hot air, but we will leave it at that. Eric Scowen was the chairman when I 
arrived and poor old Graham Wilson was appointed after him, but died. And 
then Eric Scowen took over again, and then Abe Goldberg from 1980 to 1986, 
and then Bill Asscher from 1987 to 1992, and then Michael Rawlins, and 
then Alasdair Breckenridge. Whether it was still the Committee on Safety of 
Medicines then, I don’t know. It was, wasn’t it? Right, right, but not any longer. 
So it’s now the Commission on Human Medicines (CHM) and Gordon Duff 
chairs that committee. John Griffin loomed large at the time, and I have to 
say, the professional civil service upon which such a committee – and that’s the 
Committee on Safety of Medicines – relied was absolutely terrific. 
There were huge amounts of detailed work requiring great diligence to make sure 
that things didn’t pass by. I always remember that picture of Desmond Laurence 
and piles of paper, piled up taller than he was.111 And this was just one afternoon’s 
meeting. Absolutely ridiculous, but still, you learnt how to speed-read. That 
was one of the things it taught me. And I think that there were tremendous 
efforts all round. I remember Bill Inman, probably a thorn from time to time 
in John Griffin’s skin, nevertheless did a tremendous job in raising awareness of 
111 See Figure 4, page 65. 
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adverse reactions with the yellow cards and later prescription-event monitoring. 
John, you say that I chaired working parties and all that sort of thing, and made 
recommendations that were never taken up: that was because they cost money. 
And the difficulty – and now even more so, if this giant NHS computer ever 
comes to pass – I’ll leave the silence after that just to sink home – if this giant 
computer ever comes to pass, the answer is: ‘record linkage’, where you put 
diagnosis, prescription, adverse reaction or event, and the thing clicks away in 
the night and then spews out a correlation. And then the human assesses whether 
there’s anything there or not.112 Although record linkage took place in Scotland in 
a limited way, it never really invaded the south. The Department of Health really 
couldn’t afford it; I think that was the reason. I don’t think there was anything 
wrong with the concept, it was the actual putting into place of the system. 
Many specialties were represented on the Committee – I’m talking about 
medical specialties. And it was a bit of a club; it was a good club. We got on 
well together, no, no, Joe, we did get on well together. You might not like 
that, Joe, it might be beyond your experience for all I know, but most of us 
like to get on with our colleagues, and we got on well together, by and large. 
We had our differences and arguments and so on, but the information was 
swapped between us all and we were highly informed. And I think that Mike 
and Alasdair would agree that, round the table, we were highly informed and 
consensus was usually, but not always, achieved. We did have, I remember, 
something that troubled me – I don’t know how much all of you know about 
animal toxicity tests and whether they tell you anything about a drug and so on 
and so forth. I think I would rather have it go into a few rats before it goes into 
me, rather than not, but the animal toxicity tests had become very laborious. 
So, we had a working party on animal toxicity, we did clean the thing up quite 
considerably from the point of view of the industry. It wasn’t industry that had 
asked us to do that, but toxicity testing had got a little bit out of hand. It is very 
difficult actually designing sets of animal toxicity tests to take care of everything 
from acute toxicity to long-term cancer problems. You can imagine, it’s not 
easy. Anyway, from my own point of view it was a tremendous education and 
you got to know nearly everything that was going on in drug development. 
Like Michael Rawlins knows everything that is going on about the drugs in the 
country and so does Alasdair Breckenridge. It’s a tremendous education. There 
were problems: Opren (benoxaprofen) was a problem.113
112 See Skegg and Doll (1981).
113 Dahl and Ward (1982).
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rawlins: That was my first meeting.
grahame-smith: Yes, Opren was a problem and it was a pharmacokinetic 
problem in the elderly.114 Pharmacokinetics. It may be boring, but if you’re old, 
beware, because you get high blood levels of benoxaprofen and it rots your liver, 
for some reason, and can kill you. And it did, unfortunately, kill a number of 
people.115 
Flower: Can I just remind everyone that we are trying to capture reminiscences 
here?
grahame-smith: This is reminiscence, a sort of reminiscence anyway. Joe will 
agree that things evolve and we used to sit round the table at the Committee on 
Safety of Medicines and argue: ‘We don’t really need this drug – it’s not worth 
the risk’. ‘That’s not your business’ the lawyers used to say, ‘Stick to: is it safe and 
is it efficacious?’ Well, what we needed really was a body to consider whether we 
need this drug and what it costs. And, out of the woodwork a few years later, pops 
Rawlins and the National Institute for Health and Clinical Excellence (NICE). 
It’s an evolution of the regulatory system that was in place, because the regulatory 
system was not doing that. Now, I know it trod on a lot of toes and so on and so 
forth, but now it’s fully accepted as a process and there we are. So, that’s all I have 
to say, really, about the Committee on Safety of Medicines. I’m sure that I’ve said 
some wrong things and there are other people who would like to say more.
rawlins: Can I just add something about the yellow card scheme in the early 
1980s, because it was chronic beyond belief the way it was looked after. I mean, 
this isn’t John Griffin’s fault, but the Department of Health and Social Security 
had only one computer and that was at Reading, and it produced the Giro 
payment cheques, except on Thursday afternoons when it had a little bit of 
114 See James (1985). 
115 Professor Cameron Swift wrote: ‘It’s of interest to reflect on the interface of drug regulation and clinical 
pharmacology with demographic change. The Opren events (among others) helped to drive the now established 
licensing requirements for pharmacokinetic and clinical trials information in older subjects, who are the largest 
group consumers of prescribed medication in developed societies. Indeed, the entire non-steroidal adverse 
drug reaction (ADR) story, as an example, embodies a strongly age-associated dimension. Twenty-five years on, 
we have some already dated international harmonization guidelines for drug licensing data in this population, 
ICH (1993). The story is perhaps still incomplete. Arbitrary and often inappropriate age exclusion criteria still 
emerge in clinical trials; pharmacokinetic and pharmacodynamic data, as well as prescribing, are often sub-
optimal; and the international standard for ADR identification in trials (the Medical Dictionary for Regulatory 
Activities, MedDRA) still lacks some relevant categories (e.g. drug-induced falls). Is there yet more to be done?’ 
E-mail to Dr Daphne Christie, 6 December 2007.
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spare space. So, on Thursday afternoons it was able to interrogate the yellow 
cards. But the officers on the Medicines Division had to write out in triplicate 
precisely what analysis was needed and so on. And of course, you needed to go 
back to the original yellow cards themselves and do it all by hand, and really it 
was only a mechanism for pulling out the yellow cards of interest. And although 
David’s working party may not have immediately materialized in something 
substantial, over the years there have been enormous changes and the place 
has got its own dedicated computer systems and computer languages and so 
on. And so it’s a complete revolution to what it was. But I do remember those 
Thursday afternoons in Reading.
Flower: So that’s why I never got my Giro cheque on Thursdays! Jeff has a 
comment.
aronson: About the yellow cards. Owen has said there was debate about why 
they were yellow. For those who want to read about this, it was covered in a 
Witness Seminar that Tilli ran – one of the first – on the Committee on Safety 
of Drugs.
tansey: Yes, on the Committee of Safety of Drugs, and we had four different 
accounts of why they are yellow.116
aronson: That was an excellent Witness Seminar. I recommend it to everybody. 
Tilli, is it on the web? Can one get it?
tansey: It is on the web.117 
dr Peter Fletcher: I’m really going to say a few words in response to David, 
because I think at the time, the committee, of which I was a secretary – not that 
I did much writing on it – was your first of the working parties.118 And that was 
looking at a problem that had arisen through the industry being unhappy about 
the length of time that assessments took to be made, and indeed the length of 
time that they were involved in actually doing the studies, as these seemed to be 
escalating year by year. Was there some way in which we could abbreviate the 
116 See note 100.
117 See Tansey and Reynolds (eds) (1997): 103–35, freely downloadable at www.ucl.ac.uk/histmed/
publications/wellcome_witnesses_c20th_med.
118 See Grahame-Smith (1983). The terms of reference for this working party were: ‘To consider how best 
the Committee on Safety of Medicines should fulfil its statutory functions of promoting the collection and 
investigation of information relating to adverse reactions, for the purpose of enabling it to give advice on 
safety, quality or efficacy of medicinal products; and to make recommendations.’
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amount of information that had to be scrutinized by John and myself and other 
people in the Medicines Division at that time? We came to the conclusion that 
the Medicines Act is deficient in not permitting there to be such a thing as a 
provisional licence. It would be nice if we could, in fact, allow certain drugs that 
had obvious benefits, but in which the safety profile was perhaps not as certain 
as we’d like it to be, to get onto the market so that the benefits were enjoyed 
without undue delay. This would have helped, in that delay obviously means 
money – it obviously means more intensive work – it means more patients, 
and perhaps even more animal studies. So, the first working party was set up to 
define some parameters by which we could have what we then came to know as 
post-marketing surveillance, or pharmacovigilance as it is now known. I think 
I’m right, that we hit upon a number drawn out of the air, that one in 10 000 
– something the sort of number – that we began to get worried about adverse 
effects if they were thought to be there. So, we wanted to have cohort studies of 
10 000 or about that sort of size or bigger if we could, and we would like to see 
fairly prolonged surveillance of those patients over that time. I think that, if I’m 
right in saying, was the outcome of the first Grahame-Smith working party.119 
You’ve also mentioned the matter of animal toxicity, and that’s quite right. 
That was also becoming, I think, a problem for the subcommittees as well as 
the whole licensing process. That was one thing which I think – I don’t know 
whether it was with you, David, or not – I pointed out that in non-steroidal 
anti-inflammatory agents, which were demanding very long-term dog studies, 
every single dog study that had ever been done – and there’d been about 10 of 
them, I think, at that time – showed that dogs had gastrointestinal haemorrhage, 
at the same dosage level as that recommended for humans. And the committee 
would say: ‘It doesn’t matter because we know it doesn’t matter.’ So, we’d go on 
doing it. I think I pointed out that it was rather pointless to continue doing very 
expensive long-term dog studies, when in fact we knew that no notice was going 
to be taken of them. So, I think that is a little bit of the history of that time.
Vere: Very briefly on this problem of how the legalities operate. Obviously record 
linkage is terribly important and I can remember, before the Grahame-Smith 
working parties, this being pointed out. At that stage it was impossible for the 
funny computer that we had to communicate with the rest of Europe, because 
they were all incommunicable. I remember David Finney (a medical statistician) 
being apoplectic because he wanted to advise about the sort of machine that 
was needed and which could be purchased, and the answer clearly was, ‘No, 
119 See note 118.
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no, it’s the civil service that must decide;’ and we got the wrong machine.120 It 
wasn’t able to talk to Norway or share data. That was just one thing. The other 
thing was toxicity testing that, in those days and times you had to go through 
the specified tests, which were agreed, even if they were irrelevant to the likely 
actions of a drug. And yet, if you knew what a drug might do, you couldn’t, for 
example, look at the adrenal gland if that was a likely target organ if it wasn’t 
on the agreed list of structures that must be examined or whatever biological 
system it might affect that could cause mischief in relation to the activity of a 
particular drug. Those are just two examples of the kinds of problems that used 
to arise.
Flower: In a minute I’m going to ask Mike and Alasdair to talk about later 
developments in this committee structure, but I just wanted to return to Owen 
for a minute. Owen, can you tell us something about the Committee on Review 
of Medicines (CRM)?
Wade: I think this was part of the Medicines Act, wasn’t it? There was the CSM, 
the CRM, there was the Veterinary Products Act, and then a Pharmaceutical 
Commission. I was chairman of the Committee on Review of Medicines. When 
I started, I made two changes, well, two developments really, because I’d had 
such a tough time on the Committee on Safety of Drugs with Derrick Dunlop 
at the very beginning. I made two recommendations: first, that new members 
got properly instructed by me when they first arrived, so that from the very 
beginning of their membership they could contribute properly. The second 
thing was that in MRC meetings we always had a system by which people led 
discussions and I introduced that system so there was always somebody whose 
responsibility it was to lead individual items as they came up. 
The only other thing that I’d really like to talk about is in 1972, I think it was, 
I was challenged by Squibb. They had two drugs, Motival and Motipress. These 
were compounds that had fluphenazine in them but this wasn’t clear from the 
names of the drugs, and fluphenazine was causing some adverse reactions. We 
recommended that the Minister should revoke the licence for these two drugs. 
And then Squibb appealed. We heard this appeal but didn’t agree with it, so we 
told the Minister to go on revoking. They could have gone to the Medicines 
Commission and had another shot at it, but no no, they sued the CRM, in 
120 Professor John Griffin wrote: ‘Proper monitoring could only be achieved with computerized record 
linkage schemes.’ Griffin (2009). For details of Finney’s further comments, see Tansey and Reynolds (eds) 
(1997): 113–14, 131–2.
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particular me, for advising the Minister wrongly. And there was a long, drawn-
out legal case. It was hell, I think, for the administrative officers of the outfit. I 
know I had to sign countless affidavits and the thing went on and on and on. 
Then eventually they gave up. But why did it go on so long? Because neither 
of these drugs was used very much in the UK, but they were in the US. And of 
course, as soon as the decision was made that their licence was to be revoked, 
then WHO would tell every country in the world about this, and their market 
in the US would go down. So, there was trouble there. 
Collier: I had something to say about the Medicines Act which is rarely if ever 
talked about, and it is the way in which the committees meet, in which they’re 
held. Because of the secrecy surrounding the Act I suspect that by giving you 
insights into the way meetings are run I’m breaching Section 118 now – so 
I may be in jail tomorrow, but let me tell you,121 in the regulatory system, in 
my experience, the chair always sits with people from the department, and is 
supported by them while the other members of the committee always sit on the 
other side of the table. I think that’s the case in the CSM; it was certainly the 
case in the Medicines Commission when I served on it. This meant that the 
most powerful member of the advisory body – the chair – was on the opposite 
side to the members. That relationship, i.e. the chair being very close to officers, 
civil servants, whatever, I think threw some of the decision-making.122 Now 
I see Michael saying ‘no’, but if you ask the questions: ‘How do committees 
make decisions?’ ‘How are the committees arranged?’ If you look at the table 
and the arrangement and where the chairs are seated, I suspect that the seating 
arrangement, by its very nature, will have influenced decision-making. We don’t 
know, but I suspect it will have. I am sure you’ll get a response on this matter in 
a minute from my friend, my colleague on the left (Michael Rawlins).
griffin: I’d just like to pick up on a point that Mike Rawlins made about the 
Medicines Division’s facilities. He grossly understated it. In 1979 we moved to 
the Market Towers from Finsbury Square. In Finsbury Square we had manual 
typewriters. When I went to look at the building at Market Towers, it was all 
nicely equipped from a previous government department with word processors. 
The trades union insisted that all these word processors were going to be taken 
out, because it would affect our employment of secretaries. I created merry 
hell, as a result of which we got golf-ball typewriters. Now, that was the level 
121 On section 118 of the Medicines Act, see note 93.
122 Professor Desmond Laurence wrote: ‘True! True!’ Note on draft transcript, 7 July 2008. 
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of technology that we had, and I made a comment earlier on that the Medical 
Division was under-resourced. It was grossly under-resourced. 
george: The Committee on Review of Medicines was chaired initially by Owen 
Wade, as you heard. But then, of course, there was Bill Asscher and finally 
David Lawson. Earlier on today we heard about the 39 000 products with a 
licence of right. The work of that committee was completed on time, and the 
number of products on the market reduced to around 10 000. I think overall 
that was a great achievement. I know that a lot of companies didn’t think it 
was worth a candle, actually, submitting for a product licence, or renewal of a 
product licence, but it was a very smooth process.
Breckenridge: There are two remarks I’d make to previous speakers: first 
to David, about the amount of data seen by advisory committees. You’ll be 
interested to know, David, that the Comission on Human Medicines held a 
working party over the summer this year to decide how it could reduce the 
amount of information which was going to be sent to members. Of course, 
it didn’t come to a conclusion and they’ll have to convene another one. So, 
not much changes. The second remark is to Joe Collier, on the question of 
why the chairman sits opposite the members of the committee. There is a very 
good reason: in this way, he is the only person who can see the members of the 
committee, and so that when he says, ‘Does everyone agree?’ and he will say, 
‘Yes, everyone is nodding’, where, of course, probably half of the people are not, 
but nobody else can see that.123 
Just for a few minutes I want to pick up the regulation of medicines post-
thalidomide, and this is very appropriate because those of you who have 
read today’s Financial Times (26 September 2007) and the Financial Times at 
the weekend (22/23 September) will know that it is 50 years ago this week 
since thalidomide was introduced into medicine. One of the nicest quotes I 
remember from Derrick Dunlop was that his committee only concerned 
themselves with efficacy in as far as it concerned safety. So, safety was always 
the predominant thing in his reckoning. But after that, after the CSD and the 
CSM were set up, one could be pretty sure that the decisions reached on efficacy 
were watertight and could be substantiated. The same couldn’t be said for the 
decisions on safety, for the very good reason that the number of patients who 
had been included in clinical trials was small. So, an argument started in the 
123 Professor Desmond Laurence wrote: ‘True, of course. But Joe Collier’s innuendo is also true; chairs are 
chosen because they will comply’. Note on draft transcript, 7 July 2008. 
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1970s, which is still continuing to this day: how do you get a handle on the 
safety of marketed drugs? A new title has been given to this: ‘post-marketing 
surveillance’.124 You’ve heard already about yellow cards, very useful in their way, 
but with severe limitations – very good for picking up signals. The emphasis 
today is on active methods of monitoring, and in that respect patient registers 
are important and also in testing hypotheses which have been raised by yellow 
cards. The General Practice Research Database (GPRD) is also very important 
and there are huge developments taking place in GPRD. This debate on post-
marketing surveillance came to a head in 2004 with Vioxx.125 Remember Vioxx 
(rofecoxib), the COX-2 (cyclo-oxygenase-2) inhibitor, which was withdrawn by 
the company because of cardiovascular safety at a time when regulators knew 
about the problem, but for various reasons, which we don’t need to go into, had 
not acted. The end result of this was that in European law, risk-management 
plans were included. In a risk-management plan there is a statement of the safety 
profile of the drug: what’s known about the safety; what’s not known about the 
safety; what needs to be done to get more information; and anything else that 
needs to be done. These are now part of the licence, so when this is granted the 
company must sign up that it will fulfil its obligations in a risk-management 
plan. As has been said earlier this afternoon, the record of pharmaceutical 
companies in completing post-marketing studies, that they said they would do, 
is really pretty poor. Data from the MHRA shows that one-third of these studies 
are completed satisfactorily; one-third are already in progress; and one-third 
have never been started. Until now in Europe, we haven’t had the legal ability to 
make companies complete these studies. A law was passed in the US last week 
renegotiating the Prescription Drug User Fee Act by which hopefully the same 
kinds of guarantees in the US that post-marketing studies need to be done will 
be obtained.126 
This brings us up to last year and TGN1412, which was a wake-up call for better 
regulation of first-in-human studies of high-risk compounds.127 EU proposals 
for these regulations have been consulted on and the regulations are being laid 
124 Andrew et al. (1996).
125 Mamdani et al. (2004); Sommet et al. (2008). 
126 HR 3580, the Food and Drug Administration Amendments Act was signed on 27 September 2007; for 
details see www.fda.gov/oc/pdufa/ (visited 26 June 2008).
127 See Glossary, page 107. 
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at the present time.128 This is of great importance in the history of medicines 
regulation. Probably it will not be the last event which will predicate medicines 
regulation, because all such regulation has been guided by adverse events. It has 
been said already that the regulations of medicines in the UK have been largely 
subsumed into European regulations under the Treaty of Rome. The former 
MCA and the Medical Devices Agency (MDA), which were funded in entirely 
different ways and worked under entirely different legal systems, were merged 
to form the MHRA in 2003. The story is told how the MHRA – a name that 
doesn’t actually trip off the tongue – was so called. The name was to be decided 
at a meeting of officials of the Department of Health, including the Minister. 
There was a series of suggestions as to what the new agency should be called, 
and only one person voted for MHRA. The problem was that that one person 
was the Minister, so apparently this is how it got its name. We have streamlined 
the advisory committee structure that we’ve been talking about: the Medicines 
Commission and the CSM have fused to form the CHM, and in keeping with 
what’s happening in Europe, we have formed expert advisory groups in different 
therapeutic areas. We are working very closely with our colleagues in Medical 
Devices, because, scientifically, medical devices and medicines are coming closer 
together in areas like tissue engineering.
Finally, as I was discussing with David Grahame-Smith over tea, one of the 
areas which is concerning us most at the present time in regulation is drug 
distribution. We’ve got a pretty good regulatory handle on drug discovery, and 
we’ve got a pretty good regulatory handle on drug development. But after that, 
after the licence is given, it is more difficult. The distribution of medicines is an 
area where there are a lot of problems, such as counterfeiting. You’ll remember 
that just before the summer three major drugs which were counterfeits went 
into the NHS health care system and this is a matter of continuing concern.129 
I would see this as an area where regulation will have to get its act together in a 
tighter way than it has up to now. 
Flower: About two months ago, the British Pharmacological Society was 
approached by a Chinese delegation who asked if they could visit with us during 
their trip to London and seek some advice. I was roped into the discussion 
because I was one of the only people around who was available at the time. 
We met them in the upstairs office of the society’s headquarters in Angel Gate. 
128 See Duff (2006); European Medicines Agency (2007); Boyce (2007), especially page 21.
129 The three drugs were Casodex, Zyprexa and Plavix. See MHRA (2007a, b and c). 
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When they arrived we found that their delegation comprised about ten doctors 
and scientists accompanied by a charming interpreter. As none of them spoke 
English, and everything had to be relayed through this interpreter, it took us 
about an hour or so to find out exactly what it was that they wanted to ask us. 
In the end it turned out that they were seeking an insight into how we managed 
quality control issues in the UK. Apparently, in China, there is an issue about 
pharmaceutical companies using different manufacturing methods to prepare 
drugs such that the final products are often radically different from each other in 
terms of purity. The immediate stimulus to this, I suspect, was that the Chinese 
Minister for Health was executed after a substantial slip up in drug regulation 
implementation in China led to several deaths.130
Breckenridge: They signed a memorandum of understanding with the MHRA. 
And the person who signed it was the deputy commissioner of health, the boss 
having been dispatched on July 10th. And we said to one of the translators: ‘We 
hope this doesn’t become a paradigm for regulators who don’t quite come up 
to scratch.’ 
rawlins: I was asked to talk a bit – reminisce a bit I suppose – about the CSM 
in the 1980s and 1990s. I joined the CSM, the main committee, in 1980 when 
Eric Scowen was still chairman. Eric was a remarkable chairman, he absolutely 
dominated the Committee. Most of the proceedings were a dialogue between 
him and the chairman of the subcommittee on Toxicity and Clinical Trials, 
i.e. David Grahame-Smith. He was quite clear that he wanted his way and 
was going to get it, and he did it by all sorts of underhanded means, many of 
which I have remembered and used myself. On my very first meeting, for some 
reason or other – John Griffin must have been asleep or away that week – we 
had before us a transfer of a licence from one manufacturer to another. We 
wouldn’t normally come near it. It was for Vicks, the stuff you rub on your 
chest. It was just about to go through on the nod and I said, ‘Chairman’ (very 
pompously) ‘what’s the evidence for efficacy there?’ And he gave me a sort of 
withering look and said, ‘Rawlins, we have a long tradition at this committee of 
granting licences to products the public have enjoyed for many years. So while 
you’re looking out of the window and not paying any attention, we’re going to 
give it a licence.’ 
130 Zheng Xiaoyu, former head of State Food and Drug Administration was executed on 10 July 2007 for 
taking 6.5m yuan in bribes to approve substandard medicines. See www.iht.com/articles/2007/07/10/news/
china.php (visted 22 July 2008).
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I became chairman of the CSM in 1993 and I was very fortunate with members; 
they were all extraordinarily able. There were a couple of them, very distinguished, 
who were unable to make decisions. I’ve noticed this in expert committees: 
there are one or two people who can’t make decisions and you just have to live 
with that and rely on their other virtues. As Alasdair said, the reason why it’s 
so important for the chairman to sit opposite – it’s not a conspiracy – is so that 
you can see not only whether people are nodding, but also the body language of 
those who are uneasy with the way the dialogue is going. And so it’s a practice 
that I strongly commend. As I said, the decision-making was very collegiate and 
it was generally by consensus. Conflicts, as always in these committees, revolved 
around what you might call modest issues. The big conflict when I was chairman 
was always the change in legal status from POM to P, and then to GSL. When 
you went from POM to P, the pharmacists on the committee thought this was 
wonderful, and many of the doctors disliked it intensely. When it went from P 
to GSL the pharmacists were outraged. During my time, I had a miserable time 
with the pharmacists who were quite clearly all on a three-line whip from the 
Royal Pharmaceutical Society to try to oppose this. And it took me 11 years to 
get 5ml sachets of Calpol available in the local garage, so that I could buy them 
when my grandkids were getting febrile illnesses. 
The other thing I was going to mention was pressure. And there is pressure on 
committees and pressure on the chairman and senior members of the committee, 
and it comes from a variety of sources. Once when I was standing in for Bill 
Asscher as chairman I was subjected to political pressure from one of the secretaries 
of state for health. Suddenly I got a message; he wanted me to write a letter to all 
doctors that night to say that Serevent (salmeterol xinafoate inhalation powder, a 
b2-adrenoceptor agonist) was safe.131 Now, no chairman of the Committee on Safety 
of Medicines has ever written a letter to say something is safe. I was only acting 
for Bill Asscher who was away somewhere, and I knew he’d absolutely clobber 
me if this ever got round, so I had a lot of difficulties making sure that I couldn’t 
do a letter, couldn’t sign the letter, had to go back to Newcastle, and all that sort 
of stuff to avoid it. There are obviously media pressures, and at the time I was 
chairman of the CSM, I thought the media pressures were pretty fierce. Now I’ve 
had eight years at NICE, I know that the media pressures on the chairman of the 
CSM were as nothing and really were not a problem. There is some professional 
pressure; always very difficult to know whether it is truly from the profession 
or whether the pressure has been coming from other quarters, particularly the 
131 Ullman et al. (1990); Johnson (1991).
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pharmaceutical industry. And, of course, there was pressure on the Committee 
and on the chairman from the industry. Some of it was quite legitimate; in a 
democracy, if the regulated want to make remonstrations about the way they are 
being regulated, they have the right to do so. I don’t disagree with that. Sometimes 
it was underhand. There were two occasions I now know where members of the 
Committee had entered into agreements with companies so that when their terms 
of office expired they would become consultants, but remained on the Committee 
for a year without declaring it. There was one attempt at me with bribery: a pretty 
pathetic one, actually. There was also an attempt at blackening my reputation 
when one company persuaded a Member of Parliament to ask a question about 
how much money I’d been paid over the previous year, quite clearly hoping I 
hadn’t declared it in my income tax. As I couldn’t remember, I went back home 
and was relieved to see I had declared £2 600 but the Parliamentary Answer was 
that I’d only been paid £2 400 over the course of the year, so I breathed a huge 
sigh of relief that I’d paid £200 too much; it didn’t really matter. About a week 
later, I got a letter from the Inland Revenue questioning my tax return and my 
payments from the Department of Health. So I rang them up and said, ‘What’s 
going on here?’ And they said, ‘Well, we saw this parliamentary exchange and, 
you must understand, it was referred to us. We checked up your income tax and 
we realize you’ve overpaid, and we think it’s rather hard on you, and we think you 
ought to have an opportunity to claim the £200 back.’ There was one occasion of 
pure fraud, which Alasdair sorted out after I left, belonging to a company that’s no 
longer in existence – Scotia Pharmaceuticals. Alasdair revoked all their licences, 
and I think he did a great job. But of course, that was plain fraud and one of the 
investigators was taken to the GMC and the other main investigator died and so 
was unable to be taken.132 So there are those pressures too. 
But the one other thing I’d like to say is about patients. All the way through my 
period on the CSM, we did think about patients. We thought about them all 
the time, and Joe Collier is wrong to think that we didn’t think about patients. 
We may have looked at the risk-balance ratio in a sort of patronizing way, 
and I’d accept that. We may not have had meetings in public – in that period 
no scientific committee had meetings in public – but to say we didn’t think 
about patients is completely wrong. And the one person, above all, actually – 
surprisingly – who was always talking about patients, was the late Sue Wood. 
And although she was a very difficult woman in many ways, and she and I 
had huge arguments, which apparently reverberated around the building, 
132 See Dyer (2003); Richmond (2003).
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nevertheless she was always, always talking about the ‘poor ******* patients’, as 
she put it. ‘What are you going to do about them?’ 
Flower: I’m sorry we don’t have a bleeper to disguise those sorts of words. 
rawlins: Well, if you knew Sue Wood she used that particular word beginning 
with ‘f ’ very often. 
Breckenridge: I think Michael’s very right to make this point about patients, 
about our concern for them. He knows, and I’m sure the rest of you might know 
as well, that, since his time on CSM, the CHM and its expert advisory groups 
all have lay and patient representatives as well. They do make a substantial 
contribution, especially in the area of information. 
Wade: Yes, yes, obviously all you youngsters here don’t remember, but in the 
early days we weren’t paid anything. I understand now you are paid.
rawlins: Yes, I got £200 a day as chairman.
Wade: Really? Yes, good. Not in my time. I remember that there was some 
payment made at the end of the days of the Committee on Safety of Drugs, and 
I used to get this and used to give it to my department because, you know, I’d 
been away in London the whole day and they had a lot of work. So I thought 
the department ought to get this money, and that was splendid while it lasted, 
but then the income tax people rang me up and they said, ‘You were paid this 
bloody money, and you must pay income tax on it.’ So I said, ‘No, but I gave it 
away’. And then George Godber rescued me. He explained to them that I was 
financially incompetent, that I wasn’t getting the pay, it was for my department. 
Vere: Very briefly and frivolously: we used to have those enormous bags full of 
papers, which were sent to our homes, that had to be kept sealed at all times 
except in secret when we were reading them. I can remember sitting on a tube 
train once with two of these vast bags, which I could barely carry, and one of 
them burst open in the tube. I only saw Sir Eric Scowen non-plussed and fazed 
once, and that was when we’d all brought our papers to the Committee and we 
discovered that neither the papers that had been provided for us nor the papers 
that had been brought by the company for their own staff related to the drug 
that was on the agenda to be discussed.
aronson: Before I start to say something about the Medicines Commission, I have 
a reminiscence about Desmond Laurence. There is a wonderful photograph of 
Desmond staggering under the weight of at least half a dozen of those enormous 
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green bags that used to flood on to the desk. We published it in the issue of the 
British Journal of Clinical Pharmacology that we produced to celebrate the 30th 
anniversary of the journal. It is worth looking at the issue just for the picture of 
Desmond, which was wonderful. 
Now, the Medicines Commission – I think Joe Collier will correct me if I’ve 
got the history wrong – was established under the Medicines Act of 1968, as 
the main committee advising Government. Under section 4 of the Act, the 
commission was empowered to set up committees to assist it in its work. And 
so a section 4 committee was begun: the Committee on Safety of Medicines. 
I guess at that time – I hope that somebody will tell us the story about this – 
the Medicines Control Agency (MCA) was set up to service the Committee 
on Safety of Medicines. Quite how the MCA – later transmogrified into the 
MHRA after it was amalgamated with the MDA – became so powerful in that 
area without having been constitutionally or statutorily set up is something 
that I’d like to hear about from, say, Alasdair or anybody who knows about 
that. The Medicines Commission was the main advisory committee which set 
up the CSM. I didn’t join the Medicines Commission until 2001, and became 
vice-chairman in 2002 until it was disbanded in 2005. But, before I talk about 
Figure 4: Professor desmond laurence and his monthly burden of documents  
for a meeting of the Committee on safety of medicines. 
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my perspective of that period, I wonder if there is anybody here who was a 
member of the commission, either when it began or subsequently, who has 
reminiscences about how it worked in those days?
rawlins: John Griffin must know more. But I’m not sure if your interpretation 
of the law is quite right, Jeff. The Medicines Commission was set up as an 
advisory body, but section 4 of the Medicines Act also gave powers to ministers 
to set up additional committees and that was how the CSM and the CRM and 
the herbal medicines committee and things like that were set up. And there was 
always a lot of dispute as to which committee had supremacy: the Medicines 
Commission or the CSM. The chairmen of the two bodies used to vie with each 
other as to whose was more important. Right, Alasdair? Well, you and I had no 
disagreement about it.
Breckenridge: We could talk about this for a long time. It devolved into 
personalities and I don’t think we want to talk about that.
mcdevitt: I was a member of the Medicines Commission from the late 1980s 
to the late 1990s, and I think for the last five years was the vice-chairman of 
it. Initially, during my time, Rosalind Hurley was the chairman, and then 
subsequently David Lawson.133 It basically heard appeals from companies that 
didn’t like what the CSM was telling them when they’d gone through the 
process. Ultimately they could come to the Medicines Commission and put 
in a final appeal to us. These meetings were relatively infrequent, it has to be 
said. In addition to that, there was a whole series of other issues relating, not 
just to the CSM, but to the Veterinary and Dental Committee and the Medical 
Devices Agency. There were one or two other issues that came straight to the 
Commission. One that springs to mind was when the European Commission 
was introducing various rules and regulations that had to apply to Britain as 
well. I remember we had a long debate about homoeopathic medicines, I think 
it was, as to whether we were going to agree to this legislation being introduced 
within the UK. There was great concern and there was a debate in which we 
finally agreed that we would have legislation. Then in fact, the secretariat said, 
‘Could we write efficacy out of it?’ I think that must have been part of the 
process because they said, ‘(a) we don’t want to have to make the decisions, and 
(b) we wouldn’t have the resources to have anything to do with this.’ There were 
133 The first chairman of the Medicines Commission was Lord Rosenheim (Jan–Dec 1972). He was 
followed by Professor A Wilson (1972/3), Sir Ronald Bodley Scott (1973–5), Lord Butterfield (1976–81), 
Dame Rosalind Hurley (1982–93), Professor David Lawson (1994–2001) and Professor Parveen Kumar 
(2002–05). 
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a few contentious decisions that eventually came to the Medicines Commission 
from the CSM. But, I have to say, over a ten-year period, these were relatively 
few and far between. 
I would also endorse the idea that there were all these people from a whole 
variety of backgrounds who played a very significant part in the role of these 
committees: clinical pharmacologists, doctors from other specialties, very 
senior people from the pharmaceutical industry, veterinary people, patient 
representatives, even as early as the 1980s. It was actually very interesting, when 
you got a topic that maybe one or two people knew a lot about and other 
people didn’t know that much about, to see the knowledge base growing as the 
discussion took place, so effective decisions were eventually made. I must say, I 
found it a very interesting and rewarding experience. 
Professor donald davies: The general theme here has been the contribution 
of clinical pharmacology to drug regulation. I wonder whether under current 
conditions the contribution of active researchers in clinical pharmacology to 
regulation is greatly reduced? When I was a member of the CSM we were 
allowed to have interests with drug companies provided we declared them, and 
we left the room if there was a specific interest under discussion. Now one 
cannot have any interest whatsoever if one wants to sit on a regulatory authority 
committee.134 Joe will not agree, but I’m sure that that does bar people with the 
relevant knowledge and experience.135
Flower: Joe, you wanted to make a comment about the Medicines Act, but you 
can also reply to the previous comment.
Collier: I would agree. The issue here, as I have the Medicines Act with me, is 
typical of the system. Jeff is right and Michael’s wrong, but you should know 
better, Michael, let me read it to you. Section 2 – which is the second bit of 
the Medicines Act – says: ‘There shall be established a body to be called the 
134 Professor Laurence wrote: ‘In 1964 I was appointed to the CSD Clinical Trials Subcommittee. One night 
the medical correspondent of the Observer phoned me and said he had a report that the CSD had breached 
the (informal, voluntary) agreement with industry that no committee member would have professional 
financial links with a pharmaceutical company. This was “news”, he said. I said that the whole CSD 
enterprise was based on trust, and it would be a disaster if that was impaired at the outset. I agreed to try to 
find out. I was able to meet the chairman (Dunlop) and I told him the story. After a pause he said “Oh, my 
God: I forgot!” After a brief conversation I felt able to tell the Observer that I had spoken to Dunlop and I 
was satisfied that the agreement with industry was intact. The Observer did not publish’. Letter to Mrs Lois 
Reynolds, 10 August 2008. 
135 MHRA (2006). 
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Medicines Commission.’136 Then it goes on: ‘And that is a statutory body’, 
meaning that it cannot just be disbanded. Then it goes on to section 4 and 
says: ‘The ministers (the health ministers or the agriculture ministers) having 
regard to any recommendations made by the Commission under section 3(2)’, 
which I’ve just read to you, ‘and after consultation with such organisations 
as the ministers concerned consider appropriate, may by order establish one 
or more committees under this section’, i.e. ‘section 4 committees’.137 There 
is no mention of the name of the CSM there and it’s only as a result of the 
Medicines commission and the ministers asking: ‘Why don’t we have it?’ The 
reason – I suspect – why the word ‘commission’ is in the new body is that there 
is a statutory requirement to have it there, because you cannot disband it. So 
the commission per se would be seen as the first or senior committee. It is, 
indeed, the case that the CSM was more powerful, more influential, and I think 
functionally the better. In fact, my view has always been that the commission 
has been a dysfunctional committee, but that’s a maybe. I think the CSM really 
took over many of the roles of the Commission. I think it was a shame, in a 
way, but I always saw the legislation as giving the Medicines commission the 
role of the eyes and ears of the public.138 But that’s too late now, we failed in that 
respect. But there we go. Michael, I don’t know if you want to read this again – 
but I am sure you are incorrect.
Fletcher: Before we end this, I’d like to go back to this question of efficacy and 
the position of the Committee on Safety of Medicines in this assessment. I have 
a little story about that, which I was involved in over a number of months, and 
Eric Scowen also was involved. It involved an OTC product called Enterovioform 
(clioquinol) which was an anti-diarrhoeal for travellers. We received a number 
of reports that, in fact, it wasn’t working very well, and so Eric had this put on 
136 Great Britain (1968) (c.67) S.1. 
137 Great Britain (1968) (c.67): S.4(1).
138 Professor Desmond Laurence wrote: ‘The Medicines Commission was there to advise the Minister – it 
was the premier committee to act in the public interest in theory and in law. But, one day when John 
Butterfield was chairman, a familiar situation arose – the public interest versus the bureaucratic interest. 
The civil servants said “chairman, the commission does not have to do this” (I forget the topic, but it related 
to patient/public safety). I became frustrated and said “but what about compassion?”. The meeting was 
stunned, then the chairman let the cat out of the bag when he said: “Desmond, it is my duty to protect 
the civil servants”. The meeting stayed stunned. Of course everybody knows this, but nobody is supposed 
to actually say it, it is the “elephant in the room” that ensures that it is only after the civil servants and the 
ministers’ interests have been protected that the public gets a look in (I hardly exaggerate)’. Letter to Mrs 
Lois Reynolds, 10 August 2008. 
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the agenda and we decided that we would reduce the number of indications for 
which it could be used. And it was for, I think, one or two, I can’t remember 
what they were now. Anyway, that went through and the number of indications 
was removed from the data sheet so that it was brought into line. Time went by 
and there were more complaints that, in fact, even in the ones that were left, it 
was still not particularly effective. So we reduced that down to, I think, about 
two, one of which I think was some tropical dysentery and so it was left with 
one indication. In fact a paper had come up to show that it wasn’t any use in 
that either. So now what we had was a product that kept its product licence but 
lost all the indications.
Vere: Well, that’s right. With Enterovioform, the most frequent problem was 
that it messed up thyroid function tests.139 
aronson: Sub-acute myelo-optic neuropathy did it. Well, I thought I’d finish 
off with my experience of the Medicines Commission, which, as I say and as 
we’ve heard already, was disbanded in 2005. First of all, there were actually a 
lot of clinical pharmacologists on the Medicines Commission when I joined it. 
Now there are a lot of clinical pharmacologists on the Commission on Human 
Medicines for that matter. I think we had quite a lot of influence in these matters, 
and continue to do so. These major committees are chaired by senior clinical 
pharmacologists, and the clinical pharmacologists who were there apart from 
me were Joe Collier, Phillip Routledge, Jim Ritter and Cameron Swift. I can’t 
think whether there were any others, but that’s five in a committee of 15 or 20. 
So, we had quite a loud voice and a fair group presence on that committee. The 
other clinical pharmacologist who was on that committee when I joined was, of 
course, David Lawson, who was the chairman. I have to say that he was, if not the 
best, then one of the best chairmen I have ever served under. He was superb: he 
was relaxed and good-humoured, and I think that these are the most important 
attributes for any good chairman of a committee. He listened to everybody, and 
Alasdair’s point about sitting on that side of the table is actually very important, 
because he was the one, as Alasdair has said, who could see when Joe was falling 
asleep, for example, and when people were nodding or shaking their heads. But 
he did listen and he didn’t just listen; he elicited opinions and he made sure 
that everybody’s opinion was heard. In the end his summing-up was masterful. 
I don’t think anybody went out of those committee meetings thinking that a 
wrong decision had been made, or that they had somehow been neglected, even 
if the decision went against their views. His whole conduct of that committee 
139 See, for example, Mann (1986).
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was magnificent, and I sat there thinking, ‘I wish I could do this’. I have always 
tried to model my own chairmanship – when I’ve had the chance – on his style, 
because I thought it was so effective, very difficult to achieve, and he seemed to 
do it very naturally. I’m sorry he’s not here today. 
He had to leave that committee and Jim Petrie was appointed as his successor 
in 2002, but Jim unfortunately died before he could take up the post. So the 
then vice-chairman, Parveen Kumar, took the chair. Parveen, in typical fashion, 
said that we should have a ballot for who should be the next vice-chairman. 
She didn’t like the term ‘chair’ incidentally; she liked to be called ‘chairman’. I 
managed to bribe enough of my colleagues to be elected and I was the next vice-
chairman. It was one of the best committees I think I’ve ever served on; it was 
hugely educative. Someone said that what we did was to hear appeals; well, that 
was just one thing. The range of topics that we covered on that Commission 
was huge and eclectic. It dealt with anything and everything about drugs that 
the CSM was not dealing with in addition to overseeing their reports – because, 
of course, as Joe has told us, the CSM reported to the Medicines Commission 
– and other matters such as veterinary affairs, because the human veterinary 
commission – I can’t remember the exact term – was part of the Medicines 
Commission.140 I recall one debate about residues of benzylpenicillin in animal 
products, and the degree to which a particular level or a concentration of residue 
was permissible. The experts on horses on the committee were exceptionally 
helpful when it came to talking about veterinary medicine. There was also an 
expert on fish. We covered huge ranges of topics and were educated all the time. 
The quality of debate was enormously high and I remember it as one of the 
most enjoyable committees I have ever served on. 
But Europeanization, as Alasdair has reminded us, led to the demise of the 
Medicines Commission when the CSM and the Medicines Commission were 
joined together as a single body in the CHM. I don’t know how this is working, 
but I thought the one function that might suffer as a result of that was the 
appeals function, because we often heard appeals from drug companies against 
decisions of the CSM. I don’t know how that works now and perhaps that’s 
for another day. I regret the demise of the Medicines Commission. I hope, 
and I’m sure, in fact, that the new system works well also, and that the matter 
of advising Government on drug matters has gone forward exceptionally well, 
particularly since there are so many clinical pharmacologists involved.
140 The Veterinary Products Committee was established in 1970 to advise on safety, quality and efficacy in 
relation to the veterinary use of medicinal products and reported to the Medicines Commission. 
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Breckenridge: The commission has not died at all, its function has been 
subsumed into the Commission on Human Medicines, and, please, you mustn’t 
say it has died.
Flower: I think we’d better wind it up here. I know that Tilli has got some 
housekeeping announcements that she wants to make. 
tansey: First of all, may I say thank you to everyone for coming here this 
afternoon and sharing your reminiscences with us. It’s been a privilege to listen 
to you. We’ve touched on some serious historical issues, but we’ve also had some 
very entertaining stories, and it’s been a very interesting afternoon. Tony Peck 
mentioned earlier that he was often asked, ‘Have you got a product?’ We do 
have a product this afternoon and that is a transcript of this meeting. It will be 
edited and hopefully published, probably in conjunction with the first meeting 
that we held earlier this year, and all the correspondence and transcripts will be 
put in the archives of the Wellcome Library.
It remains for me to thank Jeff Aronson, who has been incredibly helpful in 
organizing this meeting and its predecessor. He’s put a lot of work into it and 
I and my team are very grateful to him for that. And also to thank Rod Flower 
for his excellent chairing. He got us to tea on time and five minutes late for the 
glass of wine. He did say he was hoping that he would get a medal of honour 
from the Wellcome Trust; well, I’m afraid you haven’t quite made that, Rod, so 
I’m afraid you’ll have to make do with the more traditional thanks and a round 
of applause.
Flower: Thanks very much everyone, you’ve been a wonderful group and it’s 
going to be a great transcript. I’m sure you are going to look forward to reading 
it in times to come. 
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Biographical notes*
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industry as the director of Pharma 
Services International.
Professor roderick Flower
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He joined the Wellcome Research 
Laboratories, Beckenham, in 1965 
as a clinical physiologist. Security of 
tenure was promised if he became 
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Professor sir Charles george
Kt FRCP FFPM FMedSci  
(b. 1941) studied medicine at the 
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posts at the University of Glasgow 
(1956–99); was chairman of the 
Committee on Safety of Medicines 
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2000), honorary director of the 
Medical Research Council unit 
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and honorary consultant in clinical 
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Professor John griffin
FRCP FRCPath FFPM (b. 1938) 
qualified from the Royal London 
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research at Riker 3M (1967–71), 
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Division of the Department of 
Health in 1971, becoming head 
of the Medicines Division, and 
medical assessor to the Committee 
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1984. He was director of the 
ABPI (1984–94); member of the 
Executive Board of the European 
Pharmaceutical Industries 
Association (EFPIA); member 
of council of the International 
Federation of Pharmaceutical 
Associations (IFPIA) and chairman 
of the International Conference 
Safety Expert Working Group 
(1989–94). Since 1994 he has been 
director of his own consultancy 
company, Asklepieion Consultancy 
Ltd, and visiting professor in 
pharmaceutical medicine, Post 
Graduate Medical School, 
University of Surrey; chairman 
of the board of examiners for the 
Faculty of Pharmaceutical Medicine 
(1997–2003) and academic 
registrar (2003–5).
dr andrew herxheimer
FRCP (b. 1925) worked 
in preclinical and clinical 
pharmacology at St Thomas’ 
Hospital Medical School, the 
London Hospital Medical 
College and at Charing Cross and 
Westminster Medical School until 
1991. He was founding editor of 
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the Drug and Therapeutics Bulletin 
(1962–92), while working with 
Consumers International. In 1986 
he became the first chairman of 
the International Society of Drug 
Bulletins. He was extraordinary 
professor of clinical pharmacology 
at the University of Groningen 
(1968–77); and has been part-time 
consultant at the Cochrane Centre 
in Oxford since 1992, and emeritus 
fellow since 1995. In 1996 he and 
Dr Ann McPherson started the 
DIPEx project. See www.dipex.org, 
www.adverseeffectsmethods, and 
cochrane.org; (sites visited 11 
October 2007).
sir austin Bradford hill
FRS (1897–1991), medical 
statistician, was professor of 
medical statistics at the London 
School of Hygiene and Tropical 
Medicine (1945–61). A series of 
17 articles published by him in 
the Lancet in 1937 introduced 
the medical researcher to the use 
of statistics, later reprinted as 
Hill (1937). His first attempts 
to introduce the concept of 
randomization in controlled trials 
were for the Medical Research 
Council. See Wilkinson (1997).
Professor ray hill
DSc (Hon) FMedSci (b. 1945) 
gained BPharm and PhD degrees 
from the University of London. He 
was a lecturer in pharmacology at 
the University of Bristol (1974–83) 
and taught pharmacology at 
Downing College, University of 
Cambridge (1983–88). He worked 
in the pharmaceutical industry for 
over 25 years, initially for Parke 
Davis followed by Smith Kline 
and French, before becoming 
successively executive director, 
pharmacology, neuroscience 
research centre (1990–2002) 
and executive director, licensing 
and external research, Europe 
(2002–08) for Merck, Sharp and 
Dohme Research Laboratories, a 
subsidiary of Merck & Co., Inc. He 
chaired the Merck Analgesia Task 
Force, coordinating basic research 
worldwide, and had oversight 
responsibility for neuroscience 
research at the Banyu Research Labs 
in Tsukuba, Japan (1997–2002). 
He is a non-executive director of 
Addex Pharmaceuticals, Lectus 
Therapeutics Ltd and of Orexo 
AB, a venture advisor for Sofinnova 
Partners; visiting professor in 
neuroscience and mental health, 
Imperial College London; visiting 
industrial professor of pharmacology 
in the University of Bristol; visiting 
professor and chairman of the 
external advisory board in the 
school of biological and health 
sciences, University of Surrey; and 
visiting professor in physiology 
and pharmacology, University of 
Strathclyde. He is a director and 
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trustee of the Babraham Institute, 
Cambridge, president-elect and 
chair of the executive committee of 
the British Pharmacological Society, 
and a member of the Nuffield 
Council on Bioethics.
dame rosalinde hurley
DBE LLB FRCOG FRCPath 
(1929–2004) was chair of the 
Medicines Commission (1982–93), 
served on the management board of 
the European Medicines Evaluation 
Agency, was a member of the Public 
Health Laboratory Service (PHLS) 
board, and created and chaired the 
PHLS ethics committee. She was 
vice-president of the Royal College 
of Pathologists (1984–87), president 
of the Association of Clinical 
Pathologists (1983/4) and chairman 
of the Association of Professors of 
Medical Microbiology (1987–94).
Professor William h W inman 
FRCP (1929–2005) qualified 
at Cambridge, acted as medical 
adviser to ICI, and joined the 
Committee on Safety of Drugs in 
1964 as senior medical officer, later 
principal medical officer, to develop 
its voluntary reporting system, and 
was medical assessor of adverse 
reactions. See Inman (1999, 2006).
Professor sir david Jack 
Kt CBE FRSE FRS (b. 1924) 
worked at the Glaxo Laboratories 
(1951–53); was head of product 
development at Smith Kline and 
French (1953–61); research director 
of Allen & Hanburys, then a 
constituent part of Glaxo (1961–
73); managing director of Allen & 
Hanburys (1973–78); and research 
and development director of Glaxo 
Holdings (1978–87). He gained 
Queen’s Awards for salbutamol, 
1973; beclomethasone dipropionate, 
1975; and ranitidine, 1985.
dr Keith Jones 
FRCP FRCPE FFPM RCP  
(b. 1937) qualified at the Welsh 
National School of Medicine, 
Cardiff, and held posts in clinical 
and academic medicine at Cardiff, 
Edinburgh and Cambridge (1960–
67) before becoming executive 
director of medical affairs at Merck 
& Co. in 1979. He was chief 
executive of the Medicines Control 
Agency (1989–2002) and chairman 
of the European Medicines 
Evaluation Agency (2000–03). 
Professor Parveen Kumar
FRCP CBE (b. 1942) qualified 
in medicine at St Bartholomew’s 
Hospital Medical College, 
University of London. She was 
academic sub-dean and later director 
of postgraduate medical education 
at Barts and the London School of 
Medicine and Dentistry, University 
of London. She was non-executive 
director of the National Institute 
of Health and Clinical Excellence 
(NICE) (1999–2002); member of 
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the Medicines Commission UK 
in 1993, later vice-chairman, and 
served as its final chairman (2002–
5). She was president of the British 
Medical Association (2006/7). See 
Kumar and Clark (1987). 
Professor desmond laurence
FRCP (b. 1922) qualified in 
medicine from St Thomas’ Hospital 
Medical School, London, in 1944 
and was appointed lecturer in 
therapeutics there in 1950. He was 
senior lecturer in pharmacology and 
therapeutics at University College 
Hospital Medical school jointly with 
University College London (1954–
61) and professor there (1961–89). 
He served on the Committee 
on Safety of Drugs, Committee 
on Safety of Medicines and the 
Medicines Commission (1963–88). 
In 1967 he was a member of 
the Royal College of Physicians 
committee on the supervision of the 
ethics of clinical investigations and 
institutions, and subsequently served 
on the college’s committee on ethical 
issues in medicine. For 26 years he 
served on research ethics committees 
as chairman or member. 
dr Peter lewis
FRCP (b. 1944) was senior lecturer 
in clinical pharmacology at the 
Royal Postgraduate Medical School, 
Hammersmith Hospital, London, 
until 1983 when he joined the 
pharmaceutical industry, working 
first for a multinational company 
and then for several biotechnology 
companies. Since 2000 he has been 
chairman and majority shareholder 
of GR Micro, a London-based 
clinical research organization 
specializing in antibiotic research, 
which received the Queen’s Award 
for enterprise in 2005.
dr david long
was head of the experimental 
biology department, Wellcome 
Research Laboratories, Beckenham, 
Kent (1969–74); head of the biology 
division (1974–83) and director of 
biomedical research (1984/5). 
Professor tim mant
FRCP FFPM RCP (b. 1954) 
completed an honours degree 
in pharmacology, graduated in 
medicine from Guy’s Hospital 
in 1979 and trained at various 
hospitals in London in internal 
medicine, clinical pharmacology 
and human toxicology. He is senior 
medical advisor to Quintiles, Guy’s 
Drug Research Unit and visiting 
professor at King’s College London 
School of Medicine, Guy’s, King’s 
and St Thomas’ Hospitals, London. 
He specializes in the investigation 
of new chemical entities and 
biologics in humans. 
Professor denis mcdevitt 
DSc FRCP FRSEd (b. 1937) 
trained at Queen’s University, 
Belfast, and later at Vanderbilt 
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University, Nashville, Tennessee. 
He was professor of clinical 
pharmacology at Queen’s University, 
Belfast (1978–83); Professor of 
Clinical Pharmacology at the 
University of Dundee (1984–2002); 
and dean of medicine, dentistry 
and nursing in Dundee (1994–97). 
He was secretary (1978–82) and 
subsequently chairman (1985–88) 
of the Clinical Section of the British 
Pharmacological Society, of which 
he is now an honorary fellow. He 
was president of the Association 
of Physicians of Great Britain and 
Ireland (1987/8), a member of the 
Medicines Commission (1986–95; 
vice-chairman, 1992–95) and a 
member of the General Medical 
Council (1996–2003; treasurer, 
2001–03).
Professor michael orme
FRCP FMedSci (b. 1940) trained 
as a clinical pharmacologist in the 
UK and Sweden and worked for 
most of his career in Liverpool. He 
was dean of the faculty of medicine 
in Liverpool (1991–96) and helped 
to found the European Association 
for Clinical Pharmacology and 
Therapeutics in the early 1990s and 
was its chairman (2003–07).
dr anthony Peck
FRCP FFPM (b. 1933) qualified at 
the Middlesex Hospital, London, 
and gained his PhD in 1967 from 
the University of London. In 
1968 he was appointed assistant 
professor at the San Francisco 
Medical Center; was a clinical 
pharmacologist at the Wellcome 
Foundation (1969–94); part-time 
senior lecturer at the Middlesex 
Hospital (1969–98), later 
University College Hospital. He 
was also part-time senior medical 
assessor to the Medicines Control 
Agency (1994–2000).
Professor Brian Prichard
CBE FRCP FFPM FESC FACC 
FB Pharmacol S (b. 1932) started 
pre clinical studies at King’s College 
London in 1950 and qualified 
at St George’s Hospital Medical 
School, London, in 1957. He was 
appointed research assistant in 
clinical pharmacology to Professor 
D R Laurence at University College 
Hospital Medical School, London, 
in 1961, and became professor 
in clinical pharmacology at UCL 
in 1980. He is past president 
of the International Society for 
Cardiovascular Pharmacotherapy, 
past vice-dean of the faculty of 
clinical sciences at UCL, and 
was foundation secretary of the 
Clinical Section of the British 
Pharmacological Society (1970–75) 
and has been chairman of the 
Institute of Alcohol Studies since 
1993, a councillor in the London 
Borough of Wandsworth for over 
40 years and a medical officer to 
Boys’ Brigade camps. 
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Professor sir michael rawlins
Kt DL FRCP FRCPE FFPM 
FBPharmacolS FMedSci  
(b. 1941) qualified at St Thomas’s 
Hospital, London, where he 
later was lecturer in medicine 
(1967–71); moving to the 
Hammersmith Hospital, London, 
as senior registrar (1971/2), a 
visiting research fellow at the 
Karolinska Institute, Stockholm, 
Sweden (1972/3) and was Ruth 
and Lionel Jacobson professor 
of clinical pharmacology at the 
University of Newcastle upon Tyne 
(1973–2006). He was a member 
of the National Committee on 
Pharmacology (1977–83); the 
Committee on Safety of Medicines 
(1980–98; chairman 1993–8); 
Committee on Toxicity, (1989–92), 
the Standing Group on Health 
Technology Assessment (1993–5). 
He has been chairman of the 
National Institute for Health  
and Clinical Excellence  
since 1999.
derek rayner, Baron rayner  
of Crowborough 
(b. 1926) was joint managing 
director (1973–91) and chairman 
(1984–91) of Marks and Spencer 
plc and advised the Prime Minister, 
Margaret Thatcher, on improving 
efficiency and eliminating waste in 
government (1979–1983). 
Professor John reid
OBE FRCP FRCP(Glas) FRS(E) 
FMedSci (b. 1943) graduated in 
medicine from Oxford and trained 
in clinical pharmacology at the 
Royal Postgraduate Medical School 
(RPMS), Hammersmith Hospital, 
London. After a Medical Research 
Council travelling fellowship to 
the National Institutes of Health, 
Bethesda, Maryland, he returned 
to the RPMS as senior lecturer 
and later reader. In 1978 he was 
appointed Regius professor of 
materia medica and therapeutics 
at the University of Glasgow and 
in 1989 translated to the Regius 
chair of medicine and head of 
the department of medicine and 
therapeutics. He is past president 
of the Association of Physicians 
of Great Britain and Ireland and 
of both the British and European 
Societies of Hypertension.
Professor alan richens 
FRCP FFPM FBPharmacol was 
clinical pharmacologist and reader 
at St Bartholomew’s Hospital 
Medical College, London, and 
professor of pharmacology and 
therapeutics at the University of 
Wales college of medicine until his 
retirement in 2005. 
Professor James ritter
FRCP gained a degree in animal 
physiology and a DPhil in 
pharmacology before completing 
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clinical medicine at the Radcliffe 
Infirmary (Oxford). He trained 
in Oxford, London and the Johns 
Hopkins Hospital, Baltimore, MD, 
with specialist training in clinical 
pharmacology at the Hammersmith 
Hospital, London. He is head 
of the department of clinical 
pharmacology at Guy’s King’s and 
St Thomas’ School of Medicine and 
an honorary consultant physician 
at Guy’s and St Thomas’ NHS 
Trust. He sat on the Subcommittee 
on Safety and Efficacy of the 
Committee on Safety of Medicines, 
has chaired local and multicentre 
research ethics committees, and 
chairs the Thames Specialty 
Training Committee in Clinical 
Pharmacology. He is one of the 
two editors of the British Journal 
of Clinical Pharmacology and has 
been the co-author for the 3rd and 
subsequent editions of Rang and 
Dale (1987).
Professor Philip routledge
OBE FRCP FRCPE FBTS  
(b. 1948) qualified at Newcastle 
University has been professor of 
clinical pharmacology at the school 
of medicine, Cardiff University, 
since 1989 and consultant general 
physician at the Llandough 
Hospital, Cardiff since 1981. He 
has been head of Yellow Card 
Centre Wales since 1983; and chair 
of the All Wales Medicines Strategy 
Group since 2006. 
Professor sir eric scowen
Kt FRCP FRCS FRCPE FRCPath 
FRPharmS FRCGP (1910–2002) 
qualified at St Bartholomew’s 
Hospital Medical School, London. 
He became reader in medicine at 
Bart’s in 1938, where he remained 
throughout the war, serving as one 
of the Prime Minister’s physicians. 
In 1955 he became director of the 
medical professorial unit at Bart’s, 
and professor of medicine at the 
University of London (1961–75). 
He was chairman of the British 
Pharmacopoeia Commission 
(1963–69); member of the 
Committee on Safety of Drugs 
(CSD) (1963–71); chairman  
of the CSD’s Subcommittee on 
Toxicity; twice chairman of the 
Committee on Safety of Medicines 
(1971–76; 1977–80); member  
of the Committee on the  
Review of Medicines (1975–78) 
and chairman of the Council of  
the School of Pharmacy  
(1970–80).
dr Julian shelley
FRCPE (b. 1932) was a medical 
specialist in Tanzania (1958–1964); 
director of clinical research at  
C H Boehringer Sohn, Germany 
(1971–90); and chairman of the 
board of examiners for the Diploma 
in Pharmaceutical Medicine 
(1987–1992). 
100
Clinical Pharmacology in the UK, c. 1950–2000: Industry and regulation – Biographical notes 
dr robert (Bob) n smith 
FRCP FRCPE FFPM (b. 1934) 
graduated at the University of 
Birmingham and, after army 
service, went to Sheffield University 
as research assistant with Professor 
Graham Wilson, becoming lecturer, 
and in 1971 senior lecturer in 
pharmacology and therapeutics and 
consultant physician. He spent two-
years at the University of Michigan 
working on pharmacokinetics. He 
joined the pharmaceutical industry 
in 1976, becoming director 
of clinical research and drug 
development with Hoffmann-la-
Roche in Basel, Switzerland, then 
moving to Glaxo Group research in 
the UK in the same role for eight 
years. He guided the international 
development and early registration 
of many major products. He was 
director of medical affairs for five 
years before his retirement in 1994, 
founding editor of the International 
Journal of Pharmaceutical Medicine 
for 15 years, and member  
and chairman of the board of 
examiners of the Faculty of 
Pharmaceutical Medicine.
Professor Cameron swift
PhD FRCP FRCPI (b. 1946) is 
emeritus professor of health care of 
the elderly at Kings College London 
School of Medicine, having served 
as head of department and honorary 
consultant physician at King’s 
College Hospital (1986–2004), 
where he established the Clinical 
Age Research Unit. He completed 
his specialist and research training in 
medicine and clinical pharmacology 
with Professors James Crooks and 
Ian Stevenson in Dundee, Scotland, 
where he was Medical Research 
Council Research Fellow (1977–
80), working on a programme of 
investigation into the influence 
of ageing on drug handling 
and response.  He subsequently 
edited (and contributed to) the 
first international text on clinical 
pharmacology in the elderly, (Swift 
ed., 1987).  He served on the 
Subcommittee on Efficacy and 
Adverse Reactions of the Committee 
on Safety of Medicines (1987–92) 
and the Medicines Commission 
(2001–05). He was president of the 
British Geriatrics Society (2000–02) 
and a scientific advisor to the 
Association of Medical Research 
Charities (2002–07).
sir richard sykes
Kt DSc FMedSci FRS (b. 1942) 
was head of the antibiotic research 
unit at Glaxo Group Research UK 
(1972–77); Squibb Institute for 
Medical Research (1977–86) where 
he was vice-president of infectious 
and metabolic diseases (1983–86); 
Glaxo Group Research, where he 
was deputy chief executive, 1986; 
chairman and chief executive 
(1987–93); Glaxo plc: Group 
R&D Director (1987–93); deputy 
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chairman and chief executive 
(1993–97), chairman (1997–
2000), Glaxo Wellcome; chairman, 
GlaxoSmithKline (2000–02); 
director, British Pharma Group 
(1998–2001). He has been the 
rector of Imperial College, London 
since 2001. 
Professor e m (tilli) tansey
HonFRCP FMedSci (b. 1953) 
is convenor of the History of 
Twentieth Century Medicine 
Group and professor in the history 
of modern medical sciences at the 
Wellcome Trust Centre for the 
History of Medicine at UCL.
Professor duncan Vere
FRCP FFPM (b. 1929) trained in 
medicine at the London Hospital 
Medical College and completed a 
postgraduate research fellowship 
there. He was medical officer at 
the RAF Institute of Aviation 
Medicine; senior lecturer in 
medicine and consultant physician 
at the London Hospital; reader 
and then professor of therapeutics 
at the London Hospital Medical 
School and was appointed head of 
the department of pharmacology 
and therapeutics there in 1969. He 
was a member of the Committee 
on Safety of Medicines , the 
Committee on Dental and Surgical 
Materials and the Medicines 
Commission (1970–1990), and a 
member of the Nuffield Enquiry 
into Pharmacy, St Christopher’s 
Hospice Research Committee.
Professor owen lyndon Wade
CBE FRCP HonFRCPI  
(b. 1921) trained at Cambridge 
and UCH, and joined the Medical 
Research Council’s pneumoconiosis 
research unit, (1948–51) under 
Charles Fletcher and Archie 
Cochrane. He worked with K 
W Donald in the early days of 
cardiac catheterization (1951–57) 
and spent a year as a Rockefeller 
fellow at Columbia University, 
New York, with Robert Loeb. 
He was appointed to the chair of 
pharmacology and therapeutics at 
Queen’s University, Belfast (1957–
71) and to the chair in clinical 
pharmacology at Birmingham 
University (1971–86), serving six 
years as the dean of the faculty 
of medicine and dentistry and 
three years as pro-vice-chancellor. 
He was a member of the Joint 
Formulary Committee responsible 
for the British National Formulary 
(1963–86) and chairman of the 
Joint Formulary Committee 
(1978–86). He was chairman of 
the Subcommittee on Adverse 
Reactions of the Committee on 
Safety of Drugs. He was also a 
founder member of the World 
Health Organization Drug 
Utilization Research Group. See 
Wade (1996): 110.
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Professor andrew Wilson 
CBE FRCP FRCPGlas 
(1909–74) was Weir assistant in 
materia medica, University of 
Glasgow (1933–37); lecturer in 
pharmacology and therapeutics, 
University of Sheffield and clinical 
assistant, Sheffield Royal Infirmary 
(1939–46); lecturer in applied 
pharmacology, UCL, and UCH 
Medical School (1946–48); reader 
in the University of London (1948–
51); professor of pharmacology, 
University of Liverpool (1951–74); 
and chairman of the British 
National Formulary Committee.
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association of the British 
Pharmaceutical industry (aBPi)
The trade association of more 
than 75 companies producing 
prescription medicines in the UK, 
who research, develop, manufacture 
and supply more than 80 per 
cent of the medicines prescribed 
through the National Health 
Service (NHS). See www.abpi.org.
uk (visited 13 May 2008). 
astraZeneca 
A company formed by the merger 
of Astra AB of Sweden and the 
Zeneca Group plc in 1999. Zeneca 
was one of the three demerged 
businesses of Imperial Chemical 
Industries (ICI) in 1993. See www.
astrazeneca.com/article/ 
11163.aspx (visited 30 April 2008).
British Pharmacological society 
The British Pharmacological 
Society was established as 
a ‘daughter society’ of the 
Physiological Society in 1931 by 
Walter E Dixon FRS (1871–1931), 
J A Gunn (1882–1958) and Sir 
Henry Hallett Dale OM FRS 
(1875–1968). It met once a year 
until 1946 when launch of the 
British Journal of Pharmacology 
increased its activities and four 
times a year from 1968. The 50th 
anniversary was celebrated by a 
short history [Bynum (1981)] and 
its 75th with a special supplement 
[British Journal of Pharmacology 
(2006) 147: S1–307]. See Cuthbert 
(2006); Aronson (2006); Dollery 
(2006). 
clinical trial exemption scheme 
A scheme introduced in 1981 to 
exempt pharmaceutical companies 
from the need to have a clinical 
trials certificate, a process 
considered, at that time, to have 
delayed rapid clinical trials of 
chemicals of interest. See Griffin 
(1989): 13.
Cohen Committee 
A subcommittee of the Standing 
Medical Advisory Committees 
for England and Wales and for 
Scotland, an expert committee 
established in 1962 under the 
chairmanship of Lord Cohen of 
Birkenhead. The need for advice 
arose from an earlier internal 
review that legislation should be 
extended to improve public safety 
in light of the 1961 thalidomide 
deformities and that the Minister 
needed an independent expert 
body for that function. The 1963 
recommendations included the 
creation of an independent expert 
Glossary
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body with power to secure adequate 
pharmacological and safety testing 
and clinical trials of new drugs 
before their release for general use; 
early detection of adverse effects; 
and to keep doctors informed of the 
experience of such drugs in clinical 
practice. See MoH (1963); Griffin 
(2006); Tansey and Reynolds (eds) 
(1997).
Commission on human medicines 
(Chm)
A body combining the functions of 
the Medicines Commission and the 
Committee on Safety of Medicines 
established in 2005.
Committee on the review of 
medicines (Crm)
Established in 1975 to advise the 
Licensing Authority on the review 
of the safety, quality and efficacy of 
products on the market before 1971 
holding product licences, licences 
for proprietary medicines granted 
before 1976 and disbanded in 1991, 
having completed its work. See 
Griffin and Shah (2006): 474–5.
Committee on safety of drugs 
(Csd) 
Established in 1963 arising 
from the Cohen Committee 
recommendations, although 
with no statutory powers, prior 
to framing of comprehensive 
legislation. Chaired by Professor 
Sir Derrick Dunlop, it started work 
in January 1964 with voluntary 
agreement of the pharmaceutical 
industry that no new drugs would 
be marketed without its approval. 
Three subcommittees dealt 
with toxicity, clinical trials and 
therapeutic efficacy, and adverse 
reactions. The CSD’s findings 
formed the basis of the 1968 
Medicines Act. Sir Derrick Dunlop 
left the Committee in 1969 to 
become the first chairman of the 
Medicines Commission and was 
succeeded very briefly by Professor 
A C Frazer before his sudden 
death and Professor E F Scowen 
thereafter. Known colloquially as 
the Dunlop Committee. See Griffin 
(ed.) (1989); Griffin and Shah 
(2006); Tansey and Reynolds (eds) 
(1997).
Committee on safety of 
medicines (Csm)
The independent committee 
established by the Licensing 
Authority to advise on questions 
of safety, quality, efficacy of new 
medicines for human use in 1971.  
A number of subcommittees 
assisted the main committee, 
for example, the Subcommitee 
on Safety, Efficacy and Adverse 
Reactions (SEAR).
dunlop Committee
See Committee on Safety of Drugs.
european Clinical trials directives
Four main directives involve 
pharmaceutical preparations: 
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65/65: arrangements for 
granting authorizations; 75/318: 
requirements for pre clinical 
testing, pharmaceutical quality and 
manufacture; 75/319: established 
the Committee for Proprietary 
Medicinal Products in 1975; and 
83/570: amended earlier directives 
in 1985 concerning format and 
data requirements for applications 
for marketing authorizations.
international studies of infarct 
survival (isis)
The International Study of Infarct 
Survival Collaborative Group 
conducted four large-scale clinical 
trials (ISIS 1–4) between 1987 
and 1993 comparing various 
treatments for high blood pressure, 
and the prevention of angina and 
heart attacks. These international 
trials involved more than 120 000 
patients in more than 1000 
hospitals in 29 countries. See 
ISIS (1986, 1988, 1992, 1995); 
Reynolds and Tansey (eds.) (2005): 
40–1, 78–9. 
investigational new drug (ind)
The first stage of the US drug 
regulation system after a molecule 
changes its legal status under 
the Federal Food, Drug, and 
Cosmetic Act 1938 to become 
a new drug, subject to specific 
requirements of the US Food and 
Drug Administration (FDA). For 
example, an exemption granted to 
the drug’s sponsor (pharmaceutical 
or marketing company) from 
intrastate transportation and 
distribution regulations for the 
purpose of clinical trials. See 
www.fda.gov/cder/Regulatory/
applications/ind_page_1.htm 
(visited 21 August 2008).
licensing authority
The body responsible under 
the Medicines Act, 1968, for 
controlling and monitoring the 
production of new medicines by 
product licences, product licences 
of right, manufacturers’ licences, 
clinical trial certificates and clinical 
trial exemption certificates. It is 
made up of the Secretaries of State 
for Health and Social Services 
(Health only in England after 
1989), for Agriculture, for Wales, 
for Scotland and for Northern 
Ireland; is advised by the Medicines 
Commission; and was initially 






The main UK legislation protecting 
the public from dangerous 
compounds, and ensuring the 
efficacy and safety of medicinal 
products, implemented in 1971. 
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medicines and healthcare 
Products regulatory agency 
(mhra)
The new body resulting from 
the merger of the Medicines 
Control Agency and the Medical 
Devices Agency in 2003 that is the 
government agency responsible for 
ensuring that medicines and medical 
devices work and are acceptably safe. 
See www.mhra.gov.uk/Aboutus/ 
index.htm (vsited 21 August 2008).
medicines Commission
The advisers to the UK Ministers 
of Health on the execution of the 
Medicines Act 1968.
medicines Control agency (mCa)
The reorganized Medicines 
Division, so named in 1989 under 
the directorship of Dr Keith Jones, 
with a staff of 300 at that time. 
medicines division
The day-to-day administrative 
body for the Medicines Act 1968 
in the UK Department of Health 
and Social Security. It coordinated 
the professional staff and medical 
assessor to the Medicines 
Commission; was managed jointly 
by an under secretary and a senior 
principal medical officer. In 1988 
the Department was divided into 
the Department of Social Security 
and the Department of Health.
merck sharp & dohme ltd 
(merck; msd)
The UK subsidiary of Merck & Co. 
Inc., of Whitehouse Station, New 
Jersey, established in 1891.
northwick Park
A hospital in Harrow, Middlesex, 
initially housing the MRC Clinical 
Research Centre, opened in 1988. 
See Reynolds and Tansey (2000): 19. 
Pharmaceutical Price regulation 
scheme (PPrs)
A scheme to secure value for money 
for the NHS while providing 
pharmaceutical companies with 
incentives to invest in new and 
useful drugs; it is re-negotiated 
every five years between the 




(visited 13 May 2008). 
Poisons Unit, guy’s hospital, 
Established in 1963 to provide 
a poisons information service, it 
moved in 1967 to its own premises 
with a laboratory in south east 
London and was renamed the 
Medical Toxicology Unit. It is part 
of the Guy’s and St Thomas’ NHS 
Foundation Trust, providing a wide 
range of clinical toxicology services. 
See www.medtox.org/info/default.
asp (visited 14 May 2008).
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rayner reports 
Reports by Sir Derek (later Lord) 
Rayner, adviser (1979–83) to 
Margaret Thatcher, Prime Minister, 
on the promotion of efficiency 
in Government. His scrutiny of 
specific activities in government 
departments, the main feature of 
which was a radical self-examination 
of a specific policy, activity or 
function under the close supervision 
of the Minister responsible and with 
contributions from Sir Derek and 
his small unit. See, for example, 
Montagu et al. (1981).
research ethics committee
A committee established to 
safeguard the welfare of participants 
in clinical trials. They became 
mandatory for every NHS 
health district in 1991 following 
publication of guidance by the 
Department of Health HSG(91)5. 
For detail on the remit of research 
ethics committees see Department 
of Health (2001), Alberti (1995). 
talentmark
A recruitment consultancy 
specializing in the pharmaceutical, 
biotechnology and life-science 
industries. See www.talentmark.
com (visited June 4 2008). 
tgn1412 
A super agonistic anti-CD28 
monoclonal antibody for the 
treatment of B cell leukaemia and 
autoimmune diseases developed 
by the sponsor, TeGenero AG, 
Wurzburg, Germany, which caused 
multi-organ failure in six healthy 
human volunteers in March 2006 
in a phase I study conducted by 
Parexel, a US clinical research 
and bio/pharmaceutical services 
company founded in 1982, at the 
Northwick Park Hospital, Harrow. 
See Department of Health (2006). 
Wellcome Foundation 
The umbrella organization formed 
in 1924 by Henry Wellcome to 
absorb his libraries, museums, 
research laboratories and the 
pharmaceutical company of 
Burroughs Wellcome & Co.  
Sir Henry Wellcome’s will created 
the medical charity, the Wellcome 
Trust, which managed the 
Foundation until it was floated on 
the stock market and merged with 
Glaxo in 1995. For a company 
history until 1940, see Church and 
Tansey (2007).
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Abbreviations are listed on pages v–vi
academic departments
interaction with industry, xxii–xxiii, 
15–16, 20–1, 28–34, 35–40
joint industry appointments, 29–31, 
32, 33–4, 39
ADROIT (adverse drug reactions on-
line information tracking), xxiv
adverse drug reactions, 46, 49, 52
computerized record linkage, 52, 
55–6
as impetus for regulation, xxiii–xxiv, 
42–3, 59–60
monitoring methods, xxiv, 59
revocation of product licence, 56–7
working party on, 54–5
yellow card reporting system, 46–7, 
53–4, 59
see also post-marketing surveillance; 
safety; ADROIT
Adverse Reactions Subcommittee see 
Committee on Safety of Drugs, 
Adverse Reactions Subcommittee
advertising, direct consumer, 40
advisory committees see committees, 
advisory
ageing, drug development and, 39–40, 
53
American Society for Pharmacology 
and Experimental Therapeutics, 
xxiii, 31
amphetamine addicts, former, as 
clinical trial volunteers, 22
animal toxicity tests, 52, 55, 56
antibiotics, 25–6
anti-epileptic drugs, 22–3, 26
Applied Physiology (Wright, 1934), 18
Association of Human Pharmacologists 
in the Pharmaceutical Industry, 
15–16
Association of the British 
Pharmaceutical Industry (ABPI), 
10–11, 103
joint training scheme with 
Department of Health, 29–31, 
32, 33–4, 39
Astra AB, (AstraZeneca from 1999), 4
AstraZeneca, Sweden, London, 4, 34, 
39, 103
South Manchester Clinical Trials 
Unit, 5, 6, Figure 1
see also ICI Pharmaceuticals
atenolol, 5
aztreonam, 25–6
Bart’s see Barts and the London School 
of Medicine and Dentistry, 
University of London
Barts and the London School 
of Medicine and Dentistry, 
University of London, 29





biotech companies, 34, 35
Birmingham, University of, 28




British Journal of Clinical 
Pharmacology, 48, 65
British Journal of Pharmacology, 32
Index: Subject 
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British Medical Association, 45
British Pharmacological Society (BPS), 
21, 30, 39, 60–1, 103
Burroughs Wellcome Co. 
(GlaxoWellcome from 1995, 
GlaxoSmithKline, GSK, from 
2001) London, xxiii, 31
Calpol, 62
Cardiff, 22, 23, 38–9
cardiovascular pharmacology, 4–5, 
17–18
Chalfont Centre for Epilepsy, Chalfont 
St Peter, Bucks, 23
chief medical officer, xxiv, 45
China, delegation from, 60–1
Ciba (Novartis from 1996), 15, 30
cimetidine, 34
civil service, 51, 56, 57, 68
clinical pharmacologists
academic, role of, 42
on advisory committees, 67, 69
conduct of clinical trials, 13, 14, 19, 
39, 40
movement between industry and 




first 2007 Witness Seminar, 3
industry-based, 4–9, 16–19
status as a discipline, 19
clinical pharmacology unit, MRC, 
Oxford, 38, 49
clinical research associates (CRAs), 9, 
15–16
clinical research organizations (CROs), 
14–15, 34, 35
clinical research scientists, 9
Clinical Science, 17
Clinical Section of the British 
Pharmacological Society (BPS), 30
clinical trial certificates, 11–12, 13–14
abridged applications for, 12, 13
clinical trial exemption scheme (CTX), 
12, 13, 14, 35–7, 103
clinical trials
in centres of excellence, 7
in-house units, 5, 6, 7, 15, 20
older subjects in, 39–40, 53
phases, 10
rapid entry into, 6–7
regulatory control of, 11–13
role of academia, 15
role of clinical pharmacologists in, 
13, 14, 19, 39, 40
volunteers see volunteers, healthy 
normal
see also drug development; phase I 
studies
clinical trials unit, Cardiff, 38–9
clioquinol (Enterovioform), 68–9
clobuzarit (Clozic), 6–7, 9
effect on c-reactive protein  
and erythrocyte sedimentation 
rates, 6
clofibrate, 5, 6, 9
Cohen Committee, 4, 103–4
Commission on Human Medicines 
(CHM), 51, 64, 104
clinical pharmacologists on, 69
formation, xxv, 60, 70–1
volume of data, 58
Committee on Dental and Surgical 
Materials (CDSM), 47–8, 66
Committee on Safety of Drugs (CSD) 
(Dunlop Committee), xxiv, 4, 
45–9, 56, 104
Adverse Reactions Subcommittee, 
46–7
Clinical Trials Subcommittee, 47
consideration of efficacy, 48, 58
industry links of members, 67
legal status, 48
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Toxicity Subcommittee, 47
Witness Seminar on, 1997, 54
Committee on Safety of Medicines 
(CSM), xxiv–xxv, 49–56, 61–5, 
104
appeals against decisions, 66, 70
chairmen, 61, 62
Clinical Trials Subcommittee, 49–50




location of meetings, 50
relations with Medicines 
Commission, 65, 66–8, 70
reorganization, 60, 70
Safety, Efficacy and Adverse 
Reactions (SEAR) Subcommittee, 
51–2
seating arrangements, 57, 62
Toxicity and Clinical Trials 
Subcommittee, 51, 61
working parties, 49, 52, 54–5
Committee on Review of  
Medicines (CRM), 56–7, 58,  
66, 104
committees, advisory, 65–6, 67–8
amount of paperwork, 58, 64–5
members with industry links, 67
numbers of clinical pharmacologists, 
69
patient involvement, 64
chairmen, payments to, 63, 64
reorganization, 60, 70–1
seating arrangements, 57, 58,  
62, 69
see also specific committees
computers, 52, 53–4, 55–6
contract research organizations see 
clinical research organizations
counterfeit medicines, 50–1, 60–1
Department of Health, 52, 60, 63
joint training scheme with ABPI, 
29–31, 32, 33–4, 39
Medicines Division, 10, 29, 55, 106
See also Minister of Health
Pharmaceutical Price Regulation 
Scheme (PPRS), 11, 40, 106
Department of Health and Social 
Services (DHSS), 29, 53–4
Medicines Division see Medicines 
Division
diabetes, type 2, 8
digoxin, 17, 49
diploma of pharmaceutical medicine 
(DipPharmMed), xxi, 28
Distillers Biochemicals Ltd, 43
doctors, relevance of regulation to, 44, 
47, 50–1
dogs, studies in, 55; see also animal 
toxicity tests
dose-ranging studies, 6
drug development, xxii, 22–3, 24, 60
in Europe by US companies, 7–8, 
19–20, 36
marketing issues, 24–8
older subjects in, 39–40, 53
see also clinical trials
drug discovery, 24, 60
drug distribution, 60
drug and therapeutics committees, 45
Dunlop Committee see Committee on 
Safety of Drugs
efficacy, xxiv, 48
assessment by CSM, 50, 58, 68–9




ethical guidance, pharmaceutical 
physicians, 41–2
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ethics committees, research, 18, 36, 
37, 107
Europe
clinical trials directives, 11, 36, 37, 
48, 104–5
drug development by US 
companies, 7–8, 19–20, 36
regulatory system, xxv, 43, 59–60
expert advisory groups, 60, 64
Faculty of Pharmaceutical Medicine of 
the Royal College of Physicians of 




Food and Drug Administration (FDA), 
US, see US FDA 
Food and Drug Administration 
Amendments Act, US, 2007, 59
France, 19
fraud, 63
General Practice Research Database 
(GPRD), 59
general practitioners (GPs), 41, 46
general sales list (GSL) medicines,  
43, 62
generic medicines, 11, 12
Germany, 19–20
Glaxo (GlaxoSmithKline from 2001), 
11, 24, 29, 34, 37
clinical trials, 36
registrar, 15
Glaxo Group Research, 8, 37
GlaxoSmithKline (GSK), Middlesex, 
33, 34
GlaxoWellcome (GlaxoSmithKline 
from 2001), 8, 34
Guy’s Hospital, London, 14–15
Drug Research Unit, 15
Poisons Unit, 15, 106
Hammersmith Hospital (Imperial 
College School of Medicine), 
London, 14–15, 16, 19, 29
Health, Department of, see 
Department of Health
herbal medicines committee, 66
histamine H2 receptor blockers, 34
homoeopathic medicines, 66




ICI 50172 (practolol), 4–5, 30
ICI 55897 (clobuzarit; Clozic), 6–7, 
9, 11
ICI Pharmaceuticals (AstraZeneca 
from 1999), 4–7, 15, 28, 34
clinical pharmacology department, 
5, 9
clinical trials, 5, 6–7, 36
practolol, 4–5, 30
see also AstraZeneca
Imperial Chemical Industries Ltd see 
ICI Pharmaceuticals
immunological compounds, 18
industry, see pharmaceutical companies
International Conference on 
Harmonisation (ICH), 53
International Studies of Infarct 
Survival (ISIS), 5, 105
investigational medical product (IMP), 
9
investigational new drug (IND) 
applications, to US FDA, 7, 105
King’s College London, 28, 33
lamotrigine (Lamictal), 22–3, 24
legal capture, 43
leukotriene D4 antagonist, 7
licences, product see product licences
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